var title_f14_13_14544="Temporal segmental atrophy";
var content_f14_13_14544=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Temporal segmental optic disc atrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Temporal segmental optic disc atrophy in a patient with dominant optic atrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14544=[""].join("\n");
var outline_f14_13_14544=null;
var title_f14_13_14545="Lornoxicam: International drug information";
var content_f14_13_14545=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lornoxicam: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acabel (AR, CL, ES, PT);",
"     </li>",
"     <li>",
"      Artok (AT);",
"     </li>",
"     <li>",
"      Bosporon (ES);",
"     </li>",
"     <li>",
"      Lornox (AT);",
"     </li>",
"     <li>",
"      Taigalor (IT);",
"     </li>",
"     <li>",
"      Telos (DE);",
"     </li>",
"     <li>",
"      Xefo (AT, DK, GR, SE, TH, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2638167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2638168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of osteoarthritis, rheumatoid arthritis, and painful conditions including postoperative pain",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2638170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M., I.V.: Acute pain, osteoarthritis, rheumatoid arthritis: 8-16 mg/day; in rare cases maximum initial daily dose may be increased to 24 mg; treatment should be limited to 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rheumatoid arthritis and osteoarthritis: Initial dose: 12 mg/day in 2-3 divided doses; total dose should not exceed 16 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute pain: 8-16 mg/day; doses &gt;8 mg/day should be given in 2-3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2638171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Injection, solution: 8 mg",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet: 4 mg, 8 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10473 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-198.199.123.20-28C064E6EE-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14545=[""].join("\n");
var outline_f14_13_14545=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369806\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638167\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638168\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638170\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821063\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638171\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10473\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10473|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_13_14546="Snowflake calficification on CT in brucellosis";
var content_f14_13_14546=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Snowflake calcification in chronic hepatosplenic brucellosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Noncontrast CT of the liver of patient at the time of admission to the hospital, showing large calcium density without surrounding hypodensity. Serological test results at this time were as follows: rose bengal, negative; agglutination, negative; and Coombs' test, 1/80. Diagnoses of liver abscess and brucellosis were delayed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ariza, J, Pigrau, C, Ca&ntilde;as, C, et al. Current understanding and management of chronic hepatosplenic suppurative brucellosis. Clin Infect Dis 2001; 32:1024. Copyright &copy; 2001 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14546=[""].join("\n");
var outline_f14_13_14546=null;
var title_f14_13_14547="Sodium citrate: Drug information";
var content_f14_13_14547=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium citrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/6/1124?source=see_link\">",
"    see \"Sodium citrate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/21/26963?source=see_link\">",
"    see \"Sodium citrate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytra-2;",
"     </li>",
"     <li>",
"      Oracit&reg;;",
"     </li>",
"     <li>",
"      Shohl's Solution (Modified)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Dicitrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkalinizing Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Systemic alkalization:",
"     </b>",
"     Oral: 10-30 mL with water after meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/21/26963?source=see_link\">",
"      see \"Sodium citrate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Systemic alkalization:",
"     </b>",
"     Oral: Infants and Children: 2-3 mEq/kg/day in divided doses 3-4 times/day",
"     <b>",
"      or",
"     </b>",
"     5-15 mL with water after meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"     <b>",
"      Note:",
"     </b>",
"     Contains sodium 1 mEq/mL and is equivalent to bicarbonate 1 mEq/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: Sodium citrate 500 mg and citric acid 334 mg per 5 mL (480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytra-2: Sodium citrate 500 mg and citric acid 334 mg per 5 mL (480 mL) [alcohol free, dye free, sugar free; contains propylene glycol and sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oracit&reg;: Sodium citrate 490 mg and citric acid 640 mg per 5 mL (15 mL, 30 mL, 500 mL, 3840 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Shohl's Solution (Modified): Sodium citrate 500 mg and citric acid 300 mg per 5 mL (480 mL) [contains alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after meals. Dilute with 30-90 mL of water to enhance taste. Chilling solution prior to dosing helps to enhance palatability.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metabolic acidosis; alkalinizing agent in conditions where long-term maintenance of an alkaline urine is desirable",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bicitra may be confused with Polycitra",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Generally well tolerated with normal renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Tetany",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic alkalosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sodium citrate, citric acid, or any component of the formulation; severe renal insufficiency; sodium-restricted diet",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with  heart failure or hypertension; contains sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Edema: Use with caution in patients with peripheral or pulmonary edema; contains sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic failure; conversion to bicarbonate may be impaired.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; contains sodium. Contraindicated in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severely ill: Use with caution in patients who are severely ill; conversion to bicarbonate may be impaired.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Shock: Use with caution in patients who are in shock; conversion to bicarbonate may be impaired.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not established (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F221720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution with toxemia of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F221735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/compatible",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F221721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken after meals to avoid laxative effect.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F221719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Oracit Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     490-640 mg/5 mL (30 mL): $2.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Shohls Modified Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500-334 mg/5 mL (473 mL): $13.77",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13246577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum sodium and bicarbonate; urinary pH",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13246579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Urinary pH: 4.6-8.0",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Oxidized to sodium bicarbonate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;5% as sodium citrate)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9930 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-E259C7487F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14547=[""].join("\n");
var outline_f14_13_14547=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221727\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221728\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221741\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221731\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221737\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221732\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221713\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221700\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221715\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221714\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914136\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221739\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221718\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221703\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300056\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221708\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221710\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221720\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221735\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221721\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221719\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13246577\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13246579\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221717\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9930\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9930|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/6/1124?source=related_link\">",
"      Sodium citrate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/21/26963?source=related_link\">",
"      Sodium citrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_13_14548="Milking maneuver for elbow medial collateral ligament";
var content_f14_13_14548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Milking maneuver for the elbow medial collateral ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Milking maneuver places valgus stress on the medial collateral ligament (MCL) of the elbow in a throwing position. Pain elicited by the test may suggest MCL insufficiency in overhand athletes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neeru Jayanthi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14548=[""].join("\n");
var outline_f14_13_14548=null;
var title_f14_13_14549="Pancreatic necrosis drainage CT";
var content_f14_13_14549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Infected pancreatic necrosis percutaneous drainage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 358px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFmAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5r/4SbXv+g3qf/gXJ/jR/wk2vf9BvU/8AwLk/xrIooA1/+Em17/oN6n/4Fyf40f8ACTa9/wBBvU//AALk/wAayKKANf8A4SbXv+g3qf8A4Fyf40f8JNr3/Qb1P/wLk/xrIooA1/8AhJte/wCg3qf/AIFyf40f8JNr3/Qb1P8A8C5P8ayKKANf/hJte/6Dep/+Bcn+NH/CTa9/0G9T/wDAuT/GsiigDX/4SbXv+g3qf/gXJ/jR/wAJNr3/AEG9T/8AAuT/ABrIooA1/wDhJte/6Dep/wDgXJ/jR/wk2vf9BvU//AuT/GsiigDX/wCEm17/AKDep/8AgXJ/jR/wk2vf9BvU/wDwLk/xrIooA1/+Em17/oN6n/4Fyf40f8JNr3/Qb1P/AMC5P8ayKKANf/hJte/6Dep/+Bcn+NH/AAk2vf8AQb1P/wAC5P8AGsiigDX/AOEm17/oN6n/AOBcn+NH/CTa9/0G9T/8C5P8ayKKANf/AISbXv8AoN6n/wCBcn+NH/CTa9/0G9T/APAuT/GsiigDX/4SbXv+g3qf/gXJ/jR/wk2vf9BvU/8AwLk/xrPitLiZgsUErsegVCSa2rPwZ4ivHVYNHuzuGQWTaMfU8UAVf+Em17/oN6n/AOBcn+NH/CTa9/0G9T/8C5P8a6KH4X+ImjMkyWkEYGSXnXP5DJrQh+FzLIovNcsUXbuIjBc/SgDjf+Em17/oN6n/AOBcn+NH/CTa9/0G9T/8C5P8a7mLwT4bttj3Wp3lz82GWNAoPpjvV0+HPCsDSEabeyBR8pknIGfwoA85/wCEm17/AKDep/8AgXJ/jR/wk2vf9BvU/wDwLk/xr042XhOOJtmhB2J2r+8Jx7/SnDTvCEm3zdEKZXDFJT19qAPL/wDhJte/6Dep/wDgXJ/jR/wk2vf9BvU//AuT/GvVP+EG8GX1m5t5b21m9d+8KMdeayLn4W2jRs9lrqYz8omiIJH4UAcF/wAJNr3/AEG9T/8AAuT/ABo/4SbXv+g3qf8A4Fyf411EvwxvwWWDUtPlcAHbvK59ulZkvgDxAgBW2jlyCR5cqngde9AGV/wk2vf9BvU//AuT/Gj/AISbXv8AoN6n/wCBcn+NOuPC+uWxxNpV4v8A2zJrLkt5ox+8hkTH95SKANL/AISbXv8AoN6n/wCBcn+NH/CTa9/0G9T/APAuT/GsiigDX/4SbXv+g3qf/gXJ/jR/wk2vf9BvU/8AwLk/xrIooA1/+Em17/oN6n/4Fyf40f8ACTa9/wBBvU//AALk/wAayKKANf8A4SbXv+g3qf8A4Fyf40f8JNr3/Qb1P/wLk/xrIooA1/8AhJte/wCg3qf/AIFyf40f8JNr3/Qb1P8A8C5P8ayKKANf/hJte/6Dep/+Bcn+NH/CTa9/0G9T/wDAuT/GsiigDX/4SbXv+g3qf/gXJ/jR/wAJNr3/AEG9T/8AAuT/ABrIooA1/wDhJte/6Dep/wDgXJ/jR/wk2vf9BvU//AuT/GsiigDX/wCEm17/AKDep/8AgXJ/jR/wk2vf9BvU/wDwLk/xrIooA1/+Em17/oN6n/4Fyf40f8JNr3/Qb1P/AMC5P8ayKKANf/hJte/6Dep/+Bcn+NH/AAk2vf8AQb1P/wAC5P8AGsiigDX/AOEm17/oN6n/AOBcn+NH/CTa9/0G9T/8C5P8ayKKANf/AISbXv8AoN6n/wCBcn+NFZFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVe0zSb7U5AljayTH1UcD8elAFGiu60/wNHGnmazqCREHmGD5mA9z0FdHaQaBpaQiy0+Kec5HmTfMfrzxQB5jYaPqN+xWzsp5iP7qGuisvh9rE8iLcG3tlYbsu+Tj6Cusl1e9n3JG6xo3DKBt2+n/wCqkt3uI9zRtJIeRn+ID60AYkfgC1gl23+sKQB8ywR8g/jU8Phjw5bozyyXd0Fz/Ftz6dBWtFpF88u9423HByVJ3D3H5Vbg0i5eQxxWsm0AjDDOAaAMddO8P28CmLSDISpO6Ry35+laGkxwiZIYdPtIRty0gjGRWinhi/nb5GWKIfLk8Z+lTSaC1uq4cyN0IDcfnQAlzrrWUgW1jUIq8FR09fp0rMXW766j+a7mx1xux34p02k3cke4SRIMn7p7CorXwxerM4DQZByOc9e/8qAHJeyvC/mXDyNkqQfX1qjdyl+TKTt4IB5rpV8KTxwgtcJtGGA7t61XPhO7G54wrD7xZjjigDClZULZkZWwDjrUL3n2gKHeTyzyea6aTwfdzrsb+Pnr+n+fWoT4Ov0VRuRZW42sO3+cUAYNvIg3J5Xyk7lJP3enNWbJg1zsdQ3cN0B9K3bfwPevMURldwMHng8dq0rDwhNCYRcvuTopHUHPSgDOeK2tYEjVCsjck571ky3eyCXaXySTn0FdZe+Hbua5QoyHZkFffnFYzeGNSRHyAUVieTyD6fpQBjPc7HZw5MgAJAHOKRbjZl1meIuOobnNbA8O3LfvTsEmMFc8AU2XwxcyIHRd23naB19aAKsWr38aptu3Z4hgDPX61ah1rUJXSOdraVXHPnICCaZJ4Z1BLgOIWyeOO/oTVSfRtQtxJi3cEZJbGST/AIUAW7t9HeQx3Wi6fOekjRxbOfbFZjaJ4QuhtbTrq225BaGcsc/jRNHNBMEmjKqwypx/OqxaLyMMiqc52E4I5oAevgLw3doXtdXvbcYzmVFcZ/DFZr/DdH3fZNfs5CDwHQp+ua0S6+WDGCERhyON3tSsUkeR49y5+QKG645oA55/hvrm0NC1lMC20eXODms2fwX4hhdlbTJmx3Qg/wBa9BtrK5MIMTyRjAKhcnn1zUrXN5ayrIbkljn5QSf0oA8oudF1O2x59hcpn1jNUnikT78br9QRXstx4ivRIF8wPIPlAx0FRS61KpCPb20/s6Bj9P8APrQB43RXrLy6PcqY7vSLXOMl0XHPtiqc3h3w7PEzlZoCD1ibI/I0AeZUV3s/gKOWwe6sNSjY79qxSLj9a5+/8KavZKXe1MkY6vF8w/xoAwqKfJG8bFZFZGHZhg0ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiitLRtFv9ZlZLGAuq8vIeEUe5oAza19E8O6nrUgWxtmKH/lo/yp+ddvp+gaFoSRSXm3U7zg7TxGp9Md/wAa0ru9utRCwwExxKRtVF24b+7xQBk6Z4R0jTUaTWJ2u7lP+WScRg+hPetaPWpkgS2s7aOO2j+VFjGBU1no0kjNJeOQHwGXua6/SrTSbS32xEMR13dR7UAcbBot9dzSSMrfvG6g9c1p2/hVYI1WWTywvXcMkGt681N1DR2ERGT129qyJ7e6uZ/NckMTtYHnJoAuaRpumLLIksPnSKvzd8+hrorEWMTbFSMIAMjHP41zdjYapBO5QKpYYVx/e9/1q/Jp08EhMkilio5B6nrnH+elAG7O8USsxdFRMgMeMCuX1XWQpVrXczAdUHU46mpJ9KZgRcXLXCSZBXPAGO9FppMIEKRn5eg+Xsf/AK1AHKT3niDUHcGXZGoySOKS5F0bURiZggPO49PU8Vu3sUNrLLbAStBJzntn+lZ1/beWwaRyvHJXkEelAFWy03IWRrsYbPBPQf41qaa0EN8kYn3qvQg9apuqXMeF+oY9vWmxM8F0m6BSV+8FXHJ6UAd7aAuqkbGVWzyeauLa+dG8LFyR6HBznvXJtr8wZFhg2nZzgdTVVNS1O4Q+c7QTM+S+7APtQB3oKwxowyMcMvY88fQ1S1YxTBAJXyvoeevNUdO1W6a3LTlJcd1IJb6//Xq3JsmgVnRo1zljjkDHJ/8Ar0APiu44NioGGAMENkke9Ov7zzIy3YHBwcdOciseRbeNp7pZHZc+XwO3Y1WnKSWgSElMHO/Gd1AGkNcPnrgMxJYA55+gq19oupVLeXuQr3yeM8Vygu0siRuDPyVAHf0HvWhaeJSltHiNiQck+voMe1AGq0qpAxmt9vckdj6CrlhqFupO8mMIoJDduKxLbxPI2+N7YyHksAPXuKR9V0+5R1ZFB3DGB396AOk+0K4JMmY2OCT2Gc1MPnkVcJg5GcckeprnjZG4ANvKVjxg85BPfHtTD/aEEZO0kkFcg5wBmgDevba2CkG2iaQjAJ7D61yd9Y6XcTKq2235u3HPrVyHXJFRlvYGAAyD2wajg1Gw83CgKWYHD8k+uKAI28KWU6KZQysRg7ePerKeGNOV4yI/lQfd7E+tacV5byW5KSqGlJByOVI9KfJOr+V5Ug2q2TlvTrxQAWVtFbIiKqqBwSB61BcafayrKPJXceQ23GTVh5VQMEYMR83PpmoRe5eQkehAAwPpQBlyeFdNKIQu1xnL85+v5VUl8IWsyt5UjYb06sRXQjLFjcspwchc96dHL9nZWP8ArD8uxegz3x2oA5G68FkKFSQEL2P8P5VVk8K3Fsd8RUhyAFxXexjaM7sseCaQbw4UBfKAwBnpQB5jLpeqRzSq0ZCFwVCjofaoUvL+0ikDB/MVuUPPP+c16lKwwgYAEuMA896xNQs0aQuIiy7/AJj1JNAHEzmwu4GOrWazHHBHYn1NYl94FtLtJptIu/LZQW8qb+hrvb7RUc5RwO4UDBJ71z91aSxSFcMuGxjqTQB5dqmjX+lvtvraSMdmx8p/Gs6vbI7yaNPLuoo7iEDaUkAbANcxq/hCyvxNNpMi20ynPlMf3bfQ9qAPOqK0NY0e/wBHuPJ1G3eF+xI4P0NZ9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFKBk4HWu28MeG4rdorzWlXcwDw2z9/QsOv4UAUvDHhSS/WK81Etb6eSMHGGl9l9veuzluFZv7P0GHybMdEGMt7n1rTt7S88RSxqo8m1hUIF6DANdVp2lWumqkcEKvMDgseSR1oA5Sx8KtIw8xihJPyt0/P8a6GLQPJZV3KobGD6NXRyRh0zKo4554xUBvYVl8rLZHfH+c0AV4dGh3j7QxkLYBLDFXGgtY9kZRQd+Rjo341nxf2peT7IEzHnG4DBHNadj4buQpkupGIzwvXPegCu6o8yrEpjCtgN15A6Go440QPGYwnUs57+4/GtuWE8s0ZK5JLL6e/aqt+gKsV2YZcgdhxQBQDzNANu0Z6YPzH3rNuCsRWaVizICOT2+ntVmSGUl2UlGTpk8DvVaeB2f53+R02snbJHUUAZsmsQQusaqN2fkyOxqeKW5gljktwwVxkI54Pp+PNUYtI/iRFbDZIIx+AqS6eSDZNI5WGPhmJ6Y9aANC+cxaVIt2sccjP5iyEggJ715f4m8bItxJDpIWdeMzSDK/gO/1ql488YvraRWFo7fYYeS3Qyn1PtXFUAbbeKNY3ZS9eMf3VAArc034gXigxapDFcxsR+8C4dff0NcRRQB6xrPjC3sNKhktFSW4kG6HK9B6mvOdT1vUdSkdru6kcM27aDhR+FSXts48PaddMSVaSSMfhismgCeO7uI8eXPMmP7rkVvaR411zTJQyXrzR8ZjmO5SK5qigD2vTvGFtqljHLOVjdyd0Q/hIFTjXoGhUo3yKPuf4Vx/hTwhLqVjZzwMzFwSVXHevQdA8DG0ijafMhUlWX0oAzbCyuNbuoykZS3I3Fu5J7V6F4c8I2tqAbt/MUD7x6D8Knghj0iDEKxxxIPvFQd31rlJ9cu7+5eKDclsDgnPLHNAHoo0XSxIqQLGXxluwx2qlqXgqwlkbmNGb+GMjjvXOPfNZ26i3u3+0FcN/n15rOi1fVbYx/vGk3fMGfjA9aAN5fCt1bJmyuAQr52Pxk/4VBB9tgR4r23fO/rjgjtRaeLmtnb7bu8wLkD+Gul/4SfT76wVYijTFRsyRwcelAHP3LQSiNZYkIUZC46YGeax7rTLS7u8wybbhvmwf4fX6dqbqdxCt3hCF3clwcE+orkdd1N9IaW4lLyeW3ySLkHB7UAdza+E5VQ3AlMqr91A3A9a5XU7ia2vZYSsuxCCDuwMdOn+elb/wt+Jlrqdw+nXcQQbMhyOmPaovGhE+ukQorRSLwoONtAHOHXZnjiRJ/wB6fmyB19qo3njFLJhFd3OyYNhgAWIH0HSqnie9Tw/pEUtuoF5M7Rw7xyoH3nx+OPxry6WR5ZGklZnkY5ZmOSTQB6nf/EKzhbFrLcXAP91NoH/fXNVYviYqzZa2mMeMHkEn3rzOigD3jR/H2mXc0CLeDe5wyzApj8TxXSJrARoxIqhD1cNuGB/WvmOtTSNd1DSpN1rcNsP3o2O5W/A0AfShvVkJyVy/3T1+tWLZ7Z/LIAbZkbScHNedaFqjanoUV/CoQuzRsh5CuPT2qzpFw8VzEkk77mcEuBnPrigDt5LaN23KAm3OSRVaHTrVyrMGkfJ+b8apeIZUsVjdLoMMbljLhe3/ANejQNeW4gYXiLv3KE2nKgf1oAg1jQVmQvlUQuPkz29/yrKm0c20beSreWc/NjpjpXbXkkZISIoTIfl3HkA+gpRbR7UPYE8HueOTQB53dB5rVrbVYBcQMM4YZK/4VxuteB2dWuNAkNygG54D99B7djXtWo6ZBeIxLBDJ8oRfpXKXNlPp05khzEFG045B/wATQB4Q6sjFXUqw4IIwRTa9f1fQrHxJEVZBbakMhJR/Gf8AaH5c15frOk3mjXr2moRGOVfxBHqDQBQooooAKKKKACiiigAooooAKKKKACiiigApyKXdVQEsxwAO5pY0aWRUjUs7HAUDkmu60jRjojRGSFbjVJhhV6iD6HpmgBNG0NNGhFxfRxz6i65ihzkQ+hPYmu28PeGbi/Au9VYu5xjdwy47VoeGfDgjY3V8pkd8NsJyD7jtXXFZJI/LhUg4Iww6gelAEEFusC+Xbxfujjfntz/n9Kt2ttKzFSjMxPyk9x2q/pVgbgjCEKD+YHauqjtIbaDdGMHbyD0z+NAHLf8ACPyXcqh5TGRkDB6g1pab4bt7WJCCLhkbv3HpW3L1QupGQMuvGD/QUxkcO8sTq2373GD170AMtkij+UBY2DZOFxjHbNJdKAEVSRhfXI+oqaYHczKDhU4Yc5HvUUxP2dBlcE5GM9uO9AFCdiI3J2lMDGDg4PFc5eMgk+8zrt5JXpjqDXQXiLAjCRCEzkleqn6VzF5LJ9q3J8yHPAHYUAZouvNlZG5GMEg4wQfSs3V70RQ7YnV4WwQ3ofWr08UJcsyloweWHXHrTobcNIiSRRSwudwx6fT2oAwtHurmOQyzMw3sSAe/riofGMKaz4cvY9CuYJLoRfvYY5RvYA/MMVu+LdCGp+F5bLS5jb3oA2SLkBvVSe1eJ2Hg3xKt4Ggt3glVwDJ5oUrz14PTvQByrKVYqwIYHBB4INNr3DxD8N7W8itpHmZdQaNRNLGOJH7sQe9c1d/DAwtCqakCZOBuj/wNAHmlFeqL8IbhpVQapCR/Edv3a1tK+Ddo7LJe6rM8I+8sUYBP0OaAGfD7w1b6/wDD37DqG5RPK8kDJjcrDvz/ACrHvvg3rccg+w3dncRnHLsYz+XNe7aZo2nafZWtrpaGO1t1B8t/vD3zU8Z3YIw3pigD5xk+FHiWP7yWee377/61C/CnxK0zRiO03KMk+dx/KvdphFcX0VxBKySQg70J+Vvw/SryyxPEWc44weB8pP8AjmgDzfwP4L1/w2AZb628vORFnIB9jXoo1GW3t2FyqeevysYuQR/jUE8AeL+FkAyMtzx2+uKymVVaV4pZSGxnjPPY0AM8RyyXzypHlIThtg4YVlRpb6fEVgX5+oaQdM9ia2pLkkxrGNxI2ltuee4rD1DdiRWUBhlickEYPSgBkM8cSSNO6O7NvYE42n+tWYtUs2GZTvZV+9jhc96xnsnu0bYW3rnAGcN75rN060mS4MEkXkpnkE8n+vpQB0urxhwBEPvjd5jdhXNRW8xvYj5jpluWQ9c1v28Uyp5Tkk/eU4PTsBT49NfYrqu1lOSoySaAM2y0DU3lDXd8htGfjI5IOOCa6fUfClnfaetsZjOzoRuQfl+VTWlu3kAqsjPJwiseB/hXdeGNPj0+IT3zL56YG0DhPce9AHkPhv4JaxpWqxX81/Atiq727PjrgitG6tTcT3MhJMcDYDLxntmvQvEfiKG6t3hsw3lqGV26NnHU1xdkIDps02/J37M9AwHtQB4j8SmlXW4LeQnZFbqVGc9ckn8a5GvU/jrp8cV9pF/AgEc8BiLDplCMD9a8soAKKKKACiipLeGS4njhgRnlchVVRySaAOq8BazqMep2OlQsZLCS4DSQ7RjngtnrwK6rx5f3Hh2zEVkds00hXzepC4zx+dbuh2Gn+GdAgSWKJ7tRmd1X5ixGSufavM/iBr82uasqupjgtl2RpjHXkk/XigDnbu7uLyTzLueWZ/WRi3862fC3ia60K5yC0ts3DRE9Pcehrn6KANqbxNqr6gbuO8mRg2VGeAOwr1XwN44fXwtpeMsd+o4CnasnvXiFT2V1LZ3UdxbuUljYMp96APqlnYFYkA3le3AFNcQviO6Xe/QdgD6/0rJ8Fa5b+INEhuYwxvSoWQddpHXpWre2gJV3LNKTkJjGBn9OtAGBquk4m861B3LjGeAOPTua5zUdNi1u2ew1g7Jc4huGxuVs8fh7V6HZzA7Y9gLAHkjge9Y3iXQt05uId5kVt3A5z6j/ABoA+fNf0e60PU5bK9XDoflbHDr2IrNr2zxNoB8TaQLf5f7dtVZ4ueZEHVPrXisiNHIyOCrqSCD1BoAbRRRQAUUUUAFFFFABRRRQAU+NGlkVI1LOxwFA5JpoGTgda7nw/ph0Xy5ZYw+qzAbIyP8AUqe/+9QBJouktokkQ8pZ9UmG3IORb57D/ar0rwn4cFmy3V+Ge7zna47f5NN8KeGzZD7XexF3k5XcclehrrIjIGHy5Ug5B5xQAqFDK3yFeckDHHvWppFi9zIHx8nrUVjp8lzcYSIlAoZnXnPWuxsYY7RFSOPKj14znrQA228qECLARgQD3zVmRNyuhBZRydvt3ptzBHK25SQPQHFPtUJgd5dwaMgAg9T60AVj5gG+JhNFxlep57HvTpoYWKhG8tmOGUHAolmiimU7Gb1ONuf8ahLGbzESTJ+8hIwc57UAOcuGZMDyyhCYOeRTC4jRCYw6oMMjDkH/AOvSu7MHidR5g5Ur3OOv1qMzlVVZE3uoPyseT749v60AZmtXB8p1jhZi2AVB7e1cxIiMwmjYsyZ+U8EjBH+NamrTxq0hJc4O4FeTnH6VRie4dY2+zo+9cZz79TQBQeBmD7xlyMgAdeeat6dD9nmjkYFEKY5FXo4d0arhty5GHOQfWnmRtqRiPGflIY9vb1oArPbEAg7dhJBPTH1qgbVPOCgbyOO2VJ71vSvtAeWJ3iyQWU8jjuO9Upo4zJILZWJfrkYwPUelAFUECdA3z27ryWGGRumRS3MNuJAuwMiDgnkc9abdu6+TGhZw5IEvcY9fyqSRpFMkMcik43BT0/OgCMiTkRjgEdemP88VaSaOJg8g2sowABgfUmoEDF/3DqJOjp3Ix+tRvdksVmHy9MMPmH1oA1dMnLXMyHzCGXqR7dB61ZSNEtFCjaQfnxkn6gVzOj3Ek187q2FC7ctwp61t3EhXTnILCRBw27IPuKAMQXyzzOiIHEbFSNuM9xUz42gz4jfIJH94fTvWA8l4jYjXaXfIfPI9c1NcPdZxKpQnktg9KALZvnXci5d93yBuwHrSW9wZo23keduxsAxn3I71gy3E0loyKV83eXJ7MO+DUFrJMIWnhSQTL/EDnn0oA62Pejo3yAnAKqRkc9KnFgLzczLtkXoXwQfQVz2n6sFn8q5ZVkGNxZPun2+ldRbTmeNgHjSJR/3170AUv7GNg4KSE5PATA2jvipb+yBh8+OFBP2IHzMKlWZZQIsLI4B2sOjAnt606OZkfy4S8YB2yBv4l7gUAY3lLM58mRg7MFPsQP5VKrLaqfKYNnnJGAvsKfcofOJsmbyVO7p0HfNbOl6HeagWNsgWBhjc3XAPIGaAIPC0Za8bzJDkDdgDg+2aveMtaOn28NsAdsmHztxn1z3/AP1VNb+HNQ0G4kuWAkgIy+P4eeadffZdUx5yCSRV4GOB7j8KAPPYvEDzXTpIFjLnDHPXPpWksaQiGydmMbAyNsHA5qpe29ja6lA0SBnjbIUjAOPWp725KHzI9ot3GQ2BleelAHM+MbCXXdHn01Bgwyedbu33c4wRn3zXD2Hwy165K+b9lt1PQySdfyr1NPO1O3eS1BQp1Lg4H4VoSXjR2glEfnyQgA7T0/2gKAPPLX4J6rIw87U7KNeNxAJxWpH8DgxIGsF8Ln5Yu/416hZXJdFHLZX5QeDS+fK5MPmxgDDFt2Dn04oA8S1L4P6lbzEW19byxHoWBU13HhP4e2mgJB0uNTkGZJmGBH7Cu6eQgebGu8lSMk4AxVeB2kuWEuXTg7UPX60ATxaPZAb1jjlYKWO5c4PQ1zHiXwdo9/Ikl1YRSzMwC+X8pP1IrrCH+yKtuiLKznvnaPenyJDEI5X3STqp+Zf4T/h1oA4y78F6XD/Z0enaBZKjuwuZJVywT2ra1L4a+GtT0kxtpqRSiIiOWD5WHH69q37dWuGXfuUBcjPpmtKWSOKZs7hHtzgn5ie2B2oA+SPFPgfVtCvHX7PJcWpb93NGN3GeNwHQ1z0mn3kblHtJ1YcYMZr6xmhaWacAbQnzk9sZqAWe5tzQiTewwgGM8dSfSgDhvgz4c1PTNCur6+R4FnkXyYiPmIxyfau0EgkuQMbiF5bOQPpWpdypZ6cPNfeQMKo4A6d6ggjE6wsGVVK/Px09KAIFgCxxCFsFnOe/4e1XUjchljwiZKk4yTT4bdoERUj+QZAc+/U96sx4Mrjaznb8u0cfX60Acb4j0eWLZf6a7efGc5U9a81+I/hlNQtpdf0hB5sX/IQgQD5T/wA9AB29a+ixZwtF9lLb5SOVToB6Z/8A1Vxet6S/h6+e4hjDWkhInTqNp7HnmgD5WorrviF4WOg34ubMGTSboloJADhD3Q+4/lXI0AFFFFABRRRQAUUVq+HNOTUdRVZ8i1iHmTMDghR2/HpQBq+GNO+ywjVLyEsWyLWNh94/3/oK9T8J6G0jDVrr5pnXOyRc/wD1qyvC2mjVb1ZZMLZwjCoQflA6CvQYnzIiCMbU/uf40ASjzZXjxuTA5BHU1oaVC11KsTFlccO38JH1qJRuulggYmWT7hH8P1rstIsxZWMSearSbtr5PU0AWLO0/s5AIm/djjIPAx/npU25dm5wgc9XXgEdqjS4FvK4PmKpyCrjgnv70iGN48ogGSBjA5oAfIvB3q2QpYMBjj2NPM0rQCMOjHPyk8ZFQIWQSPETlePLPb/61PjC+WoaIqGPzAHt/n+dADEKAgF2Lp1z/npUCxLJI+wRgg8uh6cdxU7ABwdjMoJ2uCSwGehFN27FGVjO75SvTd6H2NADYC8qMJRHJgdRwSc8fSsvVJpFXbETvI/jPI9q09gWQeWC5AyCH6+x9qwry5eN2kTAKfLj1GaAMIXhnlX7Tam3Zsj5W3fSpI1VoGwVVlP3Twce35UkUP2m9e5DBolXaVTBwev4H+dSQLLKke/y0lXseDxQBFfG4mthFaAxK7bS4blfpUgt5rOCEeYZwvG98ZHvUuJNzyyKREx25xkZ9/pQ0Z3gskhYgEkHoaALUMxjtnjkCSJt3HHUE1TKldwaPHQDach888Go55Jx5P2ZkboCXGNgpVYJOylYwjnBAbgn1oASYsSwZcuo4PTI9TUJgjKEwyFJN4yueFH0qWeTdu83/XJnA6H/APVWSL6MozIzKycmHHI7flQBNdTxvcEAo23oY2wfxqhe7JVy80qS92Dcmq62MzM9zHIrhskseDn0qGO3vbxgFVck8yL/ACxQBJp13JBfbmd2tg21wOfxruZ2BiYwSfu3j2srKWwcd6xk8PSmA/a/JG5R8gGCD68VYSV9PjVZ4y8KJlgD/OgCosB3RMrGSMDPTGP8mmyRxIW+0TJlxjLjgVpWet2kuFkVUCjOB1I9PrVQTpqF2ApiZEG4FiAV9vegDINlLE8ctvbrJAjcA8c+orZ0n7JdsyNbOLiP70igAHv/AJNdGHhktEgZo0KAFiTgDPb+dc9qltb2V401rcbBIcb1OQec4x+VADtY8NQXiPcW42yKNwyfvAdRjvWDIZdOuIvtcYWDGOcnntzXTWeoxRzpE9xGX+7gg/rWvqVra6jp6JOiPIWwXU8Y7UAcZot5bSMwkQhl4iz1HutaaI0u5A2xgDhwvQfX+tUotISy8+OQGMxsSkg+YqPT/PrU2mjVpfmWNAmMrg5J9z2oAcVjjZ8syqxAdRwrfjXd+FNVjCi3kgZWZcIADtIz1rhhHDbXCfbW8x9wKjd0J9q9T0Wxgjs0dsLG6nIPJJ9qAJ9WvrSOznMsqt38s/TGD7V5RKHilmNqCvmZYbumD2FaHxg2aXJDJaXBjk2/ODzgdq5e4ubvV0gSAI0ccQEjL0bHQ/SgDG1FTI+5lJm343g8ClsvPa4WFQPQlxw3p/Kpr8iHciW7Yb5WBB5PrV/wtYzNqkBu1ZUJBBJ6e9AGzHpAtbBpyWUzAK6D5QB65FcZeLcWVyTbEPAWJ+Q5Yj/Ir1Dx1dW8GiPECjyEg72HAPTgVxfg3TprmaU3iZxgnD9QfSgCKz1JxZGd4XQNn5sdBjpmtCG8tkhj+bbI2PkA5P1q7rdkbLMdrIq2pwSHGSnpXETanJZebtaORnB2nk/SgDumukZTFuVeNwVASTSw+V9mlcB+CVOzjJ9K4XQL55FlkupAhdgu1Dgt9TXe6ege2fayqmwE7l5//XQBLDcGW0QzqsJZcbRyR6f1qa3SN92N7QJ8qllIDt34qtBMocxxhSyngdS3qfatAozyKkxMSK2SB3wOtADrWZmnPlxgEkp7cd6SWZY18151eVTjCrxmmvKjhRGpCZO1UXOT7mkliUM65OCMEZ6etAENuzXRdVnBgOSMHrjqOKrWl4l1B5seYoFbGWGCwGadZQQ2UDJBtW3HOwc8nrmqd9F5m22AEcIO9lVuT19KAINVuUuI4Gtm34LZMgyD+FaOih90onkjMigMAuDgjNZVxDFCmyM7lj+VFQ9B6n86t6IViYGTy1HHyqSxb60AdMriR0TJlcpu2jnB6dP61YtogIyLiQYcYCKv59OlUbOVoZCUONw55xn8a0dNmQSRK6ks3TPzEe9AHS6HpfnOPs8IAbgluMD2H41p6v4NS/sZLLhvNOHdlwoHt/hWv4SKT25nCFey5GM8cn3roaAPkT42eC77wTpkNmGF9omov5bSsnMD9uOx9K+dNY0240nUJbO7XEiHqOjDsR7Gvvj9oy+03T/hhfTaqy8SIYI88vIDwB+tfCXiS/utYlh1G6QL5gMabemF/wD10AY1FFFABRRRQAV6TpWnG00y10yJd09yRJcleSCRwvvge/euV8Haf9s1Mzuu6C0Xzn6ckdB+f8q9Y8CabJc3U17dEEHkAH8qAOl06zjsdNEVrtaTADAk/N9PerX2kaZZNM8eXJIC8ZJP/wCurpiWQGXaCpIAbdnn+lM0W3TWNfErjdZWx2rhR8x9ffrQB0fhHTpLe3F3cRI88v30YfdHtXQh4i5GwKRz0HGP8KXKLwgbCttAHGaaTDcnlGEgHPb8f1oAmYSAEoY8EcZ65zUUa4lYgqC2Cy9xS7MJ5Z3nj5WBxt+tT2Vq80+24G8KoAOAN2eeaAKwdzDuxGycgqw5HP8Ank01g/n+b5RDxrgc4PPpU13GLabbFGxBJZcDIBx/Kq7NwHB27gS3P3iO1ADdoMm6ORlJ/vd29Ke4xD5k8WcDkR9QT3x3ogYLlmc7d2Bzkc80oWAurJKFXkt2OfT6UAVrhEHyhWGOpBOTxnpWJe4lPyzuyEHd2Ckf5Nbkksqg7yZAo4kB6HjAzXP6jbhsJLJ5ZYhyQcE0AURHG0KGIoztknauM+34Uon3Rxh2Ydyccr2FRTRNGu35gwXI+bn25pzySCbP7wEqMEKDv45HvQAQu372NMupBUqM+3NS2jBkigUkMcq5YcH3zUVk07CeWSVZFO4A4wU/2f5VbTy5dhkCrOflIcYGe2R/WgDJtdTs726khjZA8D+U5WratsUFFEixMflC4I9xVHS9Ht9Oub14o4xLM26ReoYH/wDXWlEqoQv+kg9jjp7ZoAWfE8aSwLuCnBUjqPT8Kx7eCZtdT7NCqrMduXXhPxrTkURyjYGVkPLA8MfetHQY2+0zyEIm/DIWGcA+34UAaCaJp/kbZYwFHOMYO4c9KeY7W2IktDb5IBGVPHquO1O8RTXEGm+ajqJDwNh3jPY49a86vb28uFCXMu0SHll4NAHbSalHOHVPJDZ69x6jNULmdILVo28kxsMcHcQTz6Vx9ppoDGSJ5JIjy7EY4z6VfgitFdWuLlwrEYDcY+v6UAVJbWSa5byY0K/3gMBfpUsGmzRQmaPcs6/fLY6Z4xWnda3p+n5AnEkh6eWMn8qmsbxNR2EKPLx90cDntQBzssmoQsImkV1HzH2BrRtIJL5Y0wI4w2QyDIY45612VtpdhEE8zbI7AjDHhc9MeopG0aFm2WZVSRyMn5frQBkxaaioxTEvl4DPkYb1pLeX7BcI8AO3cfMiz8uM9vet/TNKdpXErQKucKwOM+5H9Klv9HtxB8ki5b5lKdCe/wCNAFKOS2MTTTFfLkGMH5iue/1p2mz2STm0D7kRfldOCx7cVnRRBRKrEYYADHH41Bc2EsdvLNHJGkg5QE8njjNAB4w02Se4t540KpvUusYIJ59a9FtL2WG2ihhUAKgB3DC59K4nStWE0aWt67qyMA3mHnPqPWukIU2AYHzuDsZn2hiPWgDj/G9rJrOoMPNyMHcQo5/CsSx0ufThKsbNtkxjpk1tw+ZO0nzOpUneBzt9Oe4q/Zac9xE2yURRqOWPc0AchdyxIXfzM46g8tn04qPTr6OLUfOuo5EjCbVA4J98Vp6/4XurNprqzlywHmElsAc8kCuWl1FptNlk3sZouGyM5464oA0PEeptq0iW0CskUfILYJKiu1+HNjJaWJubxck8j5ei/WvOfhtcwXXitJdUctbbDtBXqfcCvYPF2tWkWii0sUUyn5VUdxQBwmuO97rV26OwtmOMk4DY7Vx2rWAjt52upQpYjYi9/c+1dTODLbeeMCSIZEWPlyayNWtJdQlglRzEFwGTGC2PSgDn7UtbWplgQO7D5Wc4GPUV13gnV5LtLhJf38h4DlsqB1rB1myLeTbW6ErGu4hjkc+voateD5TaTtBGpZywcqn3QKAO5S7aC7WKOE+ZsJDBcDH481osu1A7BjgEgA54+n1qvGZFXJG2Tb1H3hn+lTJkBgGMhQAbs/d/xOaAIoLuX7W9vMq2wCs2xznch/iB7/TtTpyklmVRn2KNwG35nb/Codagt47N5rl3CxrvDqMbT22n1OQMd65e18QT3GqI10IlhkXyioXCj/a/MfzrnnXVKSjLqezhspq4+lKvh1ZRWq80vs979un3HRTxTMkcYk4x8yKOcduax9TDRyLLtYbicKBk7a6eV0WPfu3NjLEDAHtisSJ4bjVZpbqZ/IhH3cYC59a6DxjMt0V1MUaEvuAVa2tPtlidQSrOSOmTzjt+dd1aeHrRtME1rGsTOgYEkfJ71ylnpUo1VreRvLjVsmUt+XWgDVsbSSeTCM2Wj/hHP0rbtdGFs43oXfgKinlz6c1o6NZLb+XHaMJJvuAIMk+pPt712GhaEtixuLphcXjfxkcIPRf8aALGgWD2NiBcbftDnc+3+H2zWkzBVLMQFAySeABS1wXxH8QJDbnTYpggkBEzA4Yj+6P60AeKfF++l+IXi1InP/Eh0xj9mjHPmv0MhH5ge1eNeLNNKeFryFIkU2N3uABBOw/y5r2l2EtyxhR1jVcD5OmP6V5xrVqLubX7Npcb7Uy7VHJKjd/SgDxaiiigAooq5pFm+oana2kYJaaQJx6d/wBKAOv0OzNrpNjbqri4v38x9nDBOij6d69r0a1hs9Lt0RkJIGBjBH41wfhuxj1DxIzpujithsjyh4x0HpXp8UTZUlhuC7gDjDUAU9cu47ey/csvmudqoT90kD8a67wnpb6ZpMUe4LKwDyMBkOTXB6RFJrXi+BcAQW5LMMZB9v0r1MxlVA3BQvRs8flQBJyGfawAY5wFyM9D0piyMFyyZ3cFlz8v4UNGMvtnwQcgAk5PfikRCru4HJPPJ/ljmgBABCDGsrAHkrtyCKktJ5LaTMB2gMRhjweeMVC0uNsjIytnB4I4qe5yscDIVKyHgkH/AD1oAgupJZLhmuyvzZ5ABA+lMcSGBliCyIWzkDkevFPQvGQpUhASADzk9qUQsVUABCCcZfBA9P50ADhUYLtIjcYznj8vWomhUSqEbcQ3KHg4/kaSdSImMjNuVyFLD7wPQZqTzygIZt2BgqeCD9aAI7gP5hCxPGoHI24B+tY17GyJmKQswGFR+h/GtwOG+ZXkAXBZS/8AKsq8EkbyGIwpvJ2oW4J6+lAGJcCV1b73Az93O0/X0qAebb581jNb8E/LjaPUVJblrcGDGC5wwZyw5qaNUz5Xm7CrHBA+6O9ACxQbpH8h4hvbiMjGeOvNIsgMEgnZEc9WKc4/z/KpmYNM8RkSZMfKR1aqkUeH2xNhidjLIc4/E0APEPlxtJIQZNvDqeT7/rSRsp+dmcsBypGT9Qe1Ryr9jZjgiTORs+YHNWTLIIUdUYbiCD069QR3oArGS3cAopZW5wTj8Kdomqw6fqLeYXMUnyA4yEPUBainulXzFjLbhkhNucZH+eKpNF9osBFbiMuSCSuSwINAHT380csBZZVU/dcL19siuc1eKDyzDA7s0gDFQBnPcio4VvbRljaR/LI9AAnua09BC31yZtwOxtqNJj5TnqPWgCnpYvJIREts7Rr0ydpPua0pfDcN2AL0s4IyNvGw/X0ropkiZRhg4XkEAgg1Wki8tmmVg5wMFuOx7fSgDnP+ETsIA/2VCdx3HJyR7g+lXbOwht4CbYKXX7x6YNaix70EsQKyA8BvT0HtULRCJvmt2RWXfk+vpwaAIILXcyBvMeEYHX7p/wAmpPKKB0tQ6I2WLs5J+vvUsbSLsAVg33sBsjBqNpvL4DIV2lRAB0980AJateISkTgKDlvm+Zx6g1tS2dxcWrQ3BIz9wDuPX61V0mJGkEiiNg2AzBc4474rom3jAEuIwvDlMEfSgDidR0mSwkZwtwYWx3HH4f56VUneSa0k+zJExY8sDlgB7V1HiGdRpjLJKhwdoDE5/wAawoJTpu0bVkgJ5dFw2SMkZoAzU05jb+ZdP5Fxk7CBw31P0roPDcStp3l3E2HJJzu4A9vSo1kiuIPMymzJVSG5X/gP5U5U/dKJMsob7i8MB/k0AMu5IdPMsSMrMCGVg3J9jVO+1C7lhEluFLOMMOTn8KbeKzFpA7Ls+XGeBzTF/eHzVwoHX5uuP6UAUJDeT2zvK/DjB5++P7uKxP7Fewup3kH7mZeN2M/Q4rtUhW6bzPs0Dc43Akj8qkFlPPCySQqyICAx4BA7AUAeVQW8ml3KyxRgRZ+bK4C59B3qa2uLl9SVpSWj5G589K9AOkw3kZBIVB1kbk8dsVjanpE0Mqso86NF3sg6j6j1oAxP7Whiu5FtdznJGIxke5JNT/aYLu6ihcopbnPQL7cdaz3ijmkNvbwSZcHI2lSvcGpoNJliRFcFWizgAZGKANHVtPKRI0zLFHjGE/j9M461gmMKBHFIDgkHaOfbJq9JBOqEPcpHEvPAJxmls7UCJ1SN5Fxu80Hgfh3oAsaZqlza2iRTqX3HBkJ6gV0ekapBdbowGyD0U4Vf/r1i29mUhHl4aZu7rwq5prReTIzLE7sSMknao/r60AdNOYb4fZpY/OTBLbiCAPUelc3qHhwFPNsCygniOT+eew+v51Pp94qW1wYfKyAc54/WkimuL5SgleTaMYHC8dgKyqUYVfiR6GBzXFYB3oTsu26+7+mL/aksdlHFNGwnjXyjg/eP9ar6JZtPebbrMpklBIYAjH/1quWOnLdXLtcNIEXDKqrtGa6DRdDaKWW4lHlwEfJCp+d2/KtIqyscdaoqtSU0rXd7LZeh6JPNFbaRgEExIAgHHP8AKqWgeGJ9SuvPvA4PUkngD0+ta+g+Gbi+SOfVlEFsCGS2XIZsdC3p9K7mNEiQJGoVF6ADAFMzK2nada6dEEtYlTjkgcmrZOBk9Kr317bWFs9xezxwQJyXc4Arxnxr8U3upprLSbeRLNSQZzwZB0/AdaAO08YeNIbVjY6XMHuP+WkiHOznoPevJb6ZZZHEpbeVLNubJOfYU+1M9zbJLGY1DrkgnAzn/wDV3pBbiJyss6sepWIFs/h0oAqxQ+b95jsYEAE4Gfp1ri7uGGHxb5W35Jl2tgZBz7da9BQRb14/eBjyzDOT9K5DxczQa5a3MRXauAxHUEdPegD5y1GA21/cwMpQxyMhUjGMHFFdL8VLH7F41vmDbo7nbcIwBAIYZooA5Gup8AQE6jdXgYD7LAzDIz8x4H9a5avQvCEH2XwhPOWXfe3AjUAjOF9fxoA9G+H1u0enTXEnLO2SVB5/CurfyktzIzsofnKn7vufSs/w9BHbaXaQtydnPqRUuvv9ls2eHayhMYGMHPTg0AXfhhbAnUNRXfiWXCsvHTvnpXoMWHVgzq+McY/yKwPBdl9j8O2gSNYppF3keoz3rb3oqgkiFxlMxgHP1oASUQkBmchW5wO59aFYEgeZuRvlwevT1pqOBbqhZGbsNpwaSD96BtWLcpz6GgB1vIJIjHI25zkLnPH4/nUtwkksKCMsQmTjHb1+tMK3LM6bFwezYPPtSKXZlZGdHY4AY/L7igCIMWUK7MzE7sDqOP8APFNeO5WIqSsyZyCc7xVmSCU25adCi8MGB3fn6VFscZDeZIB8ww3ykUATTSAwAptZXxkNgY+hqFdyghgqOR95zndSRRpNCN0cokzh23DrUiwskqFSWVc9Tx0oAjMigKQI3K/L8nOGqreRMylUSF1Ay2UxyatkqzSGIMGBySnIb3NV50WQHzCzo3X+En6UAYNwfJciWNlIPBA3YB75qjul2KwdB8xH3c59DUt2331UvuxwrtwQPQ1lLJFJKIS0isW/j4z7ZoAvQzC5uy80ZLBg2Ym6n6fSrV00Dzq8UcpLk8MAFPbiqFrHsZjErb1ODt+bH41oRhZgJViKMv3iASD7igCmYpYpZPLSRnGDtLA7Tmrlxue0QuAjAZIY8t7j/CojLgyLFgknBfG0n8P61DqbRpYjICyou1hjse9AGWPKSJ5UMiMzFBlu/tVjTMxRlFl3P1bHGM81m6N5knnhZlYA4IPPP+HNbEjw2luS/wC6kYYYHnB9QKALhaWTAhjLAjJLn5QfbNJp4YXMm1Y4QPm2bSQ/vWZJqk5iMTBdpGFbHC4pugam73WV3An+M8jH07UAdzaXEc5bhlZMsMH5c9MVDf3EkCtJcRow4+YsFBz9aoNPjy1RwhPzEoww3Pp2qh4hmklRo5ImwoA2bc7iOpoAsRahiVHXczH5dgbK9fWrRuNkEk1yUJPbrs9v1rmNCspZJEkZ3t4mGGVvl3H0xXQSwlbc+SrGFflkRSW3dc9OtAFCG8nWfEN25jY8tGAc56D6VtxrMloN/wA0IGCeM55x79eaz7O08pjNb2j7lGVCYwK1FgZ2iYAgkgkscFfr2NADLK6i07VIyFlVJQBkDapP/wCquov9Utba2hdJyLZFL4l+YD6GuV1WdGbaw8ySN8JKW3Rj/wCvVLUNQN3pF1azyLICP3bBeB70ATwanL4nuZZLdU+zo2AMdQOmc1LrenzjSQi+aV52heAfWuc8Ij7FBsljZoy5wx+VseuB/Ouhv9cYWEoeRlTYQB1YetAHI+FvKluX+yEu8f30ZiSfau+8hmgiQxxN5nOYz0NeM6XcyWeoebCkkas5GQ3Dex9K9isbtZLSG4DqBsGACMj8qAKcSyeY8Eir5hzhn6/5/nWYkctrKGLL5jH5iy/Lj0x61e1RXE7TtGzR52F24LH8Kqf2jI3yWqR7EXDqw/XNAGjA8ahOiknCsD7enpVm0mjglUSSC5YLh1c8c1z8cyC3Z5WjNw2VPzcA/U1d0mJmaOK1Q3EmQvkwYJB9zQB1WpaNLHpsd/pqieMZ8zYMiL1z71gWrzJC7rG/lM2CzdW9R9K9y0LTxpulQWxALBcvgcFj1riPHn2VJpYLUNGxG6QKMAk9cfh6UAcBJpy3S/Z2SKN3OWfo34kGs5tBktX2wTmSHofMyFGfSpp3vEn8trOMKM7QWzt+p9frWvpckv2FchSjHoT09wDQBhz2cS27sIY4nHysT2x3561BLZouBBcMxxnpgfQDv3rpLuzmlh321qHkUACRjyx9KwLjTdYZtl5iLjO1B82PrQBUuC8UUm0gyIm4gjrWKLGWYrJcb98hBILkHp3FddBYSQWwW5xB8uSCdzt9T2q3aQgH90sQjXgyuR8w9vWgDmrfQmYFvLKgHG5xweeK2LPRrhsxIQqKQXKkAfSum0m0l1K4EdhDNdtuwJSm2NfU5rtdI8DQ+aZ9YbzmOCIEYhFoA5LwzpE80jJpdgXkz811L/qlHoD3PNek6BoEOlp5ku2e9b78pHf29BWtbwxW8SxQRrHGowFUYAqO7vLezUNcSqmegJ5P0FAFiqeq3y6faPMyM5AOFUdasxSiSISAMqnn5hg1yHjPUhPbCC3lYLk7ivegDyzx1qlxrl8r6hcSmBATHbLwiE9Dg/zNcoYIXjljeJRgjDDGR6E9s1pa/dPJOYFwC6kruIycd/TtWFDdzRbt52xsNu5R1oAs+HNQuINaktbyQlGyiFsBV/zmupMW23yVVncHI24Gc/rXOxy/a7iKSCN1VWBLLwSfrXYmKM25O0blU9OxxQBgWswY7VRWKtyxx+Q965vxzHH5SF9n+sJJroIohErqxCk/Njb/AJxWT4liaTTt6KxTGS4UcemDQB5v8VbRdS8K6Vq0Efz2Z+zztnna33Sfx/nRXQwWT6j4V8QWrkyMbd2QcY3DoeP60UAeC16lptsIdO8O2qKcSRiZhjuxyc15eil3VUBLMcADua9x0tlfxhbwE7Ps0SIFY7QCFHc0AegRxqZIlRl27MKrDBz+VZfiGLz7q1gVPLkeRMFW4bp1raiYRznDKcAZDYYdPaq8UBu/FVlF8uyM78rgjp6UAd7arstYU4JUZG3tUy3LM7ABXi2jGFAb6+9Ku/ABEau3+1j/AD3qGUARSCQhmHQgAHmgBzO6/K6F41fK/Nkg1NbTbG3+SSoJJIxn8RVdQpwIZMPgY4wD/j3oQF5C7htpU4aI46euaALryPI4BQPuIGQdpHNV8OH2jaG+8Q/JX6VEMO6bp95A+UbajiSdl8yMsR39uaALNzOZoFTavlqcblb3qHZIkJJ7HaDvwR+GfpUFzLKdr8x7HCnvn6VNCWkkYecgYjuOGPpQArgk7XmVZRyCwxn2B/OokiAclSCd2doft9atPGIgBNIrohAK45HtUEjxMdqq6BuAVXggdzQAMkUZ2ymUKBkFiMfpUEoPlsJN5AyAMZBHtzVks0wcAEqepHPT0HvVa+jMcJdbp48DGXQkD6UAcnqEkjPiGdosHb25PtTLaOZlYN5UipyCU5P/ANfrTbp3mI2ssylskmlKyRXKsMGM8lSe3qCKALlu1vDIymNkBbcSSc5+lSgo7bUkZVVTkRnFVBcRYYblQrjcGBO7PqalWRnwY2jWJcY+Y80ANuGj8tmeYBB0AXJrJe7M0zrBGPLP3VkGK22e6LM0CxPtwGKqMH2yaw9caZ5dwlUxqR8vQj8R1HvQBLpKCEyh4kRQ+5Ci4OfTNR6hcTy3DtdEiQg53DoD6VDptx5EpVLpSHHzKQfl+hrT1SzkmSMwySvheePvZ757UAc9aW73jeSZJJVGQQB1HrWzZ6ZHbYQGQNgYz3weKmstH+xMJDLyCPmAyAferMMjm5kd17bVlC5H5etADVufJuFUMgRTmRZBxn2x9K3BOpVJJxEMLxgZUj0P+e9V7KBC7wyoJATuVmIH/wCs1KqSJIgjjCqD0dsKD2x60AJLNFJgTyrtPI+U7aiK28SefFMfkwTGrdMnoMVfijZrmSP5fKbJJdflNRTWkEStAkUajYdyxjduPrn0oAzzqgkZ1sxNJcYACoc7x9adcR65dbWEKwg4+RgCQB/kVe8OaOYj5+4goOIh/DWn9jMytJuKOc/OZNo59BQBy8On3ktwsM08EZVwTCRhOT1+tTzeHzLK2Lpgz4UhDhMfSs/WdQksZCFmhkC8BiPmbnABrW0SbUriJXe2aRMZG0ABj9PpQBSbwpLHJuF5NbBuN27c2B6H0qpqGiXQi/0K8eVweY3TBx9a7p/PhUzRR+U6p8xA3BfUYp9jd/2gfJuIRLOi7gzjBYewFAHkH2cQM1tMzpMfvNIowMen+NXvDeuRabcSWfkRzISRv34z7D0rvdf0OK/t2+0+VHc7flcr0AHQV5Hq3h25s9TX7RPG46kBsHBPr9KAPUkv4rqGRZgzBv4V4A4rFv40LmHTkJjH91sY74JNcdBq5somDSM5/wCWakZXH1FadtdT3tv/AKqHIXJfcRk+uPyoAZqgjRXeUnzTwUb5+PXjpXK+HfF2peFviNoGo3LOdON0sUsYGxWRvlz6cZzXX6bIl0DCxBaMne0f3iKmstAtNc1KIzWzvBE3yB84+vIoA+rQQwBUgg8gjvXFfEq0nS0XUYCPKhX96AhZvYjHNdD4cuBJpVtEylWjjCD0IAwMflR4iOri2iOhLbPN5g8xbjoU7496APG4vInUSPA7Aj7rDZkn1qzp0Ev20pFaNtHUkZBH9Bwa9W1Pw9a3yEpi3mONzxqD+lc0vgW+TVrm4GsFrWVQFg2bQp9eKAL/AIf0qRrUm5hWNScBI8Zwe9S+ItA8xIRYKyBT8xVN7Nz6muh020FlapCCGKjGQMZq1QB5Bc+FJZtWkNlBLLMMBiT8px3J6V12keBNPgKy6gouZcZKH7gNdjVe9vraxhMt3PHCg7sf6d6AJIIY7eNYreJI4h0VRgD8KJ54rdN08iRr6s2K868R/E21tzLBpihyPl85zjt1A/xrg9V8WXV1G013eSKuPkGcs3+HWgD07xH48s7UCDTmMsrNt8wD5VrnrG8nvbhrieT962doY7n/AMBXF6TI9y/mPbo6J8y8cD6+/Na8dyQyICkbN8rtg5+maANzxb8Q7Lw7pcraxKttHtA2Ftzt6CvGdO+OFv4g1xdOks/slnLlUkduc9vzrL/aH0G81OLT9RsN9ysAaOaNBkr6HHU15N4Z8J6reeIbG2nsbq3RpAWd4yu0DknmgD6I1mMwLJMuHZj5cfb5fbNZDxzzSqpQJFHydoHGB370+W5lEotjvYRjYoUbufXmrEJYooyQW+UgqBnHuO9AF7SZGF5bhchVXHYjPqc16FaW3nqkCKVZxkkDA/E/WuB0EFNQXYrFlYYwefbg16rbWU4ksEMZJlcfeIJxn27UAcx4u8Jz6HbLdv5YR3x97PPpXEauBJp9wJCxwuMZ6YHTFey/Ge4Eeg2sRPMk3TOOg9e1eH6tKZNOm2kbcEEplicdqAOb8JbE1Wa3+Zg8Lgjp2PFFR+FP3esW/nSFSwIC9cD+lFAHimgRedrmnx8fNcRjnp94V7d4OaGXxZqDStH8pKBTkjg+4ryDwLEs3i3TEc7V8zJOM4wCf6V7F4DR/wC2L4NtZnYlRjnr1zmgDuraGBQwSSOJjyU29s0nhyInxVPIJPMEMWcMuP5UqqrAKpQOMg8k5qx4OR49Tv3ecnYwRgQeR+FAHYSKqoDI7qCd2OuD9cUvWZ1VyOxGP5GhZzuRTwzdQVI4qOYefGMxbWHJxwx/TmgBMwtGGJkEitgsoxx6mlZ2Einy5WcDDMMY/GnBZRIHjKfvOCpGOfX+dR7H+ZTGwiZu3Y/4UAKk00eZHyUHBxjI/ChXVZw53rLjBB4DDp9KjxaFsKzg5OQec+nStDSbeK4lkaceYoACrnJJoArfJvKpuVBgkr0z1FQNMDM4RZcFdzEHjj3rV1G3SGNZkt3U4K7D1PpxWYbgtGsaDyip2lTx+tAEkCzukhjLbCMqzfNikkknjYllUg9MdKe5Bj/eyMF6bkPDf5xUDYjK5DBUOzc3zZ+vtigBRsdwx/d8DafpVHWBfw2rkSF0PVVIxz6Cr5bey8qibSAB90kex/Oue8SXKIAFjlEbDBGeh9aAMqZkaTy2hUOFILhsH6YFSpuRxvWOaPaOIjtbP4+1VYriEv8APvcBQoKL82PetFsq6Sx2+QnVQcFhigBEBkwBAWbom4Yx7GoWjuoHaPMRZgMxyAY/DFTRh52RSoTj5lZ6ndRGQluqIcZZnbKn/A0AZ/mSm4n82dRtPCR4H51UvZwFdYwWklbLbD09v5VpXVwfPUvJa25PRTgH86wb7EolBKB8fKF53fnQAM4MSxwwxomMMGwcjr1PerMV7exRhLefIwARtHp0x3rL068WV9l1KI0J+6q7vm+tbeoTiysnkMasVX5dx+Zh2yRQBDYtNc3scEpZ2GMqTgbe5x6V1VvauYvKtQvkAEguOlcJ4B1A6lqkrX0qzz7TtHKnjtXew3Nusrt5EybeCP4Sfz6UAJErQ7onihnYjd1xj8e1WooY0UByQpwxQDLKexB9KrQGN4m2RvHID8pKZB/GtB3jt4PlYszD5mOWPvQBJK4t4jIHm8wrt/eD5Qc8E1nLatOqyXDRIxYnHm9fQDHGPapZnN48ZZ38jHyoSSAe5NZs96sKlLGBDLJkNt+YqezY7UAaU2p2tuY4Y2aW4UcLjaFJ+npXF+I/El1b3areBktTyc8Ix4/GtsEwortP9qmdeVVSmSDyOfxrI8Y6aNUsB5cUQkQbgjkkAAcnP40AVfD9pb+JNbiaFFeFOSqghW9ya9Te28i3jhBeONQMYYcmvMfhMLmykuITJF5jE7T0wPxr0u7WcRiNkWXb950BOT7+negC1DaKXR5JxBjjIPzfQisHxLaNot2Li0lLxkb8jPT2roNANj9v3ziQ+VhsuM7iO2Kv/EwRvpCmKSKJox5ikrj5TigDA068tNTjSeG4jdmGCpyB7/yrnfFmnWV2si7EJZSGdF3EkdhXLCcpLFtlKO+RlCQnr93HH41cl1/yLQjLJIpGUHLHtn+VAHCa7obQW7Q6fA4VzzIzhQPYDvUNo72tuN9wYXAwcAbjjtiuxubKXWU8+CZoC/WR8sTngcdqwpfDz6XG0koMk5b5MruUn+nNAFzQXCRLBZoEEh3O55Y/nXo+gho4w0cs0oLYIUYAHT+leSWCXUeoG3XYsr/O7hsj6c8V6Pp13KsC+XLjcNhjVtoye5PegD0QX7xxIsjOpB2hi/ykexpsPje60yfZLH9vtT0KOMr9GPWuTCvGpUmN4yBmR2JA/A9aqXFqZyqDEqoflEZwB+AxQB7LYeLdIu4PMN0sJwMrLxg/Wte3vrW4UNBcwyAnA2uDz6V4BK5sVeYi3jGMEu3AA9s81P8ACzXbHVfH0NvDaqLdUciZlwrOBwB+PSgD6ArI8Q+IbDQI4mv5GDS5EaKMsxHoPxrXrxD41NHf+IrKT7Sxj0+JgsSHG526/oB+VAG3rHxHvmCGwsvs0R/ilG5v8O9cHJf6priCa/Exk3MF8w8sM9vaq1tJd3Sxkyl0H3U4xx29TWgTK5Cs4G0bf900AZg0uEs5WOOS4ySFTGBWe+iP9siMu8ydeRwvTvXUW0YjYPGqgRgZKrgt68VCitc3MrRhueQwbjHp6UAS2MLW1ugaVYwfuqoJ/E1ZcM4QShcLy56kflTgqxqzFpSYx8ufuk0399G7cxtuO35BnB/rQBE6xSSunkiJDyu7AAH0701YYmukflxGDtwvqOhqaRon3TSDMsY25kGPxxUUJluljjQhEVtwKjJPpQA230S2Z5pjGodshQ5x171V1e2ktSojt4xtHIX/AOvXQ29pbQRg4k3Kdpyc5PpmqWoxIkDyGIOOQzZyOPQUAc7pReO/WWVFVSQR3J7V9Babb2032G7iYFVhyMHpxzXzvArwXW4mXB+ZQrbRye9es+FdWkudFeyWUx+ScnuSpoAw/jBfRXn2XIZ40csDjtXmuomSXTWUxCNRztOMfjj8K7Tx4rvtCs7HOQGG3ArkZrdY7ViyAsVz82D+mcUAcJow2a3aqrjJkyQq+h6f/WoqzpfOuWyq7ERzYIGMH60UAeVfDpFk8aaYrNtBducf7Br1XwOI18RXMY3ZYleACB1/+vXkHgyUQ+KtLdhlfPVSPrx/WvVdDZYPGciCOVMuygEjB59KAPTreeRt8JiVlz2wM/iKd4FuFfVNY6p5cmNpJ9PQ1DBbNFdOY2AOQdp4P86k8IyNb+KtTUhz5gDYCjBx6UAdpE9yRtVl3NxkA/8A6qRIXUgtvEm7BOecUSBWZHkTYGJ524IP1pcFhmKTc6evQg9qAIzGquGmG4OevTFODgBFjYIMndzkD86dh3ZVZAqg55Yk/gaawgWRcqTnvnIoAUvbzbkmiG4924walhlETYt5VWQYwSeuPcdaY6lVk89UI67l9agj8xQxCbASM5XOMd6ALc1w9xIn2gESINxbd1qvNKwbZKFOMHgf41bgtjPA7zFHC9PmwfY1UnnWFxvVhk7QM/KfSgBAWjLFwyEc/JjA/Cpw+FJl3S4IwQOvpioZV/esX+TcMfI2fxOe1JtdUdWVWwMEO/yn8O1ADb9kt4RI0kXmDJw4xurz7WZZJbhmg/dmTtnKg+h9BWtrertMpt1QxiPKkqc89ufSuYFziUKG86U5wMZz/nNAGlZ3EpVRKI4yoG7B7+xrSWf52VVeR3UY28q2as6B4Vu79Ct8GW3HIG3BI9z2612Nl4b022t42hYkr95ByPwNAHJR6PdTRpDJDChYcKQQ2O1PvfDt66eRM/BXG0oQM16F9lAhWFVmZ9wxI6DIA7ZqYwQbkz5nukjcdO/86APENW8I6kwaSG4DeWMFW5B7c1xdza6hbXghumZdh+8vAUd/r3r6amt4MYDqCxI27ByPb9K4Dxt4ZOo3tr5KeXE0oDsTncB9OlAHF+GNLm1PUoWSN2tk4808YPqD36V6I+hWUqiKa3EgOQGzkfU1pWOnmytY7a2iZBEcBowMA1YOyJSbp24ORtXoaAPKvFmlt4Y1OHU7FiNmWKxxjhfaul8P69YaxY+cbgwyMPmW4TYQe31qfX9Ph1K5ge6kkFuGJVB8p5/pmqd3oWn3sqxQoVRcbcjI/E8YoA1X1S2sn2Ql7lpBiMo4AB/wp0dtPM6TTxNJ83K787fqO/4VmWlkLcBoRBAV+UrJ0P1PSsy/1iGLcF3yPGSGWE4wf8KAOh1e88vTHe2cNKGwVDDBb/d6isa0S5RfOaaNZioZixAJ9lrEtNZtoLic3wmnDLuQD+E+ua2vDtlq3iFlj0vTlnAPzTEbQucfxH8aALcDCaFFhglaQgnIySCf5VHqFtI1hLGu0fIRtfO7OK9M0H4dTwKjarqTSHGTHCuAD6Z71uTeBdDeExzxylDwR5pUZ/CgD5a8PLLHrjTu0siqRGyK2F3eo/OvUrHV54sxwwM4Izy4QY9Pf613c/wi8KkF0iuopBk71mOR+HSqV58J7WKItpt27SAcLOTz9GHSgDm4tcnI2rbiPr8wPP8AnvXKeL/EavGkBuXG5eiEvuPXknjFN8f/ANteHt0N5pFxg4HmJnynHswryy9ur2+lMphazVV2gBt3GaAOiuvEsTSRG8zCM4cg4Ofr3rRu5ftloGstoTOQwB3E/wCe9czaaFb30GL47piCcSMAPqBUtneXOmvJFAhePG0M3A9B+NAGv4fu9QN3GlyGwudozn9f61qmdprjb5wK/d2k4x/jXNXuoSWNkZSrSFzgLHz+HH41iaVeS3moK9+72wIxGvJxzzn3oA9JkW3toz57IxY87FyQR71saDO6yFVi4J/1kuWx+FYMUVq1rm3jeN14LO3Lcdqb4c1KM3UkUT7wuQ7v39loA7K6n8tg9zMvy8sFHLt7fyqJ7yOMN9hRBK4wCVLE5/rWfqkAmMSlJIkLZfB+YjjrnpTo7uOK5MVmix5O0vJJx+FADX0Sa7cS6nPG0aruYyN0PpjvU1lpywyrJpyyRRg7UuSuAP8AdHrW5p+l7pPMvJ45m4KoF3AevNaM9wEiCxRt5aknajj09BQBLda3NBZRWUV9eNLF1Z33Kzdge/4Vw14bjUJiNS27w5DjdjjpXUJLbu2+WZzLJwkcaZ2j3A/CpL+3huiqLBwgwG28tjqTQBy9mlza3xht7VktmwAwJP0x7VdeMwFtskIVhksfmOfrV8I0MbbJWljbKtGO1U3lQHZH8u4coFwOKAIGnYoViZdm3Lsv3sen6UWYzCW2OqnhAxxn3qCRdgCICWODJs5q1E6RoyyssUWBhiMnPpQBZ8uR02uHY9APugAe/rTTcghQi7GUZAz/AEpsjNt5mypXIZXPH+eaWKIsY3UssezYoXke5oALdLidjKHRFPBB5JHuK0LFYxGJXZIyzglcYyPanQ2fm23nDdhuMM2Dj1PNWsWqtGqoRIVCY2kgfjQA4tEmEwruOgJwMde9Vbg7myw2qB93PABq0tu0TExYJKkE9DURhlhgm3yoF7YXP55oA5TU0WOfExIVEHCttFaWlaklmIp7JJeM79oz196ydVQsVxt9TwCT+dXtPkQIilkzgg5Gf0oAp+J7wX92HJHPAJaqE7x/Ypf4jtwNq5FWZlRVmAChsld7L2zzxUN7PCNPZUVG2jnpz/n+lAHFaQJP7Wi2RxITIDjbznPSipvDsPmazE8aMp39QcficUUAeFaLOLbWLCdvuxTxueOwYGvZLycW3jVnRhtLCRQxCjBGeB+NeHV7V4gmWa30nVI0zFc20bZI74A6gccigD0+JlZkbIO/HATOPwpIFa1162u/L8oSDYxQcmqGjTedpEE29VIXrknpWnFm8tizSb9pyAFwMigDs1MTkoskjA44c4z7U/y8KWUDdnojECqum3XmWquBknqNx4/DFTvJGp2mJUbGeVBH6UALJDyfMaRlPKgc4pk4g8lAEuFZf7x4zSxmV9uZkUdTg5208POxJE0MnfCng0AQRxxiJXBJkZgOG+76VaUTeWXkErR44+UYqvGwWMyH5nzuIzj/APXzU0lzGB5e59z44Q0AOkvZpA+23DD7owOVx1qtGZRuX5o1bJwF709nTy3c7gykjK9fxoUHyiTK3zDKZJBoAYdskgZpXIx8wC9vesTxHqVvaWUgJWPjB3sOR/jWnqF6LW3E0jiQY6Dhl964220STxVqayzKy2g+8QMgn6UAYMNnqPiO/kt7GErHwXaNsZHr6V6P4S8IW2jxBjGxuUOQXXdzjsa6bQ9HtNOtfIsoWTauXZhgOPpWtGdseFaRAeN33hQAxIZFjVpofkPBCkccenap445LRIjbNHs3bNuNrCo4baUTOWjRyxCs3m4/Eiqmq3MqJ5ECOGY7QfvAfTuKAL896sTzNsKs3yM241Qj1B7vhbb5Bx5rdccVQiivHuVDyE4UgFyNucdPetKws57XZ9pVVikBy8fOBQBcmuMxgoiMBjKMcmuc1ATT3RMW4SIchkXBT8B1rVvZHdUOTs27dzLhj9fastyQzIeQASCp2gfU96AI5RMmUYxGRjklmIOPXjvUV7eQabbSzT3CSCMEsDwB7A1k6lfHftsYzNKQM85Cn61SXRpdQCf2qw2t8wVByO/T60AYMWrX+rXguLWFRaq/CMM8fWrWt+Io7KLBLCT+IKDgcdMGu50/RIoovJtLbehGcuoGf8Kh1fwtDcWki3EcEUzkkM+HI/8ArUAee33iZD4YnazlBuZgAElXjn+tO0dbXS9NjSUrNeuoPzgNgkeue3pXJT+GfK8QzRXd0WjRt0YbsfUAV0+g2cd/q0dvaeXNK7+WqOfvNnrntQBt/D7wKNc1Vp7l5biLeWcH5UX2FfRNpa2mm20dtZxJBEuAEjUDj3/xqj4X0aHw/osVrGFyq7n29Ce+KbOWvpC6OYnDGKPuDx1oAkvLkW92J4d0mSEdAx6eoFULi5S8vJ7WKMC4b7u84/H6iptNC20r20qSCbq0ucgGmXsdpFdK8UqrJIhVJAoJHrmgCxNJeWflxqVwFG5gud5+tNkmexh868fqQFLucj8O9SXNtFPNZGSXgR8fMQTgcHFRym4u4BMBBIR8p3jOznqB+NAE63EOpxG1vYU2SAgCQjLcdQMV85/EPwXd+EtfluYbaa7sZSZEl4YIvcHsK+gZJ1iYsFWa9PEfzbmCg8k1Y1PTrfxFpBhvrcjOdobjDY68dqAPkGeW3ubtms1wM7mBXlD7etZ2vRz/AOjIsqx4f5JCoy34f15rsfEEcGh6rOn2YB432McHJI7YrmPGLm7ggMERgmJDB2OAPYDt9aAOktIFTRWuJdxbb0K5OcdcVw0tq8uoefAssKu54YZDYPUeld3pl3FDoaC6uFefZgRjqB6muEuNX8uaaS0kEkLsVId9hHrtHrQB0dprZFs8Nz5kQxjY6gZ4qLQrl3nVnVY4Q3DL1Pt9cVz4M+pSRJFCxkyB84yTXc2fhfW7m3SOC0Yx4GXlGOnfJ7cUAdFY3J1BPKkmjVDwAFzkep9a1zp1qNgMTiQfdBjwhznBrH0nT77TAVvz5wA5aKPB+ma2GmdlTyiR3YycsM9hQBZLObYQPLG7D7kQ4HHXpToYkgjMjGVpGI3KuMfTFVJpnhiEUULA8HO+oYzcsVe6cx2+MARkZOPX2oA6CNxEEdEhilwPlUZKr7n3pUllhVnVx8xOOO/c1hRXtusgCSPI+MKM4DYqxFciQM6TlZVfbtxnav17UAXL2VoojI8W7ORxx+Ix/nmuUklJkLK0j7+pY42j+tal7K0V5+4WRy3DMH4Ht/Kovsp3faBHGis3Tkn160AMkd3iXztsZV+qjOPrTFYxxl90UiEk8g5B9aL+62mGGBlkkc9FzkfU1esNPlV0F8FaIsSAq9T6k0AQaaXuJUjikG8cMu3IArfWEZMkitGpxt2DCj3x3qe2RAhMSCEMuWxjr7mmIVDRnzJJADgLt64HWgCcWqeZg5dVXrkAA9TThFJLMitKBFH8yrjp+lQbX2yny9q4PDNn8frTFASFY0kb5sDbjoPzoAnZN0jyeZsjxndnqfbH0qMPstnWH5sA/M+cZ9P1pkbeRlc5bOOTnAqRnbyEV0d1ODy3c0Acf4jaRrhVkQJuwrHnjv0+tSW6rHZpKofavGCoAz9etQX7ZvGaWIyYbpu27aWc77NVEeATnkZCj3oAhkzLueTeIg2dp5Un0wOap6y0MenSeUrKXXnYpHP41eto2Ee1FckMWO0cD3rN1uQtG4cAhQGBc8j8aAMjQLWEXizbX3qrNh244B7DkUVnG/e30PXNRiKgQWrhCcfeIwP50UAeA16vpcy6h8NrAuZDJayNAQrHgdRn04FeUV6R8LLhbnRte0pwgyi3Sk5ySvBAx7UAelfDiRpdM8ra+Vzjcegxiuy8GRm5murdgSYSTkEj8q8n8EXT298Ywi7mfBwccepzXtnwxhiTxv5NyB5V3AwA3feYfSgC9FHPas6FofKY5JY8gVb2yHOZxkjPyrzirmsadDFc3MUke5oyQCGGRx06c1iwq7RqAg4bbxn8OtAFuTy94ymX6kn5R+tL5iFCYx5Z25OEyaSNLgPnKkZ6Mc44qFo0V0Ex8tsHABzn360ASIYTkkyEAYIb0p6LBgBXREPOCuSMDpntUSCSYbU27R0LJgDmpFC+eYzGCx9B047CgA/1bko5z/00PDD2NRfaBtYOg7kHGcH6Usg+VGnhyw4Vh2HvjpVLVdQ+yWTMkJUA56bs+4oAyLtDrt4ljCGFuH+eRWyT6jFehWFjHZW8dvabVUADL8AeprJ8IWMK6QtzLanzpPm8wDBGfpXWwNBEsgnGFbB+Rs4GO9AD0URt8r7gV+Vc9T7Zqjc6wFkAEEcZPGFbI3f0qneXnzrHZw75CceY3OfY+1SaZpyQurztFKWbcU3evtQBHNpbyk3cZKynB2iTgYzxmpLBvs6SSXSjeW4VTyfxFXNRmjw6OiGHptPNQR2qLaiSOXYHIIIJzQAySUzodsMcYLZAl+ZqiSb7NCNzCCV8g9x+FXzLHt2iVHfu2Pm//XWfeznyZHXdlgQFkUEn/wCvQBXmmZnVhM0oPJPTHp/Sqt3NEqNvKuUzIFk+XcT+lC3JMigyo2VwNqZOPQ+lNihN1OscSReQhyyFSf50ASaXYicNPcstvI2CI4SG4+taJiWMrvjg2/wMGzIT/TrTIrWDepCMu0HAU/MR6AelMvdluAjB4yOQ07dAemB3+lAFmKO5Zw0gby1BIUnkj61NP5cJHmRq7uPl2k5H41R0uO8muV80szdVXd+7Of5Vc1GF40KybUXHzkPjH+fagDzXxHpOfETysIg7LkncOMe9aPwY0azTxzezSBnkEZkVWGUB46e9c/rkMd1qciwCSRAccttBNdp8B7d4tY1ZnRQoRVUKxbaM560Aew6iZBYzeTtMhXA3dK5qOeSSySGIeRKCdxjQtnnt711M67omUoXB/hGOaw1gnlkYtE6KrEII+MfU0AFvbNPEblLlkeQY2su0gfjV2HTre3CDysykYGD29KnsoXaLddL+8OQAew9qtqCBjOcUAQPbhmVyAdo+VcDj8arfYy0sLyRj5O0ZwD6A+uK0cc5ycelRzO6DKKGGDnnpQBi2lvs117rd5aTAqq7cZxWrp8KQW/lxiUKGJ/eHJqvZWzySrczzGQclFxgLz6VoDOBk5PrQB86/Fi0tLLxvexToUa7UPG6AluRzgfWvGiP7N1R0vRIUUkIZSWBz6jPFe/fGqaGXxZbKuDPDAFyDkgE56fjXgvxFs1jmjkeOQR8Dg/zNAGXebnu2jhuH8uTkR2x6H0z3ruPCfw9kupoLzUIlYY+XbjKj/aB71j/CrS7XVtZFxOmPJ4wMkLX0dZWJW3CxQNHGgDMOgK/Q8k0AYWj+FYrBUmEMe6PsVBbb7e9dKIxK4UbkicZyGwFHpgdTUJngAMsIQSbiAjKwGMdqltoU3Hz4UUrg+WJMkfX1oAI7ZColQlkHyrleOB3qlc6dbzIxjTDoDmQL0IrYgkJAHloIl5IX7oPpn1p10w8mM+Y0RbgIoyCe3FAHn2o6b5RLusk7EcFcj8zXKXiXMBYyho1X5AyqT+lemX95J5xjiaMGPhpF4Yfh3NZ93A1wsckoWRc/Kr8ZA6nA/GgDy6TU/shXznkOCCJGxkcfp9Ks6b4kVt21lZnGSD2FS+J7S2e5ZljjjJORnoOlchf+dp80iebEJDHnKpwW7UAeqWV1HPCXVS6jlvLUEnj+VCz+ZJ5aSGScj+MZ2+x/OuZ0C5ne2VZc7nUH5e5PXpXa2GmW8TyecXR2xz1C+36UAFpZNaRbpIRJK527So4zV8AYImJUAH5WHr61OIC0pYzRRhV6AnOelQJvhGNsjM4K5bqcnrQAkZVUiWJfMI4DEfeH0q1HJ9pRlVHSQMTuzgVFFKVcLllUZGM4xn1qacSQblwjDHLJx9MH2oAbL5wVQzM0RbCgnGaU3D+W2EV3B+UJz9TTeYpo9zSSNzwe3+f6UT+WVcoQpGBgcZ/DFADhOzD5oxGyr8oYfMST1ps0zGIKsuH24JIOQaRC+9JfLJzkZXJ7Y55qtqEjpEF3yDI/i4z1oA5q8d5ZRFvCHJbLL1piwyKfkxIQMngAfhmiUiaTPA2jljk/0qSUtwwnb5uNyoOBQAyzuLiONlIRSRjr0/Ouc128ht4JmnyWxgLkEYrYvLiS0tGdY1m5JLNnJ/EVxGtO93e4QIGkI+XPJPtQBi+NZIrH4cvzia/uFRcdcL8xBorI+M14EvNM0dCR9jh3yjPBduf0FFAHm1dP8ONQTTvF1k8xAhmzA5LYADDGf5VzFORijqynDKcg0AetzQfYdcmgcFCr8Hp36816p4Eu4LfXNC1CTc5jlAJLluDx9K8y1i6bU9H0vW4dhFzFtkIUcSDhv1roPCWrs0axhQr/AHlccdKAPr250iCa9abZgsOT615d4hspdO8RXEDMNj/MuG455712/gjxEdY0S1kkcCZPllB5J965z4v2whutP1GP7zKYzg4zjn+tAGH5RLHLZYjIAByalgTa/m9EHBB5IqGxaeSPzEERIA4K7fbrQm6N8STEuPmwmQp/HvQBMzW3mhp5sh8hVzg/hS3Hlwynb5jt2LHFFu6blLqNueu0DH4//WqKSWDzCXaV8jH3Tx+NADkba5dGAYnLKxx+HpWDrDSXd9FamUrHwcccj6VtXE0KDzFDDZ8zblyD9Sa57Qniv/FLPHaiZU/jJxigD07SLCGGJI1WVUQceYeMfhT79JW3qUVAVIzu5JqKDzFkAhzER90v0xT/ADZyhMYeVyOQOAPpzQBDFbpEnz7VlKgqex/z+tNgYywuFXa/IyTgZ9s06Ke5mkIkhzkfeVBx2prxp5g85hGw43EdB9KAHS+WjbnunZ1xkqoODUkssTW5NvG2ehY9R7gHrTHiSI8S21wW4DA4OaiucCBw5E8nLIIx8vbuKAIv7QZ3KCZIBj+BfmJxXMeJ9ajtpHt/mlZvvuGwfqKnvGkiguJ5yke0l1APYe9cT9ik1i5M0s6Sxn7io2Ap9/WgDrNNvW/shpgkskb/ACgsNuR/M1u6HIHtkLMiIx+Vomyfoc1DpensdNhjukAiCg464Aqa6s4oFjniePy1BJjB2kjPt3oAu3t/FZWToreXMv3T1P8A9asO0+06lODdbpAMfMD2/Gr0Nm8g+0NmMMCWWQ7iRTNK1N0vkihg8pWOGOMhv8KAN1UFrauHZrYMMIMfMPfjvWJq0ps9JnnQLKVQgPK27t6VvXOoW077ZgjoOgAyFPfBHWvL/ipq8SCHTbFJXeU5Z9wAH4AUAYkCPPCrSrIoY7vm6fQfnXf/AAj1CKx8UTWMsrI1xGBGjL6dB/8AXrgbKHybaNCJJFC5yrnce9bXhcXcPiHT/KhIk85CshYM2N3OR2FAH0fSEHIIOAOo9aWigApgQhywYkbcBe1QXWoWdoCbm5iiA67mAxWNL420CK7Fu+oRhj/F/D+dAHRJu2jfjd3x0oZQwIYZBqjp2q6dqB/0C7t5mAxhGBOPpV+gBAAoAHQUtFZ2v6xaaFpc19fyBIoxnHdj6D3oA8J+KIin+IV2wmXKKowgywIHOa8Y+JDwrcWkYkdt24kM33fwHX6V6Tc6ld67qN5qd1GALiXeqdGUDp/OvMfiVdNPq6WcMURaOPcMAgj60AdH8DNdtbPV7mxkaJHfBRtvX8+9e9LsEbTeZLJCORGxLHnpzXyTa2t3pTx6hHcwxgYIVMlmP9a+hPhnrw1vSA0kqpdICrru4I+lAHW208FxNtcq7E5HmNyg/CmahPFE6xQtGgYEknjn1zWdqPySJ5UDfMc5U4B471k/b1e+jEpZoM7HQcZ+lAHRRSbYzIjTMwHDr8qsO+fWrttqzSS7CcyEcF0yPpmuQ1TWDH5lukMqxr8pwTt+g9+lVdB1G5udWWCSCVipIXHy4HbI/D60AdZqMb3NyHk2GMDlQoAHvVtPs1smZAqrs2qAQcDuag1+Zbe1VkaOJ2PzBvTHSub06SRroGV49snVg2aALOr2EcsUk42bNpbgA5HJFeWawjR30kLRGUg9CoI59c9K9qnSB9PkLyIdnYLXkOr28dxrRVLgsJX+ZHOMfSgDofBWmsLbzLZMEchXIGTXaDI2x5jHAbAbjP41n6DbJb2Ef7goqjB3HknFXwsQVVfnauEK846+tACQwk+YPOWSQtzgVJM6M5eR9rLgAgnHXk0oWE7VKOcn5XA6+pqFGEcpAZpIzyQRjNAFi2lEkhGRIoB2k8k0rEIrGRQCcKNwyFHt602OIB3nZkV2jwiDr+FOaBMIfuNtzgnjP0NACzSXAaRY0icR87jkY461H5jxxCSSUBiPQf1pZFaQxBymWJG5eeBUcsEoUhSrvxwDyKAJDMN0SyyGTauTgEc1la7NHhXiLKSuAWUnmtCXzIY2UDbkc5P9awbyeWS5KvJuVVIG0/dHrQBSiiYFQWxkBiQcYFLJb4XKvIvXBAII+tIz7c7JHGOArVRvr8wh8qGzgnIBFAGFrt7DuW3BZeTko2Sef/11l+HY7a61wTTynyoMu5kOQFFQau+243mLBDYUBQuaq+KbuLw58P7gwjy77U28lcA/d6see2Mj8aAPKfFWpnWfEV/fnO2aVmUZzhc8fpRWTRQAUUUUAej/AAtvBqVpe+G53I83NxbHIGHA5GT6jsPetLTWn0+/a3uJSqhsHDc5/SvL9OvJtPvoLu1dknhcOjA4IIr13Vhb63plr4h00ARzDF0g58qQdQc/nQB694P1Sa0VPsszMrgAgEnJ+vSvQvEMsmt+FSJTE93ZuHy+MkY5r5/8Ea0k0f2eSVWdTxySK7mXV1tFJknm5AV40bjHT/69ABpuoLa38cczAQOxU4OcGuvicLsKFHjPzAng8+ma851eKOVpRal9r/NHyOGqx4S8WC5U2d+rR3ER2MSev+NAHbSCGKJWmbknkKQcUgliVkfz3j5IAKHj61NExmUeWiDgEttzx7D1pZpCmfNZHA5XcOfyFAGVrF2LWxk5Pz/L9aX4fxmaM3ARGOcnIx/Kub8Y3xA8ppFH8f7voK6v4a+Y2iFo9jR5znpkUAd1LFOkMRki2A5AUNkH3x+NV4laIHchIXqFUjg/SppC5iiYBiSeucnP9Ka8U5BEs7E9VjVe3ue9ADZ3iKBo0mAPy4Rtp/GkuGjklHO7gfLIetK5mZx5k3lR45Rl7UMk7HbAgVR82+UcdKAGPNG8xUugx2UYzz0qrFw8iIdhbgqeCB7VdVookP2lYyXPLr6jpiqcjFyGjnQDB+QLlz9KAOK8XM1xcGxjlBh/jYDoO/NO0XT/ALNClvHD5qowYyZx+tbFrpbNLMYv3jE7nyOKRI7iWRoUZNoHCouB9M0AbAFuJYxsdycZVTkdPWnGRZXYQR+SQeEPOcfyqaNZLa1hTbHuyMAkHH9af8rTE3Eu0AZAjXAH1HcUAPgYMzARZ3fKVkP54qG8t4YpGldEj5yQP6+1NupbUKTCrGVsfOeCBXP31/5BZURZtw2ZifJPoCPxoAs6rrMcFs+/yFwBtCYH/wBavLLi0k1LW5L67nkDZ+VSflAzweK7zTPBuq+JbgCaA2VnG2ZJLlSGPsBXUXEXg3wRbmMRW8s3UyTtvYnpgD0oA83s7CWSQmztH2qMmVwflP07V2nw80RdP1mLUb6UCVvmJBJGPT2qvD4o/tq9VdOCxxA9I0GPauw0dIZb1RJICRjeoPzfl25oA70HIyOlc/48ttRuvDVxHo7FboENgHBZQckCugooA+Ute1a5ubswzPOxzhkOVGfx96ywZXYpKEwOVC5O4fXt/wDXr1j4vWemTao08CFb+PAY87H46cd+K8yMEzZlk2+U45QHhaAIrS5lgmR4y8TqdvmJIQQfwr1v4ceObyXxFBod/K9xHLHlJJPvJxwM9x9a8wtLczpsiC4QjHyZA+pHPrX0R4V8J6TpS2t9b2+b0wKDM7FiMjJxQB09eTfG+Q3Mllp75MJUuUHVmz2r1mvOviRp0Gsgk25a7tULRsGwQP8AOaAPB9MSS2llhubraiSYSPbjGO3vXnXj6x2a1PNcPII5WwWVe3uewr1j+znMpkhjE04JDhckCsLxFbLIPJnimHmnKiTIX8/rQBy17eWd3oscccZWSNPLDq2M+9afw01OfRfEMMZKPHcNtc9wtZOpaY6SGFonVcHaI+f8n/Gq4tZdP8p3SZZQAASPmHegD6qvQjWZuEjyWXIZgRx/WuEvfluDuaQkZB+XaATxnNW/hj4mg1nSPsFwFjuo8cFslhitDWdNZmBWNvKJ6tkY9BQBwt5cTwE7C20EY5zk/U0/TdVubO9je4UF3cKqnqefWt2a1YmIJtDEkhsbse+Kzri2bQBHes/2q6lYje65C59u1AHZauGubbfLEij0Zsn61gaZbmS6QeZD5gz+HoAK6Hw7qa3XnJfrDnaAFwQR71NLo9vHMjKsQyckpnr7mgCPWSkehlJN4ZhkqqAD868i0iCW48VNIbXzdrfMW7d+1eu+M7iOPR5BE6u/RQrcdO9ec/D6xQXz3LzlSxJypOM0AegxLJGiZjUYIC7ycL61IJoST50eZP4dvAx9KimiaVfLZk2DneTwT3FLIjoSWRW4B6ngdKAJp5kGxAXXcpfj/PvUKt+5K/M4QFguMZ9PwpDKvmErAMnAGDzmnEFnUOwOF5GeT7fWgCNlX9zuykqjLD+7npVmMhZi7BW8teGDbifwprmURCRovLYfxKePoaajbjLIAqL90A9DQA6JAyh8M20E/KcfN6Y/Kgs5RsxOJOAGAPFSskqQuYjHlRjaDt69T+X86gkkeKECZmXknd3x+dAFLWHYlljO1iDncQD/APqrHjhuULtJsYOoOMdvetHT9OXWdXRE3dcHgt+BqfxnZxabPJGsiIix+hOT70AcbdTRLLKgjTylPJEuMmueZpbu5lk3r5YywPOBWtGWvLKXywDAnzFmAXOPeuU1d2gtgIy2XbH3sYFADLa1l1bU4oMui7hk/j256V5/8VNbTVvEr29rKz2FiPs8PPBI+834n+VdtrOonwt4Pa4ypv74GG3zyyKR8zf59a8XJycnrQAlFFFABRRRQAV1/wAO/EyaHqEltqG59JvBsnQc7CeA49xXIUUAewavEdFv0ntCstvN80TKSwcZ4OelegaRfQa1pqTFd9wq4IY5wfpivJ/AHiGPUbNPDOtShYycWU7D/Vsf4D7Ht710OlTy+H9ca1uYmliQ8k5AP49KAO2mjikiKtMscwbIz/TArlPFVo8M0Wo2gZXHySqNxy3976V199aLq2m/uSAeCpRulY+n6lJvey1IB1+5uzwR/jQBN4a8ZNOUhLN5hUDByM4FdBda+jruG4Oeox1/wrzzWPDktpcifT5GZeWDKfXpz+lWrWO8uI1dowTuJL5Jwf69KANDXr9XUnzAoAJAf36iup+CeuBpJ9NadgX+eEtx/Pv1rzjVbSaBXmdgz9lwaq6Nqk1hqEdxZF/NRsq2OPpQB9dQzR+Yqi6EpPQEdTUV1GzCUu23auSy8/SuZ8GeMLHxBZQqNqXcY+ZAwGT6111pICrgJ1P3evFAGbEII7bKys5dvnDEnJ9hVlsBfukArtIDdff6VZ2fMJN0US46jn/P4VFNbJGPMd3aQnBagCsYFkO15tkIUFsJ05p8P2OGMjcHP+wPmIqApFGRsDyFsrkjIUenWpmtzNEmVJ2cEBNo/wDr0AQTuwkldWeKIjCrkE80+2iZIwxQxs2Mep9x+dSW9ntgTcEIJySx4/z2qWLfEJFjdmBOWPXA9qAKc5mE8bTw8c7Nx6/U+tTSrM1spURwv6HlmH1/OoptlvEZFkkMpP3m6KPX2rndYv2kUKtyMHhnd8ZPtQBD4g1NY3EcYUYO3cF4z9K5rTtdtdH8RwahduJxC24oyFcn60zUpxDE7STuGXkFlxk1gzCWZ4pB5pVhyhA+agDrvFHxWvda3xacGsoB/FnqPWvIvFDia6N9cTGRzw8plP8AL8qj1qORrknT5JY0J5Ru3tkdqx0tNRvJ9ksTFDgZcZXH9DQB2Pgm+kF9A0EhEaNhiRgAV9I+BkE9yrx/MUO52HHX+lfLFkt7pipaR2yec8g8vn3x09K+vvAiPHYxpPAsVwYULeWcoePX1oA6miiigDhvHHg8XtvdX2mKGvuZPLc8Meeh7GvmnVtUuLDVxaXNv5VxISdrOT+AAr7PrxTVvhymo/FFJjCy2ynzS4Gfl4J57ZPFAEvgfwJe3em2+oTzLAsgDxptKt9SK9ddmtLeHA3ogCuQOT2yBVhFCIqoAFUYAHYUMAwIPQ0ALXmfxZkl02Ga+t3KZQBsDk/SvTAMDA6V5x8YrRrrRZiXWNIwHyw/z70AeInVVkYS2kx+0HqFO3JrS0rWodVb7JqdkJGzkSM2NvuCa5HULyK2EN7F8kUh2Egdff6VrWk1tcRjz5cRN0I5J9OnSgDrdT0OPH7p4pIWGN2QDx9K5m88MwTwFkZcN82XJzn0FXZL63ghjSGeUqTyduQR6Z7VbLyTqjBUDkYCA9qAPPlhvvC2qQ3doG3IeGXgbc969n0DXrXxPp8e2QLd7QGQNznpkVyOr6fBdwEbWWQDGQON1cP5914X1lLpSsYLcHJOfYgetAHvmn/aLeCaSWJZ0jO3GzBP0NcxqpS4mfOwZ+bDsBg/1rb8M+JLfxHpytBPGk20h416keoqC80ny5SZAXjAJBKgsPqKAMrR5pIdTTzJPlfjPY9OlddfQ7bdCJjGWI5Az+tct9jeOeNyCFIwMKc4z1rroEki0lxM5UY3KByR6ZoA4LxyszacQGPy/KpDcY9ad4ISG005g+BIFyd44/L61z/i+9X7VGouHIxuYEYwa6LwddM0IV3ifzOQWHWgDoEjLImNqxnLBi/UmrAkMMW2MBsclscf/XqJlG8J5QJGPmV+OemM1NFHcRMEELMF+ZgW7UAJ5k0bKCka5yBnGPeoY3jiucukRj53YU4+tKzh5IxJEzoScfLkke9JGyg7XQhUzgAdPz/KgAWZZoyyz8k8rg/56Uu2KPejl3yecHGO1DgSyIQsaFP4gcDNMuHaAhP3bkjBLcH1zmgCSMxpIzhm2rwB3as+8eS5ukgiZ5C5CgD1qldX0YXbbM6ynO4npn8a7v4QaL5lm2tXkbiR2KwK5yABxu/GgDpPBXhmPRbRZpxvvXXlm6qPSvMfirqdvqHiC5toG37AIfkHQ/xc16l4/wDEaeGfDdxefeuXHl26Dqznp+XWvnOO5dUM14Ymc5d3IwSep/WgCtqs8GnWohzhNuOAM+2a5rS2hunlvtUkaOygBclhgAD2p13dSa9qSwxDYg+8x/ziuI+I/idJV/sLS2UWkDYmkQ/61h2+goA57xt4hk8R65LdY2Wyfu7ePGNiDp+PeufoooAKKKKACiiigAooooAUEqQVJBHII7V6r4U1yPxdZppWrSgatEuLedz/AK4DsewI4+teU0+GV4ZUliYpIhDKw6g0Ae1+HtTudH1H7JqWCUOzJyP1PFdhPDBqEXmxIjhxncCf59BXnOgeIrXxdBHZ6uUj1mMYincjEx/HgNWtY6pd6BdfZr5d6rwu84I9DnpQA97u70m98uUym3LYXPQfjzW3EI3RJ4WYSbRhSMH8qufbbXVbdGV0xgbsgHH41n/ZPs8++zYupIJQ8gfjQBuaXDa31ytttzO/94ZIqr4n+Huowo9xbWszAeg2rj14plpfNCyXCkR3UZypGSK9m8FfFTT7+CCx8RxfY5/urMwBifA7/wB00AfM0Emo6Tcp5MEkVxH/AHSRXpPhP4oL5axa/FIyg4yuR+dfRWo+GNB1mNXutPtZlPzK6ADPvkda5PWPg14U1CB0igmtJG6SRPyKAM/TvE2j3wWSzctkcKH+7+FascqliXbeg5KhuPqa8g8S/CDX/C7SXOm3b3unrljJGSJFH+0vT8a5201/xDbZiF47ICMb8Z/E0AfQnnMXDqkahec5wCPWnS3Ek48t5Md1yOBXitv461RcR5juJcZULzt/zir8PjXXLhMJYhX4X7/f1oA9X3JB+6O1yxBPBIz14NUNQ1IWqzefOkefuqvHFed3Gsa41mEc+S2eqMGx/wDXrGlS6lnDzvc3k7c7GkwBigDqtR8QyXwKQ7lROA27rXOaprMduqiWWEBjwGOAKrT2F5PG5PloFGAFzx7GsSXwpJN/pMrIr8fLy3IoA3dLLXN39pkb90vAPXcP5Vdu78iOQI0UZXIUMPUVn2lzO8CKzJbQR8YK9foKqRaMbu5a6lvt/YYB/KgCbTNOjgi/fK8zO24qqYFaL2kRSOOWLy1HzbScf/rqZmNsqK7CSJhtAz9w460LKHdvOk27FzjO5v8A61AHO6zZxwa3p2qQKTHBKu8kEhsHoP1r6Im8e6RDoQk0zc1y0YKQFOVJ/vduK8XVZJ41aMLKy/dUttH4A0/Q3kiuXW7KswztU8/r3oA9C8K+Or61uWi1LdPbbmd2K4kyeeO2K77wv4osvEKzfZmCvG2NhPzEfSvFIp5ZHLXAXyv4UA2lfbNOjeWxuBPZMYZI3D7Yxjdj9aAPoijHOe9UNCv11PSra7XOZEG4Hse9XJpUhieWVgkaAszHoBQA8nAyelc9deMdFtr02zXiuy5DtGNwQjscV5p408YXWuzyW9lP9l0pcr8pxJL2yfb29K5EG3hjcsW8tTwo6t75oA9j1L4i6bbi1NtHLOsswRzjG1c/eq147szeaHqEx3NCtszAdQeK8cgBulDfLFGhzuPBUfSrfiTxJrA8Ny6Rb3DxwTLs3suSE74PoaAPJFli1TToLO1iEc4LFx9Dx9PrVW60zWLAK5X90T8hibcfyrq9B8ORaftkkneSc8s6jH5VvXIWKIrA5DnkYjyM+lAGZ4f2nTlVoZo3B+cSnJb3q26lmPkh48npggfhVMXMls7G9lYh8BMDBB+lakUjXVkwinRkAx84xn6UAMtrpZI1VpTJEpI3Jg4+tMvLC21GIpOm7AyrYzj3zWZc6XerC62dwII2+ZmAzir+jWNzp0EhnnedX4Cq/A9uaAOWUXfhq/RrXfA6nCzRtlW/Dt6V6FoXxAsZEa11yPbcHjzBuwfesS/gt7+M2s58sHoH6n6GuM1KO4sbkwSRPKg+WJx39cnFAHuq6noUoJj1GMSJyu584/DvXMeOPiNHa24s7JDPj7xHRjXkDP50wW0n8mSPgRy55P1pk3nDP2hVL5I3Bic0AaTavcahc+dJboSTloy/OeOK9E8JzSR2YSV1QFvmVvm/CvNNHuGjvchIc8BRt/UmvQ7C+jWIKbbLHnjBoA7ZGztVnjMQ5YHj5ulSO6lnbks4xwxG32rA0+5YMxlH7rO4ZHT6GtuKfzQMNuRc4BHegCyg24EEhIReQT39fSogC0i7gwLnr0znrQxU2pUnG87SvZqp3ElzGvOWjI+VmHQcUAW7liipEVCgNwWPNYWpag8YZVUMCOMDJHPWql9qUvmFXAQjAztOM1g6l4gRJPIUN8g5bOcn/H60AdHoOmPrmr22noWVZHCu3TavUkV7zf6lpfhrTI1uJVgghQJHGOWOOAAK+YtE8XXsOqB9GBQkbQ54wfWta9vLiRTNqV1LPJksWbP16ZoA0PHHilvEt+s90jJawEiKEfwj+8fc15nqupHUp1s7WN9ueSOOn+e9TavqH9o3gtbAspb7xPT8DXIeMfEkOhwtp2kyCTUDkTXAP+rz2HvQAni7xFH4fsZNI0hgbyT/AF02OYxj7oPrXmBOTk9aWR2kcvIxZ2OSzHJJptABRRRQAUUUUAFFFFABRRRQAUUUUAOVirBlJDA5BHBBr0Lw140t7yJLDxWXkUcRXo5dP9729687ooA9kutMu9OH2nS7g3NlKMo8Tbhj8KsaV4qNkGW4iA5+bd3B7+/415b4c8S6noE26wuGERPzwvyjfhXc2fizw/r4WLWIW024P/LRfmiJ/mPxoA7m21ayvGUtKshIGORge3tVuH7Pdt5aYMeeODxzyPeuMk8NzMy3OmSpd2ar8rROG9+g6VTttU1DTZGW4EsbdD8pyR/X9KAPc/DfiLVdAURWN+GgTGbeQblx/Su5g+KDMuJrBUbHJViRXzhY+J5VC/eIkzjd1P8AhXQ2Wu29yyec4BIxtU/e/wAaAPRvEPxLRhIHebeRgID8rfl2rz+czXN9HcGNFiY7lRUP1q6whukYJGoXPyscdff+VWLZ/IXCOTInJBGAPpQBWht4bh2f91AvTavDH6VNFbGMuse4RAAbu/8A9arAlhyChXz0wcZyWFStM2Mb92R1x0z1FADYVeM58tpAFHBHJ96cCYm3AKOexDED060zzd21zDJtA24LYDfSmSNndsXocgDFAE08gkkBeVio6sRVTUJGnIS3OVOAWCELxT8scHaS5GAo6U4RAOJAXI/uB+p+lAEbbIrb51LMMHcDnB9eamVCo2xrwcEqn86jDNLuQfIU57cip1BSKQBhGSeVxy39aAIiA8GyCJS4bK5TGTQzyQPuiKmVgCwMfAPp/wDrqyzJGVEDsuRhznNQtFGys8LSLtbBL9G+lAE0bRlSwjUlz9wDJHrzT0A3BxGihR8jMMfmarEQiY7Dle5XqanJk37/ADQEbJGT0HpigB8c2NonZFQcs7HPftSTXCojNiRoyT98bQRz0NQKcytsVTuyAGHStPQ/Dk/iy/8AsL7jAhDyuxwEHcDHrigD1r4XwvH4UheSMx+a7OoJz8vQf1qj8X9Yi0/w19kaVUkvG2YJIyo5NdrZW0dnZwW0ChYokCKB6AYrwz463c934pg02KJpVitwwGOFLE//AFqAMDSdsluJMqrHKqAc8eoqxMnlo3moJN/PHPHv6VXsEFtbJC2yOVVHBPyg49qlaNXbdtXG7LEPnigB8dwB8piYKBwwORVB7aa7uDIsybcDafX3x+VXX8tEVSSFdiAwboKgkTywojj2onRh3980AIJFCBSjsO53cKaQIyLiOWSMsOAOc+mad5h8nBmZAOgReadBMxCMrsXbIKt2/PvQBSubSG7OJ0YSKchm5GfpVY2otJCYgDg5xyQB9a05DNlUmbC4zhuSPxFQWpnFyyRgkPycnhRk0ASpGssILDzI3HLKcYpEhRHAjZkjLZDY6/nUjWh+dFQKTzlTgfQUzyxuUgNtPAO7d+H1oAf5CFX+dPM6IxPT3qG4tWdBFJGjjGdu3t6VLiKRn/eeUVPK4zTF+0xFnL5VzgPnnHvigDnr3w1bXRz5ahhgrt4wfQVz+paTNHLJvWQAfKpK8/WvQ5JS7sUXORt+YZxx1qJo8qC0QcH5dzdvegDhdC0a1ubwzzXLRRqMKW+U112m6alpGJRMkuQTu3jOKum3tnQiRRwNq4XP864vV5JLO7eG1mEhf/lmRwPp70AeneH9Hu9YliitCkUbH55mcAD6969H8PfD/TbdS11fPeSE7yEfCg188aUmrCIPNdyRRZyoQnA/+tXonhTxBe6EXMU4kyvIcnB/P/GgD2+HRNMgiCLZw7VHVhk/ma88+Jvifw3aabNY2hgutRPyhIjkR+uSK5LxT4t1rWo2tbq7NrbkYZIBgN9T+VcS+mwREfIu1ssSD971oAytQ1K+uJsb8E8qoP8AWn6LpDT5nvI9x3Ho+Afwq4H06Hc8yMrpkEnoRVebVwriO0DZfJAB6fX0oA3Hls9MsysTKd2D2yPxrlNRvbvU7kiGXyrUZyzkBeOtZeu6jb2cRn1iUqpzsRTy3sBmvOvEXi681VBbw/6NaKMbEOGf/eNAG14n8XrbLLp+hlMEbZLkAEn2X/GuAJLEliSTySe9JRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAF7StWv9JmEunXc1u4Ofkbgn3HQ12Wm/Em6JK67ZQX6nAMgGyTHfn/9Vef0UAew2F94P1uSMRXb2E44VLngZ+vTFXT4Ovlj+06fIlzbk5Do+7j8OvSvEa09I13U9IlD6dezQHGMK3BHpj0oA9XF/qGmFTL5zYbDELgLj17Vt2vi5biMfbI44UU4Dlck/QVxOnfF7UNgh1rTrO+h+78q+WQMfzrZTxH4F12IJdNdabKccSJlffkUAdrbXdtPF51jcKGYYG8daU6w1pMBdp24kjrnrPwrBcwCXQtatLl1Py4nBOPQjNVbyHXNMK/bbf7RAejBcj1oA7qG5trsIyMGK9Mt6+lTkOqudgWTptbrivNbfUYxLG1rKtrIOdrdfpXR2fiacORdRLJEQMy5wRjvQB0/mJ5R8s5uAMHBHB9qF+YEBo45Rglxkmqen6lYXziOGYK5IPAAJ+taGUMylHVghwHAHFAATiQyZBZeQSP5UsYEwMhZdp/iJ/kKaVdsjLAtz05NNZlRSeFHqexoAm3Av5sMY2jn1H1poY5Zii88A7eFqJ0mVFO4DPI44NRQ3ZuFeLcVkT3yB70AWHjW3lAKhsnJ2n+ZoMoVB+7DA9AAcj/PvUO5Y5CpkJLHgHnFSfaBFKPmCHHHH86AJJfKgjZ5mxj+Fe3413fwk1BLfVWiaTfHdoApx90jkCvMrq9MT4njDJI2SR6Vcs9YistQtrtCIhAVbYXK7gPWgD6hrx/4hRNJ4ruimOIl5xk9Omf6VYf436Grf8e0uwD5jvHB9K8s8VeI5td1U6hDd+SZHyo3ZGPSgDSlUSth4ymf4n4B98Um5ECmWFlXu5PB/WseC+vL2N4Lm48tA+VkHOT71pQuvyRtMHAOMg9qAJXZWlDG3DR55I42+houGRotoiPoCDgkUFI4x+7kZgTyDnp9TTVxvDM5QgYB/pQBOd/lhIAyOvL/AC8mo13zMQFVjjPTFIrbTh2IT+LBpjnJIG3IHagCYNtVWmkCKTw5PP0oj8z55pG2MScZ/iHYCq4jilCick7eoX1qVAjMRJuZfX0FADlVVjUuGR8E555PUYqKR3R8Mf3gOQc8bqeJGUttZipGMN6UTMNgRXOxR196AG7i29biJS+eTng/hS7SV3fKMtjGaV024O4FCeo/wqKe5h8gDzFDA8MB296AHh5JVVCMEEqufrT0dypKqQn3SB39T/8AXrNm1KFcIh+Y87u3bH9aglvVAaW4mKwBcfKeKANK7vkaIIDtZjwAeQvtVEw2zTAtbDno78fl/nvVNdQsWjHzo2TuBPbjisfVvEnl3JjXaAgyCORigDrmkjtomVX3AHoTWbfa4LX74GcjOT1Ncm93fX9w7WqZBOODjApkumNCPO1G8it4AD/rGwfrQBrXvipAdoGc4+QDNVIdQv7oxvGSqlTlT2zXMah4r8P2BdbSFr6ZTw3RT7Z7iuV1fxrqt/uSJ1tISc7IeMe2aAPSdVv7TTovM1W9RHblYt2WP4Vxeq+P3VfL0WHyfWaTlj+FcNNLJPIZJnZ3PVmOTUdAFi9vLi+naa7meWVurMar0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAPjkeNt0bsjeqnFd14c+KOu6TCltdNFqNovAS5XcwHs3WuCooA9mtvFfgrXGLX9rJpt03IJGUz65H9a1oPDcNzALnSNZhukc8eXKCCPpXgdSQTSwSCSCR4pB0ZGII/EUAe2T6Jq9oxRrRjx96MZJptjqV1aShHkuIAM5V0PX+tebad458S6fGI7bWLnYOzkP2/wBrNdJZ/FvVE2i+0+wuhjDsUKs3rzQB3Nh4nlL7GuQVHVsDkVfGvShQw8lwB90NyR61wX/CzNIm2/afDSA5+Yxy/wAsirEfj3wnkMdGvFOPulgf60Adt/wkwCeZIsaRepfv9Kim16CSMZHlytyuwcn0Oa4eX4geHFcmLQp3Oe7gD8qbL8UrNA32Pw7CmRgF5c4/SgDtYdfmCAW9u8j/AMWEJ/pRNPrt+pW0tWXnJLg8fT/PevOrj4ray0LRWlrY2qdisZJH4k1z9/428R36bJ9XuQnTbGdg/wDHcUAexy6TPHEZdW1aC1AGT5sgBWs5/EXg7To4jd6nLey/xeSC+fxrw6aWSeQyTSPJIerOck/iajoA9nb4jeFVlZRpNw8fADFVGR71bj+IPg65Ro7iC6giByoWPofwrw2igD3qG68MajIo07xCLcudwjlbGOnGDWlBp+qxySS21zFdLkDerDb+ma+c6t2eo3tl/wAel3PCM5xG5AP4UAfQT6zfxKTf2zqoPBQZB9OaVfEcbELIZUA43Yx+deR6f8R/EVoEWW5ju40OQs8Yb+WK3rX4n2s7g6tokbN3eB8fpQB6XHq9s3mRGRmbuQ35AVPHrUScTGRdwxuIGPp7V5xH4t8J3L5eO7t2OSQy8foatf234TngI/taVHznDqxx+lAHdjXbXzthJ2/3qZ/wkEKxBwjFW7Z+9XDjXPC1uqgas0ik/MPKPH6UreJfCjFxHfSJnABKN0/KgDsJvEYlbdDCDgfNzjb7D9KpX3ilxhBEiA45P9RWClz4Yzul19DAMEDnJJ9vzqtd+JPBVlLGVNzfkA52KQM/jQBrz+ILtpSrFWHr+HtVcahcSo4M64PI5/n37Vg3HxF0cOot9IlK98sBge1Qy+PtIlKuNNnjccHDA0Aa/wDakiSF53yf7ijgj3qJnv7oAR27LCTnkHnmqP8AwsTRoYy1vojvO3XzGGBWfqnxQ1S4ythbW1mnYhdzD8aAO2Tw9dyBZbmRIExyGIAHsM1RvNR8MaJu+2XP2q46GOHk/jXlGqa5qmqnOoX08/bDNx+Q4rNoA9F1r4lzsBFoFqtjEM/O3zMfeuF1DULvUZfNvrmWd/V2ziqlFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography (CT) scan showing a percutaneous drain catheter (arrow) inserted into a necrotic pancreatic fluid collection for drainage and lavage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dia T Simmons, MD, Santhi Swaroop Vege, MD, and Suresh T Chari, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14549=[""].join("\n");
var outline_f14_13_14549=null;
var title_f14_13_14550="Yellow fever vaccine: Drug information";
var content_f14_13_14550=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Yellow fever vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/40/9857?source=see_link\">",
"    see \"Yellow fever vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/14/38117?source=see_link\">",
"    see \"Yellow fever vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      YF-VAX&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      YF-VAX&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F235050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Live (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F235042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     SubQ: One dose (0.5 mL) &ge;10 days before travel; Booster: Every 10 years for those at continued risk of exposure",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F235047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/14/38117?source=see_link\">",
"      see \"Yellow fever vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;6 months (unlabeled use [CDC guidelines]): One dose (0.5 mL) &ge;10 days before travel; Booster: Every 10 years for those at continued risk of exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &ge;9 months (per manufacturer): One dose (0.5 mL) &ge;10 days before travel; Booster: Every 10 years for those at continued risk of exposure",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F235043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Monitor closely due to an increased incidence of serious adverse events in patients &ge;60 years of age, particularly in patients receiving their first dose. The ACIP guidelines note that if travel is unavoidable, the decision to vaccinate travelers &ge;60 years should be made after weighing the risks vs benefits.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [17D-204 strain]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     YF-VAX&reg;: &ge;4.74 Log",
"     <sub>",
"      10",
"     </sub>",
"     plaque-forming units (PFU) per 0.5 mL dose [single-dose or 5-dose vial; produced in chicken embryos; contains gelatin; packaged with diluent; vial stopper contains latex]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F235024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ injection only. Do not administer I.M. or I.V.; if inadvertently administered I.M., the dose does not need repeated. Use of expired vaccine is not considered a valid dose and should be repeated after 28 days. For booster doses, if the date of previous vaccination cannot be determined and the patient requires vaccination, the booster dose can be given.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Blood donation following vaccine administration:",
"     </b>",
"     Transfusion-related transmission of yellow fever vaccine virus has been reported; wait 2 weeks after immunization with yellow fever vaccine to donate blood.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F235022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of active immunity against yellow fever virus, primarily among persons traveling or living in areas where yellow fever infection exists and laboratory workers who may be exposed to the virus; vaccination may also be required for some international travelers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Persons traveling to or living in areas at risk for yellow fever transmission",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Persons traveling to countries which require vaccination for international travel",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Laboratory personnel who may be exposed to the yellow fever virus or concentrated preparations of the vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Although the vaccine is approved for use in children &ge;9 months of age, the CDC recommends use in children as young as 6 months under unusual circumstances (eg, travel to an area where exposure is unavoidable). Children &lt;6 months of age should",
"     <b>",
"      never",
"     </b>",
"     receive the vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F235048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Frequency not defined (adverse reactions may be increased in patients &lt;9 months or &ge;60 years of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, fever (incidence of these reactions have been reported to be as low as &lt;5% and as high as 10% to 30% depending on the study), focal neurological defects, headache, malaise, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions (edema, erythema, hypersensitivity, mass, pain, pruritus, rash, warmth)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Guillain-Barr&eacute; syndrome (GBS), hypersensitivity (immediate), vaccine-associated neurotropic disease (rare), viscerotropic disease (rare; may be associated with multiorgan failure)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vaccine-associated neurologic disease (YEL-AND) may manifest as meningoencephalitis (neurotropic disease), GBS, acute disseminated encephalomyelitis, and bulbar palsy. Vaccine-associated viscerotropic disease (YEL-AVD) mimics naturally-acquired yellow fever disease; risk may be increased in older patients and those with a history of thymus disease or thymectomy.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F235027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to egg or chick embryo protein, or any component of the formulation; children &lt;9 months of age (per manufacturer); children &lt;6 months of age (CDC guidelines); acute or febrile disease; immunosuppressed patients (eg HIV infection, leukemia, lymphoma, thymic disease, generalized malignancy, or immunosuppression due to drugs or radiation); breast-feeding women",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F235012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use. Use is contraindicated in patients with immediate-type hypersensitivity reactions to eggs. Less severe or localized manifestations of allergy are not contraindications; in general, persons who are able to eat eggs or egg products may receive the vaccine. A hypersensitivity screening test and desensitization procedure is available for persons with suspected or known severe egg sensitivity. Consult manufacturer's labeling for details.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: Immunization should be delayed during the course of an acute or febrile illness. The presence of a low-grade fever is generally not a reason to postpone vaccination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Patients who are immunosuppressed have a theoretical risk of encephalitis with yellow fever vaccine administration; consider delaying travel or obtaining a waiver letter. Patients on low-dose or short-term corticosteroids are not considered immunosuppressed and may be offered the vaccine. If vaccination is only to satisfy an international requirement (as opposed to decreasing risk of infection), efforts should be made to obtain a waiver letter. Per the ACIP guidelines, use is contraindicated in patients with symptomatic HIV infection or patients with CD4+ counts &lt;200/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or &lt;15% of total lymphocytes in children &lt;6 years of age); use caution when administering the vaccine to patients with asymptomatic infection with CD4+ counts 200-499/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or 15% to 24% of total lymphocytes in children &lt;6 years of age). In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Due to an increased incidence of serious adverse events observed in older adults compared to younger adults, use with caution in the elderly &ge;65 years years of age (per manufacturer) or &ge;60 years (per ACIP guidelines), particularly in patients who have not previously received the vaccine. The risk for vaccine-associated neurologic disease (YEL-AND) and vaccine-associated viscerotropic disease (YEL-AVD) is also increased. The ACIP guidelines note that if travel is unavoidable, the decision to vaccinate travelers &ge;60 years should be made after weighing the risks vs benefits.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: The manufacturer contraindicates use in infants &lt;9 months of age due to risk of encephalitis. The CDC allows for use in infants 6-8 months of age when possible exposure with the yellow fever virus is unavoidable and the risk of infection exists. Infants &lt;6 months of age should never be vaccinated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Avoid use in pregnant women unless travel to high-risk areas is unavoidable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gelatin: Product may contain gelatin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood donation: Transfusion-related transmission of yellow fever vaccine virus has been reported; wait 2 weeks after immunization with yellow fever vaccine to donate blood.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malnutrition: Malnourished persons may have a decreased response to vaccination",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Adverse events were not observed in the mother or fetus following vaccination during the third trimester of pregnancy in Nigerian women; however, maternal seroconversion was reduced. Inadvertent exposure early in the first trimester of pregnancy in Brazilian women did not show decreased maternal seroconversion; no major congenital abnormalities were noted. Cord blood from an infant whose mother was vaccinated during the first trimester tested positive for IgM antibodies; no adverse events were noted in the infant. Vaccine should be administered if travel to an endemic area is unavoidable and the infant should be monitored after birth. Tests to verify maternal immune response may be considered. If a pregnant woman is to be vaccinated only to satisfy an international requirement (as opposed to decreasing risk of infection), efforts should be made to obtain a waiver letter. Women should wait 4 weeks after receiving vaccine before conceiving.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F235044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F235031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Laboratory confirmed transmission of 17DD yellow fever vaccine virus via breast-feeding has been documented. Yellow fever vaccine was administered to a nursing mother 15 days postpartum. She was exclusively breast-feeding her newborn. Eight days after maternal vaccination, the infant developed a fever, was irritable, refused to nurse, then was hospitalized for seizures the next day. Yellow fever virus specific to the vaccine and IgM antibodies were detected in the newborn CSF. The child was discharged after 24 days in the hospital; growth and neurodevelopment were normal through 6 months of age. Breast-feeding is contraindicated by the manufacturer, particularly in infants &lt;9 months of age. Breast-feeding does not adversely affect immunization.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F235019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion. Monitor for adverse effects 10 days after vaccination (specifically in the elderly).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Arilvax (NL, ZA);",
"     </li>",
"     <li>",
"      Stamaril (AR, AU, BE, BG, CH, CN, CO, CZ, DE, DK, EC, EE, FI, FR, GB, HK, HN, IE, IL, IN, IT, KP, MY, NO, NZ, PE, PK, PL, PY, SE, SG, TR, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F235026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Seroconversion: 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &ge;30 years",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Red Cross Eligibility Criteria by Alphabetical Listing. Available at  file://www.redcrossblood.org/donating-blood/eligibility-requirements/eligibility-criteria-alphabetical-listing",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2004, 49(RR-10):89-90.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14550/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC),&ldquo;Syncope After Vaccination -- United States, January 2005-July 2007,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14550/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Transfusion-Related Transmission of Yellow Fever Vaccine Virus - California, 2009,&rdquo;",
"      <i>",
"       MMMR Recomm Rep",
"      </i>",
"      , 2010, 59(2): 34-7. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/PDF/wk/mm5902.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/PDF/wk/mm5902.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Transmission of Yellow Fever Vaccine Virus Through Breast-Feeding -- Brazil, 2009,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(5):130-2. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5905a2.htm?s_cid=mm5905a2_e\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5905a2.htm?s_cid=mm5905a2_e",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14550/abstract-text/20150888/pubmed\" id=\"20150888\" target=\"_blank\">",
"        20150888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Yellow Fever Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMMR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-7):1-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14550/abstract-text/20671663/pubmed\" id=\"20671663\" target=\"_blank\">",
"        20671663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14550/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14550/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suzano CE, Amaral E, Sato HK, et al, &ldquo;The Effects of Yellow Fever Immunization (17DD) Inadvertently Used in Early Pregnancy During a Mass Campaign in Brazil. Campinas Group on Yellow Fever Immunization during Pregnancy,&rdquo;",
"      <i>",
"       Vaccine",
"      </i>",
"      , 2006, 24(9):1421-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14550/abstract-text/16236402/pubmed\" id=\"16236402\" target=\"_blank\">",
"        16236402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10051 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14550=[""].join("\n");
var outline_f14_13_14550=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235039\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235040\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235050\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235042\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235047\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235043\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235021\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235009\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235024\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235022\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235048\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235027\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235012\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300231\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235015\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235017\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235030\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235044\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235031\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235019\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038857\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235026\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10051\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10051|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/40/9857?source=related_link\">",
"      Yellow fever vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/14/38117?source=related_link\">",
"      Yellow fever vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_13_14551="Argatroban: Pediatric drug information";
var content_f14_13_14551=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Argatroban: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"    see \"Argatroban: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30995?source=see_link\">",
"    see \"Argatroban: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F998934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticoagulant, Thrombin Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F998969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"      see \"Argatroban: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Infants and Children &le;16 years:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Limited data available; dosing regimens not established. Titration of maintenance dose must consider multiple factors including current argatroban dose, current aPTT, target aPTT, and clinical status of the patient. For specific uses, required maintenance dose is highly variable between patients. Additionally, during the course of treatment, patient's dosing requirements may change as clinical status changes (eg, sicker patients require lower dose); frequent dosage adjustments may be required to maintain desired anticoagulant activity (Alsoufi, 2004; Boshkov 2006). If argatroban therapy is used concurrently with or following FFP or a thrombolytic, some centers decrease dose by half (Alsoufi, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Heparin-induced thrombocytopenia:",
"     </b>",
"     I.V. continuous infusion: (manufacturer&rsquo;s recommendations):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial dose: 0.75 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dose: Measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5-3 times the initial baseline value, not exceeding 100 seconds; adjust in increments of 0.1-0.25 mcg/kg/minute for normal hepatic function; reduce dose in hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     A lower initial infusion rate may be needed in other pediatric patients with reduced clearance of argatroban (eg, patients with heart failure, multiple organ system failure, severe anasarca, or postcardiac surgery). This precaution is based on adult studies of patients with these disease states who had reduced argatroban clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Conversion to oral anticoagulant",
"     </i>",
"     : Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expected daily dose.  Once combined INR on warfarin and argatroban is &gt;4, stop argatroban. Repeat INR measurement in 4-6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained. Another option is to use factor X levels to monitor the effect of warfarin anticoagulation. When factor X level is &lt;0.3, warfarin is considered therapeutic and at which time argatroban can be discontinued (Alsoufi, 2004; Boshkov, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adults:",
"     </b>",
"     <b>",
"      Heparin-induced thrombocytopenia:",
"     </b>",
"     I.V. continuous infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial dose: 2 mcg/kg/minute; use actual body weight up to 130 kg (BMI up to 51 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) (Rice, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: Patient may not be at steady state but measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5-3.0 times the initial baseline value, not exceeding 100 seconds; dosage should not exceed 10 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Critically-ill patients with normal hepatic function became excessively anticoagulated with FDA approved or lower starting doses of argatroban. Doses between 0.15-1.3 mcg/kg/minute were required to maintain aPTTs in the target range (Reichert, 2003). In a prospective observational study of critically-ill patients with multiple organ dysfunction (MODS) and suspected or proven HIT, an initial infusion dose of 0.2 mcg/kg/minute was found to be sufficient and safe in this population (Beiderlinden, 2007). Consider reducing starting dose to 0.2 mcg/kg/minute in critically-ill patients with MODS defined as a minimum number of two organ failures. Another report of a cardiac patient with anasarca secondary to acute renal failure had a reduction in argatroban clearance similar to patients with hepatic dysfunction. Reduced clearance may have been due to reduced liver perfusion (de Denus, 2003). The American College of Chest Physicians has recommended an initial infusion rate of 0.5-1.2 mcg/kg/minute for patients with heart failure, MODS, severe anasarca, or postcardiac surgery (Hirsch, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Conversion to oral anticoagulant:",
"     </i>",
"     Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expected daily dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients receiving &le;2 mcg/kg/minute of argatroban: Argatroban therapy can be stopped when the combined INR on warfarin and argatroban is &gt;4; repeat INR measurement in 4-6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients receiving &gt;2 mcg/kg/minute of argatroban: In order to predict the INR on warfarin alone, reduce dose of argatroban to 2 mcg/kg/minute; measure INR for argatroban and warfarin 4-6 hours after dose reduction; argatroban therapy can be stopped when the combined INR on warfarin and argatroban is &gt;4. Repeat INR measurement in 4-6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The American College of Chest Physicians recommends monitoring chromogenic factor X assay when transitioning from argatroban to warfarin (Hirsh, 2008). Factor X levels &lt;45% have been associated with INR values &gt;2 after the effects of argatroban have been eliminated (Arpino, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Dosage adjustment is not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Decreased clearance is seen with hepatic impairment; dose should be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &le;16 years: Heparin-induced thrombocytopenia; I.V. continuous infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Initial dose: 0.2 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Maintenance dose: Measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5-3 times the initial baseline value, not exceeding 100 seconds; adjust in increments of &le;0.05 mcg/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Moderate hepatic impairment: I.V. continuous infusion: Initial dose: 0.5 mcg/kg/minute; monitor aPTT closely; adjust dose as clinically needed.",
"     <b>",
"      Note:",
"     </b>",
"     During PCI, avoid use in patients with elevations of ALT/AST (&gt;3 times ULN); the use of argatroban in these patients has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 125 mg (125 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in water for injection: 50 mg (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 100 mg/mL (2.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F998974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.V. use only. Solution must be diluted prior to administration; dilute each 250 mg vial with 250 mL of diluent; final concentration: 1 mg/mL. May be mixed with NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or LR. Mix by repeated inversion for 1 minute. A slight but brief haziness may occur prior to mixing. Do not mix with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1000",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F998959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Compatibility when admixed: Compatible",
"     </b>",
"     with fenoldopam, lidocaine, milrinone, nitroglycerin, vasopressin.",
"     <b>",
"      Incompatible with",
"     </b>",
"     amiodarone, furosemide, sodium nitroprusside, TPN solution (composition: 2.7% amino acid, 24% dextrose, 15 mEq each of magnesium sulfate and calcium gluconate, 40 mEq each of potassium chloride and potassium phosphate, 110 mEq sodium chloride, 1mL trace elements [no fat emulsion]), nesiritide",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F998955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unused vials at 25&deg;C (77&deg;F) with excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) in original carton (to protect from light); do not freeze. Prepared solution is stable for 24 hours at 25&deg;C (77&deg;F) with excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F) in ambient indoor light. Do not expose to direct sunlight. Prepared solution that is protected from light and kept at controlled room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) or under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) is stable for up to 96 hours. Additional light resistant measures (eg, foil protection for I.V. lines) are not needed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F998935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT) (FDA approved in adults); anticoagulant for percutaneous coronary intervention (PCI) in patients who have or are at risk for thrombosis associated HIT (FDA approved in adults). Has also been studied in children with HIT for procedural anticoagulation including cardiac catheterization, extracorporeal membrane oxygenation (ECMO), and hemodialysis/hemofiltration",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F136573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Argatroban may be confused with Aggrastat&reg;, Orgaran&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F136571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all anticoagulants, bleeding is the major adverse effect of argatroban. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, bradycardia, CABG-related bleeding (minor), cardiac arrest, cerebrovascular disorder, chest pain, hypotension, MI, myocardial ischemia, thrombosis, vasodilation, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, headache, intracranial bleeding, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin reactions (bullous eruption, rash)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, GI bleed, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Genitourinary bleed and hematuria, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hematocrit decreased, hemoglobin decreased (&lt;2 g/dL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Bleeding at injection or access site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Abnormal renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, hemoptysis, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, constipation (infants and children), GERD, hypokalemia (infants and children), limb and below-the-knee stump bleed, multisystem hemorrhage and DIC, pulmonary edema, retroperitoneal bleeding",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F998940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to argatroban or any component; overt major bleeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9729898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and reduce dose in patients with hepatic impairment; may require &gt;4 hours to achieve full reversal of argatroban anticoagulant effect following treatment in patients with hepatic impairment. Avoid use during PCI in patients with elevations of ALT/AST (&ge;3 times the upper limit of normal); use in these patients has not been evaluated. Use with caution and reduce the dose in critically ill patients, patients with multiple organ dysfunction, heart failure, severe anasarca, or postcardiac surgery; clearance is reduced in these patients. Limited pediatric pharmacokinetic and dosing information is available; the appropriate goals of anticoagulation and duration of treatment in pediatric patients have not been established. In pediatric trials, hypokalemia and abdominal pain were reported (Young, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Argatroban prolongs the PT/INR. Concomitant use with warfarin will cause increased prolongation of the PT and INR greater than that of warfarin alone. If warfarin is initiated concurrently with argatroban, initial PT/INR goals while on argatroban may require modification; alternative guidelines for monitoring therapy should be followed. Safety and efficacy for use with thrombolytic agents have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F998941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to initiation of argatroban therapy, all other parenteral anticoagulants should be discontinued and adequate time lapsed. Hemorrhage is the most frequent complication of argatroban; bleeding can occur at any site in the body. Use with extreme caution in patients with increased risk of hemorrhage. Risk factors for hemorrhage include intensity of anticoagulation; bacterial endocarditis; congenital or acquired bleeding disorders; recent puncture of large vessels or organ biopsy; recent CVA, stroke, or intracerebral surgery; severe hypertension; renal impairment; recent major surgery, especially of the brain, spinal cord, or eye; recent major bleeding (intracranial, GI, intraocular, or pulmonary); GI lesions (eg, ulcerations); immediately after lumbar puncture; spinal anesthesia. Monitor for signs and symptoms of bleeding including unexplained decrease in hematocrit or blood pressure. Argatroban is for I.V. use only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F136560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal studies. Information related to argatroban in pregnancy is limited. Use of parenteral direct thrombin inhibitors in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F998976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HIT: Obtain baseline aPTT prior to start of therapy. Check aPTT 2 hours after start of therapy and any dosage adjustment. Monitor hemoglobin, hematocrit, platelets, signs and symptoms of bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F998960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Argatroban is highly-selective direct thrombin inhibitor which reversibly binds to the active thrombin site of free and clot-associated thrombin. Anticoagulant effects result from the inhibition of thrombin-catalyzed reactions including fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F9729899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action:  Immediate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F998962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes primarily to intracellular fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : 174 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Total: 54%; Albumin: 20%; &alpha;",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein: 34%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via hydroxylation and aromatization. Metabolism via CYP3A4/5 to four known metabolites plays a minor role. Unchanged argatroban is the major plasma component. Plasma concentration of primary metabolite (M1) is 0% to 20% of the parent drug; M1 is three- to fivefold weaker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 39-51 minutes; hepatic impairment: 181 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces via biliary secretion (65%; 14% unchanged); urine (22%; 16% unchanged)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients (seriously ill): 0.16 L/kg/hour; 50% lower than healthy adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric patients (seriously ill with elevated bilirubin due to hepatic impairment or cardiac complications; n=4): 0.03 L/kg/hour; 80% lower than pediatric patients with normal bilirubin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult: 0.31 L/kg/hour (5.1 mL/kg/minute); hepatic impairment: 1.9 mL/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis: 20% dialyzed",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F998982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Molecular weight: 526.66; argatroban is a synthetic anticoagulant (direct thrombin inhibitor) derived from L-arginine. Increases in aPTT, ACT, PT, INR, and TT occur in a dose-dependent fashion with increasing doses of argatroban. Adult studies have established the use of aPTT for patients with HIT and ACT for patients with PCI procedures. Therapeutic ranges for PT, INR, and TT have not been identified.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A reversal agent to argatroban is not available. Should life-threatening bleeding occur, discontinue argatroban immediately, obtain an aPTT and other coagulation tests, and provide symptomatic and supportive care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Infants and Children &le;16 years: Doses reported in the literature for infants and children with HIT for procedural anticoagulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Cardiac Catheterization:",
"     </b>",
"     Dose not established; the following doses have been used in limited reports: Initial I.V. bolus dose: 150-250 mcg/kg, followed by continuous I.V. infusion at an initial rate 5-15 mcg/kg/minute; one case series adjusted the continuous infusion dose to maintain target ACT &gt;300 seconds (n=4).",
"     <b>",
"      Note:",
"     </b>",
"     Data is limited to an open-labeled study of a mixed population that included six pediatric cardiac catheterization patients and case reports/series (n=4 patients) [Alsoufi, 2004; GlaxoSmithKline Result Summary, 2007 (manufacturer unpublished data); Young, 2007]. Further studies are required before these doses can be recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      ECMO:",
"     </b>",
"     Dose not established; data is limited to an open-labeled study of a mixed population that included one infant on ECMO, published and submitted abstracts, and case reports/series (n=16 patients) [Alsoufi, 2004; GlaxoSmithKline Result Summary, 2007 (manufacturer unpublished data); Hursting, 2006; Potter, 2007; Tcheng, 2004]. Further studies are required before these doses can be recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     The reported argatroban doses used to prime  the ECMO circuit have varied widely; more recent reports utilize an ECMO priming dose between 30-50 mcg based upon patient's clinical status and ACT, followed by a continuous I.V. infusion at an initial rate of 0.5-2 mcg/kg/minute; continuous infusion doses were adjusted to maintain target ACT of at least 200 seconds; reported ACT target ranges varied from 160-300 seconds or aPTT 2 times initial baseline value. Dosing requirements ranging from 0.1-24 mcg/kg/minute have been reported.  If patient not previously anticoagulated on heparin prior to starting argatroban, an initial bolus dose may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hemodialysis/Hemofiltration:",
"     </b>",
"     Dose not established; clinical data limited to case series/reports (Alsoufi, 2004; Hursting, 2006; Young, 2007). Further studies are required before these doses can be recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     The following doses have been used in limited reports: I.V. continuous infusion: Initial dose:  0.5-2 mcg/kg/minute; infusions were adjusted to maintain target ACT at least &gt;160 seconds or aPTT &gt;50 seconds; when reported, ACT target ranges were 160-200 seconds and aPTT 50-75 seconds. Reported dosing requirements were 0.1-2 mcg/kg/minute. If patient not previously anticoagulated on heparin prior to starting argatroban, an initial bolus dose may be required; initial bolus doses of 65 mcg/kg and 250 mcg/kg have each been reported.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alsoufi B, Boshkov LK, Kirby A, et al, \"Heparin-Induced Thrombocytopenia (HIT) in Pediatric Cardiac Surgery: An Emerging Cause of Morbidity and Mortality,\"",
"      <i>",
"       Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu",
"      </i>",
"      , 2004, 7:155-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/15283365/pubmed\" id=\"15283365\" target=\"_blank\">",
"        15283365",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arpino PA, Demirjian Z, and Van Cott EM, &ldquo;Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning From Argatroban to Warfarin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2005, 25(2):157-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/15767231/pubmed\" id=\"15767231\" target=\"_blank\">",
"        15767231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beiderlinden M, Treschan TA, Gorlinger K, et al, &ldquo;Argatroban Anticoagulation in Critically Ill Patients,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2007, 41(5):749-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/17440009/pubmed\" id=\"17440009\" target=\"_blank\">",
"        17440009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boshkov LK, Kirby A, Shen I, et al, \"Recognition and Management of Heparin-Induced Thrombocytopenia in Pediatric Cardiopulmonary Bypass Patients,\"",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2006, 81(6):S2355-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/16731103/pubmed\" id=\"16731103\" target=\"_blank\">",
"        16731103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Denus S and Spinler SA, &ldquo;Decreased Argatroban Clearance Unaffected by Hemodialysis in Anasarca,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(9):1237-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/12921506/pubmed\" id=\"12921506\" target=\"_blank\">",
"        12921506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      GlaxoSmithKline Result Summary, Study No: SKF105043/013, \"An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulation Alternatives to Heparin,\" July 2, 2007. Available at:  file://www.gsk-clinicalstudyregister.com/files/pdf/22691.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsh J, Guyatt G, Albers GW, et al, &ldquo;Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):71-109.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/18574259/pubmed\" id=\"18574259\" target=\"_blank\">",
"        18574259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hursting MJ, Dubb J, and Verme-Gibboney CN, \"Argatroban Anticoagulation in Pediatric Patients: A Literature Analysis,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2006, 28(1):4-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/16394885/pubmed\" id=\"16394885\" target=\"_blank\">",
"        16394885",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Potter KE, Raj A, and Sullivan JE, \"Argatroban for Anticoagulation in Pediatric Patients With Heparin-Induced Thrombocytopenia Requiring Extracorporeal Life Support,\"",
"      <i>",
"       J Pediatr Hematol Oncol",
"      </i>",
"      , 2007, 29(4):265-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/17414571/pubmed\" id=\"17414571\" target=\"_blank\">",
"        17414571",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reichert MG, MacGregor DA, Kincaid EH, et al, \"Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(5):652-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/12708939/pubmed\" id=\"12708939\" target=\"_blank\">",
"        12708939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rice L, Hursting MJ, Baillie GM, et al, &ldquo;Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2007, 47(8):1028-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/17525167/pubmed\" id=\"17525167\" target=\"_blank\">",
"        17525167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott LK, Grier LR, and Conrad SA, \"Heparin-Induced Thrombocytopenia in a Pediatric Patient Receiving Extracorporeal Membrane Oxygenation Managed With Argatroban,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2006, 7(5):473-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/16807510/pubmed\" id=\"16807510\" target=\"_blank\">",
"        16807510",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tcheng WY and Wong W, \"Successful Use of Argatroban in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2004,104:107b-108b.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Young G and Boshkov L, \"Prospective Study of Direct Thrombin Inhibition With Argatroban in Pediatric Patients Requiring Non-Heparin Anticoagulation,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Young G, \"New Anticoagulants in Children,\"",
"      <i>",
"       Hematology Am Soc Hematol Educ Program",
"      </i>",
"      , 2008, 245-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/13/14551/abstract-text/19074090/pubmed\" id=\"19074090\" target=\"_blank\">",
"        19074090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13081 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-190.92.87.115-DA0D917308-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14551=[""].join("\n");
var outline_f14_13_14551=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998934\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998969\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136522\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136507\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998974\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471318\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998959\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998955\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998935\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136573\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136571\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998940\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729898\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998941\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136560\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136515\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136518\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136531\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998976\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998960\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729899\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998962\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F998982\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13081\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13081|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=related_link\">",
"      Argatroban: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/17/30995?source=related_link\">",
"      Argatroban: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_13_14552="Anterior skull anatomy";
var content_f14_13_14552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Anterior skull anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior view of the adult skull.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL,&nbsp;Dalley AF II. Clinical Oriented Anatomy, 4th Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14552=[""].join("\n");
var outline_f14_13_14552=null;
var title_f14_13_14553="Overview of occupational and environmental health";
var content_f14_13_14553=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of occupational and environmental health",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/13/14553/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/13/14553/contributors\">",
"     Rose H Goldman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/13/14553/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/13/14553/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/13/14553/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/13/14553/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/13/14553/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental and occupational issues have an important place in primary care practice, emergency medicine, pediatrics, and various medical specialties. Work or environmental exposures may be linked to an individual patient's symptoms. A patient's reported environmental exposures may prompt important interventions to prevent future illnesses or injuries, and work-related injuries or illnesses may require physicians to make assessments of impairment, disability, and workers' compensation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32326?source=see_link\">",
"     \"Social Security Disability Insurance and workers' compensation in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concerns about chemical or biological terrorism, as well as industrial disasters, have made it imperative that physicians be able to immediately recognize patterns associated with exposures to key chemical agents (such as cyanide and nerve agents) and biological agents (such as anthrax) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=see_link\">",
"     \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To be effective, physicians need to know how to take a good",
"    <span class=\"nowrap\">",
"     environmental/occupational",
"    </span>",
"    history and have a reasonable understanding of common environmentally related illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, physicians can play an important role in occupational and environmental issues that extend beyond the office practice, preventing occupational illness in other employees at the work site and promoting general global environmental health [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of occupational and environmental health is found here. Occupational lung disease is discussed in detail separately, as is adult lead poisoning, arsenic toxicity, and female reproductive toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link\">",
"     \"Arsenic exposure and poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=see_link\">",
"     \"Occupational and environmental risks to reproduction in females\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The full extent of occupational injuries and illness is difficult to measure. The United States Bureau of Labor Statistics (BLS), which details statistics based upon surveys of private companies with greater than 11 employees (an underestimate of the true totals), reported 4547 fatal work-related accidents (3.5 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/6\">",
"     6",
"    </a>",
"    ] and 3.7 million nonfatal injuries and illnesses, or 3.9 per 100 equivalent full-time workers in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/7\">",
"     7",
"    </a>",
"    ]. A total of 2.1 million injuries and illnesses required recuperation away from work, job transfer, or restricted duties at work.",
"   </p>",
"   <p>",
"    Analysis of data collected from several data sets (including the BLS) produced the following estimates of annual total occupational injury and illness in the United States (US): 6500 job-related deaths from injury; 13.2 million nonfatal injuries; 60,300 deaths from job-related disease; and 862,200 work-related illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/8\">",
"     8",
"    </a>",
"    ]. Total costs were estimated to be $171 billion. In a study of health maintenance organization (HMO) members with adult-onset asthma, 21 percent were found to meet criteria for asthma attributable to occupational exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidemiological studies of first responders and firefighters are worth noting. The World Trade Center (WTC) disaster in the US in September 2001 produced large exposure to toxic dusts and gases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Studies of first responders within one month of the WTC disaster showed bronchial reactivity that was three times higher among those who had been on site the morning of the disaster, compared to those who arrived later. Studies of pulmonary function of rescue workers from the NYC Fire Department during the year following the disaster demonstrated substantial reduction in average FEV1 compared to pulmonary function studies performed five years earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/12\">",
"     12",
"    </a>",
"    ]. Subsequent studies of firefighters have continued to demonstrate changes of airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/13\">",
"     13",
"    </a>",
"    ]. An increased incidence of \"sarcoid-like\" granulomatous pulmonary disease has been reported among NYC Fire Department workers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/14\">",
"     14",
"    </a>",
"    ]. Research into health effects of firefighters in general has demonstrated an increase in fatal coronary heart disease when comparing firefighters involved in emergency firefighting duties with those who are not involved in urgent duties [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The environment can also contribute significantly to illness in both adults and children. The following are some key representative findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An important and growing area of attention is children's environmental health. A study examined the contribution of environmental pollutants to the incidence, prevalence, mortality, and costs of pediatric disease in US children by examining lead poisoning, asthma, cancer, and neurobehavioral disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/16\">",
"       16",
"      </a>",
"      ]. The authors developed a model that estimated the environmentally attributable fraction of lead poisoning to be 100 percent; asthma, 30 percent (range 10 to 35 percent); cancer, 5 percent (range 2 to 10 percent); neurobehavioral disorders, 10 percent (range 5 to 20 percent); and the subsequent estimated annual costs to be $54.9 billion [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/16\">",
"       16",
"      </a>",
"      ]. The authors concluded that the high costs of health care attributable to environmental pollution are significant enough to merit a greater investment of funding for research and prevention of pollution. Along that line, the",
"      <a class=\"external\" href=\"file://www.nationalchildrensstudy.gov/Pages/default.aspx\">",
"       National Children's Study",
"      </a>",
"      launched in 2009 is a longitudinal study of 100,000 US children age zero to 21 that examines the effects of environmental influences on health and development [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Air pollution has been linked to increased rates of morbidity and mortality, in particular from cardiovascular and respiratory illnesses [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/18-26\">",
"       18-26",
"      </a>",
"      ], as well as adverse effects on lung development in children [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/27\">",
"       27",
"      </a>",
"      ] and decreased lung function associated with increased carbon in airway macrophages of children [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. During the 1980s and 1990s in the US, there was a decrease in the concentration of the fine particulate pollution (PM25) by 10 micrograms per cubic meter which was associated with an increased life expectancy of 0.77 year [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/30\">",
"       30",
"      </a>",
"      ]. It was estimated that these reductions could account for as much as 15 percent of the overall increase in life expectancy in the study areas. A systematic review found an increased risk of myocardial infarction associated with short-term exposure to a variety of air pollutants (carbon monoxide, nitrogen dioxide, and sulfur dioxide); the population attributable risk was estimated as 0.6 to 4.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Home environmental exposures to dust mites and cockroaches [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/31\">",
"       31",
"      </a>",
"      ], and work exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/9,32\">",
"       9,32",
"      </a>",
"      ] appear to have contributed to the increased incidence and mortality of asthma in both adults and children [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/33\">",
"       33",
"      </a>",
"      ]. Concerns continue to be raised about the potential health effects related to dampness and mold in indoor environments [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. Occupational asthma is the most common occupational lung disease in developed countries. Guidelines are available to assist health care providers with diagnosis and management of occupational lung disease [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=see_link\">",
"       \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      On a more worldwide level, pollution has been linked to the buildup of carbon dioxide leading to global warming, climatic changes, and a multitude of adverse human health outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/4,38-41\">",
"       4,38-41",
"      </a>",
"      ]. Climatic and ecological changes have been shown to influence the emergence and reemergence of infectious diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Release of chlorofluorocarbon gases used in refrigerators destroys the protective ozone layer in the stratosphere, thereby leading to an increase in ultraviolet radiation and skin cancers, particularly melanoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased attention has been directed at contributions of the built environment (eg, homes, buildings, streets, infrastructure) to adverse effects such as asthma, obesity, lead poisoning, and road traffic accidents. These conditions disproportionately affect poor people and people of color [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/43-47\">",
"       43-47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nanotechnology involves the production and manipulation of materials in near atomic size (1 to 100 nm) to produce new structures, materials, and devices [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. Although this new technology promises advancement in many areas, health concerns are also raised since nanosized manufactured materials begin to exhibit unique properties that affect physical, chemical, and biological behavior. Preliminary animal research suggests that breathing certain types of nanomaterials may affect the respiratory system [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/50\">",
"       50",
"      </a>",
"      ]. Numerous workers continue to be exposed as this industry expands, and there are efforts to create registries, approaches to medical surveillance, and guidelines for exposure protection. Consumers are also potentially exposed through the use of numerous consumer products such as clothing, sunscreens, and cosmetics, and the US Food and Drug Administration is formulating an approach to regulation [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]. This area will continue to evolve over the coming years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental and work exposures can cause or aggravate a variety of common diseases such as asthma, carpal tunnel syndrome, dermatitis, hepatitis B, and cancer. In many cases, the work- or environment-related illnesses do not have unique clinical presentations: asthma caused by latex allergy does not differ from asthma precipitated by a cat allergy; median nerve entrapment related to repetitive motions has the same constellation of symptoms and signs as carpal tunnel syndrome due to pregnancy; headache due to carbon monoxide poisoning can be mistaken for severe tension headache or migraine. Symptoms related to hazardous exposures can appear as complaints involving any body system and mimicking ordinary medical diseases (",
"    <a class=\"graphic graphic_table graphicRef67211 \" href=\"UTD.htm?27/19/27964\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63506 \" href=\"UTD.htm?18/22/18796\">",
"     table 2",
"    </a>",
"    ). Some exposures cause immediate or subacute symptoms (such as allergic reactions and acute chemical reactions), while others lead to more delayed effects (such as cancer or pneumoconiosis). The distinguishing feature is the linkage to an environmental or occupational exposure. The occupational and environmental history can be the critical first step in recognizing, treating, and preventing",
"    <span class=\"nowrap\">",
"     environmental/occupational",
"    </span>",
"    illnesses and injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OCCUPATIONAL AND ENVIRONMENTAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the",
"    <span class=\"nowrap\">",
"     occupational/environmental",
"    </span>",
"    history is a survey of all patients, including relevant questions and attention to the chief complaint (or diagnosis) for clues suggesting a relationship to activities at work or at home (",
"    <a class=\"graphic graphic_algorithm graphicRef81539 \" href=\"UTD.htm?27/26/28067\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Questions may include a list of current and longest held jobs, a brief current job description, and inquiries about changes in or concerns regarding exposures or hazards at work or at home.",
"   </p>",
"   <p>",
"    In looking for a temporal relationship to work, it is better to start with non-suggestive questions such as, \"Are your symptoms better or worse at home or at work? Weekends or work days?\" rather than more leading questions such as, \"Does work make you sick?\" Any suggestion that the symptoms may be related to recent or past exposures, or to some change in environment, either at work or at home, then precipitates a more detailed series of questions to obtain additional information about potential exposures and timing of work- or environment-related symptoms.",
"   </p>",
"   <p>",
"    In some cases the screening occupational environmental survey reveals suggestive temporal relationships pointing to the role of",
"    <span class=\"nowrap\">",
"     environmental/work",
"    </span>",
"    factors: the painter who has been scraping old paint and has abdominal pain (lead poisoning?); the lab technician who gets hand itching and a rash when she puts on latex gloves (allergy?); the mother and other family members who develop headaches in the fall that are worse in the morning and when at home (carbon monoxide poisoning due to a faulty furnace?).",
"   </p>",
"   <p>",
"    Some cases of acute poisoning present with the sudden onset of characteristic signs and symptoms (\"toxidromes\"), due to accidental or deliberate release of toxicants, which need prompt recognition and treatment, frequently before diagnostic laboratory tests of the poison can be obtained&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, persons presenting with miosis, dim vision, eye pain, rhinorrhea, headache, sweating, and diarrhea should raise strong suspicions of overdose with a cholinesterase inhibitor, such as an organophosphate pesticide or sarin nerve gas. When a religious cult released a toxic nerve gas in the subway system in Tokyo, 5000 persons required emergency treatment, and 11 died [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=see_link\">",
"     \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finding a clear temporal relationship between symptoms and exposure is useful, but it is also important to realize that in some cases current exposures do not always lead to immediate symptoms. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A car painter may have worked for months at his job before developing a dry hacking cough that occurs during or after work. He might be experiencing bronchospasm from exposure to toluene diisocyanate (TDI), a well-known sensitizing agent, and one of the chemical components in the car lacquer that he sprays. In the case of allergic responses, it may take months of exposure before sensitization and clinical allergy develops. Once the asthma occurs, symptoms can sometimes extend beyond the work period, and then be triggered by a range of irritants. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=see_link\">",
"       \"Occupational asthma: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms of hyperreactive airways (persistent dry cough and shortness of breath) may develop after a single large exposure to an irritant such as chlorine gas or sulfur dioxide. This has been termed \"reactive airways disease syndrome\" or \"RADs\" [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/57\">",
"       57",
"      </a>",
"      ]. Some firefighters and rescue workers exposed to a variety of inhaled materials during and after the collapse of the World Trade Centers developed severe cough and persistent bronchial hyperreactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/12,58-60\">",
"       12,58-60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms related to current exposures may improve on non-work days or vacations early in the course of illness, a helpful clue to the potential relationship with work. However, prolonged exposure can lead to the persistence of symptoms beyond the work week. As an example, aching in the wrist and hand of a stitcher due to repetitive wrist flexion and pinching might initially resolve with rest in the evenings or on weekends. Once carpal tunnel syndrome or chronic tendonitis develops, the symptoms can persist into non-work time and be aggravated by other activities such as sewing or gardening. Furthermore, other diseases such as cancer or asbestosis may occur with a long latency (15 to 30 years from the time of exposure to the onset of the disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link\">",
"     \"Asbestosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some diagnoses, termed \"sentinel health events\" (SHE), are more likely to be linked to current or past jobs. A SHE (occupational) is a disease, disability, or untimely death that is occupationally related and whose occurrence may provide the impetus for evaluation and interventions that prevent future cases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. A patient diagnosed with a SHE, such as pulmonary tuberculosis, asthma, contact dermatitis, bladder cancer, peripheral neuropathy, or pulmonary fibrosis, would be another prompt to taking a more detailed",
"    <span class=\"nowrap\">",
"     occupational/environmental",
"    </span>",
"    history in pursuit of potential underlying (preventable) exposures. Sometimes, recognition of unusual presentations, particularly when seen in groups of workers, leads to discovery of new diseases, such as a cluster of employees in a nylon flocking plant who presented with interstitial lung disease (\"flock workers lung\") [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/63,64\">",
"     63,64",
"    </a>",
"    ] and groups of workers from a plant producing microwave popcorn who developed bronchiolitis obliterans (\"popcorn lung\") found to be caused by a butter flavoring additive, diacetyl [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The occurrence of an illness in an unexpected person (eg, lung cancer in a nonsmoker) should prompt the clinician to delve further into potential contributing environmental or occupational exposures. In another situation, work or home exposures may appear to worsen an underlying medical illness. Symptoms with no clear etiology may indicate toxicological etiologies.",
"   </p>",
"   <p>",
"    The practitioner needs to proceed with more detailed questioning once there is a suspicion that symptoms could be related to occupational or environmental conditions. Questions should include the place of employment and products manufactured. The worker should describe the tasks",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    performs, the agents handled, and the working conditions. Getting more information about chemical exposures can be initiated with obtaining the generic names of the agents used. This can be accomplished by having the patient bring in a label or a Material Safety Data Sheet (MSDS); the latter is the manufacturer's description of the product's generic name, ingredients, known health hazards, and recommendation for safe handling. These sheets vary in accuracy and completeness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/53,67\">",
"     53,67",
"    </a>",
"    ]. MSDS's can be obtained from the manufacturer or employer, and some can be found on internet sites (one good source is from the",
"    <a class=\"external\" href=\"file://siri.org/\">",
"     Vermont Safety Information Resources",
"    </a>",
"    ). Information about health effects related to these toxins can also be found by consulting other sources, such as poison control centers (1-800-222-1222), consultants, agencies, and useful references. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=see_link\">",
"     \"Information and educational resources for occupational and environmental health issues in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once it is clear what is being handled, the next question is whether or not there is an opportunity for actual exposure. The patient should describe how a substance is handled: What are the operating or cleanup practices? What protective measures are used? What type of ventilation and exhaust is provided? Does the worker need to wear a respirator, and if so, is it the proper respirator, and is it worn and properly maintained? A good source for information about respirators can be found at the",
"    <a class=\"external\" href=\"file://www.cdc.gov/niosh/topics/respirators/\">",
"     NIOSH website",
"    </a>",
"    . Then consider the mode of entry: Is it inhaled? Is it ingested by eating at the workplace? Is there skin contact? Is there use of protective clothing or appropriate gloves to prevent skin absorption? Are other workers exposed? Do others have any symptoms?",
"   </p>",
"   <p>",
"    It is also helpful to consider if the person exposed may be particularly vulnerable to the exposure. A person with renal disease, as an example, exposed to lead at acceptable (regulatory) air levels, might accumulate higher levels of lead than expected because of decreased ability to excrete it through the kidneys. A pregnant woman might be exposed to toxins, such as lead or carbon monoxide, at doses that would not be dangerous to her, but would be harmful to the developing fetus, who is more sensitive to the adverse effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=see_link\">",
"     \"Occupational and environmental risks to reproduction in females\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exposures also can occur inside or outside of the home. Household exposures may result from the use of household chemicals, performance of certain hobbies, home remodeling, or bringing home contaminated work clothing (",
"    <a class=\"graphic graphic_table graphicRef74415 \" href=\"UTD.htm?19/32/19980\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62461 \" href=\"UTD.htm?38/32/39436\">",
"     table 4",
"    </a>",
"    ). A household products database is available on the",
"    <a class=\"external\" href=\"file://hpd.nlm.nih.gov/index.htm\">",
"     National Library of Medicine website",
"    </a>",
"    , and provides health effect information on over 4000 consumer brands.",
"   </p>",
"   <p>",
"    The home, as well as surrounding air, water, and soil can be contaminated by nearby industrial plants, commercial business, or dump sites, or through disasters such as hurricanes, flooding or earthquakes. Depending upon the patient's complaints, inquiry about home insulation, heating and cooling systems, home cleaning agents, pesticide use, water supply, water leaks, recent renovations, air pollution, hobbies, hazardous waste contamination, spills, floods, or other exposures may be warranted. The potential for exposure to children should be considered if possible home and neighborhood exposures are identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pediatric environmental health history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child's physiology and behavior puts him or her at an increased risk for adverse effects from many toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/68\">",
"     68",
"    </a>",
"    ]. Most attention concerning environmental exposures to children previously centered upon lead and second-hand cigarette smoke. More recently there has been increasing awareness about the potential health effects of other exposures, including chemical allergens and irritants (eg, formaldehyde resins), indoor and outdoor air pollutants, pesticides, and other toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/28,69,70\">",
"     28,69,70",
"    </a>",
"    ]. The pediatric history involves asking screening questions at the initial visit and follow-up visits that are relevant to the child's developmental stage. Questions are directed toward describing the home or other environments frequented by the child, as well as the parents' jobs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/69,71\">",
"     69,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DOCUMENTING AND QUANTIFYING EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the history raises concerns about exposures, it is usually necessary to measure the exposure in order to assess the level of risk",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    relationship to any symptoms. Documenting and quantifying exposures can involve performing biological monitoring tests of the affected person as well as evaluating the work or environmental site. The practitioner may find it helpful to seek assistance from specialists such as",
"    <span class=\"nowrap\">",
"     occupational/environmental",
"    </span>",
"    medicine specialists, toxicologists, governmental agencies, and industrial hygienists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=see_link\">",
"     \"Information and educational resources for occupational and environmental health issues in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Within the office setting the patient can be tested for evidence of exposure in body fluids (biological monitoring) or of adverse health effects upon target organs. The practitioner must know what agent to look for, the desirable test medium (urine, blood, hair, tissue), appropriate timing, and influences upon test results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carboxyhemoglobin is a blood test that indicates exposure to carbon monoxide; the measurement of a carboxyhemoglobin should be performed as soon as possible after exposure since the half-life of carbon monoxide in the body is approximately four hours when breathing room air. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Arsenic is excreted rapidly in the urine within a few days; it is a good marker for recent but not past exposure. Recent consumption of seafood can lead to increases in total urine arsenic due to the contribution of nontoxic forms of organified arsenic, thereby leading to mistaken interpretations of elevated arsenic levels. The solution is to speciate urine arsenic into inorganic and organic arsenic, if elevated levels are identified. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=see_link\">",
"       \"Arsenic exposure and poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some chemicals are detected by measurement of metabolites. As an example, several biological monitoring tests have been proposed for evaluating exposure to the solvent toluene, including measurements of the urine metabolites hippuric acid, benzoic acid, and o-cresol [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hair analysis performed by commercial laboratories for multiple toxins and elements have been found to be of poor reliability and accuracy, and have little applicability in the primary care setting [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/73,74\">",
"       73,74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory tests may also be performed to look for toxic effects or end-organ damage. As an example, a blood lead concentration could be ordered to assess exposure, and BUN and creatinine to look for effects upon the kidneys. Pulmonary function tests and a chest radiograph would be ordered to assess the effects of past asbestos exposure on the lungs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link\">",
"     \"Asbestosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the environmental or occupational site can be performed by governmental agencies, such as the Occupational Safety and Health Administration (OSHA) or the Environmental Protection Agency (EPA), or by private consultants such as certified industrial hygienists. Air sampling is performed with area or personal sampling devices to get results that can lead to estimates of exposure based upon an average eight-hour exposure. Many regulatory standards such as OSHA permissible exposure limits (PELs) are based upon eight-hour, time-weighted averages. Toxins can be measured in air, water, soil, and from surfaces.",
"   </p>",
"   <p>",
"    In some cases, the correlation between exposure levels (in the environment or the body) and health effects is good, and in other cases poor. Lead, as an example, can be measured in air",
"    <span class=\"nowrap\">",
"     (micrograms/cubic",
"    </span>",
"    meter) with a reasonable correlation between air levels and blood leads measured in exposed individuals. Although there is considerable individual variation, there is a general correlation between recent lead exposure and acute responses in adults. Generally, there are little or no acute clinical effects from recent exposures leading to blood leads below 20",
"    <span class=\"nowrap\">",
"     micrograms/dL;",
"    </span>",
"    gastrointestinal symptoms may occur with levels of 50",
"    <span class=\"nowrap\">",
"     micrograms/dL",
"    </span>",
"    and above; and anemia seen with levels above 80",
"    <span class=\"nowrap\">",
"     micrograms/dL.",
"    </span>",
"    In contrast, manganese levels (of potential importance since an organic form of manganese, methylcyclopentadienyl manganese tricarbonyl (MMT) has been used as a gasoline additive) measured in the air are poorly correlated with measurement in the blood. In general, blood levels of manganese do not correlate well with the appearance of the adverse side effects of manic-depressive symptoms and parkinsonism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of musculoskeletal stresses can be performed qualitatively by observing the workers performing job tasks, and more quantitatively with biomechanical analyses performed by an ergonomics expert.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MAKING A CAUSAL CONNECTION BETWEEN EXPOSURE AND ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Making the causal connection between an exposure and the patient's symptoms requires consistency between the known adverse effects of the toxic agent and the nature of the illness; the presence of an appropriate temporal relationship between exposure and effect; and a sufficient exposure to cause the presumed effect. There are a number of excellent written resources describing the health effects of various exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/75-83\">",
"     75-83",
"    </a>",
"    ], as well as agencies and consultants to whom the primary care clinician can turn for assistance in this process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=see_link\">",
"     \"Information and educational resources for occupational and environmental health issues in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Poison Control is another resource that provides quick information about chemical toxins (1-800-222-1222). There has been a great deal of publicity about health effects and exposure to damp environments and mold, and there are several excellent resources that summarize current information and approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/84-87\">",
"     84-87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to consider whether others have been exposed and need to be evaluated and treated once the diagnosis of a work- or environment-related illness has been made. It may be necessary to make an intervention to decrease or eliminate exposures in order to prevent illness in others. The physician may find it necessary to alert the company medical department, a company health and safety committee, or the state public health or labor department. It is often necessary to obtain additional exposure information to follow up on the initial leads. OSHA performs work site inspections routinely on a priority basis, or at the request of a current worker or management. Fines may be levied in some cases if OSHA standards are violated.",
"   </p>",
"   <p>",
"    Other consultative sources include academically affiliated occupational health clinics (",
"    <a class=\"external\" href=\"file://www.aoec.org/\">",
"     Association of Occupational and Environmental Clinics",
"    </a>",
"    ), board certified occupational and environmental medicine specialists (",
"    <a class=\"external\" href=\"file://www.acoem.org/\">",
"     American College of Occupational and Environmental Medicine",
"    </a>",
"    ),",
"    <a class=\"external\" href=\"file://www.aoec.org/PEHSU.htm\">",
"     Pediatric Environmental Health Specialty Units",
"    </a>",
"    , and worker",
"    <span class=\"nowrap\">",
"     education/advocacy",
"    </span>",
"    groups such as Coalition for Safety and Health (COSH) groups. The National Institute for Occupational Safety and Health (NIOSH) can provide the practitioner with toxicological information and perform health hazard evaluations of workers to detect work-related health problems. Industrial hygienists from private consulting groups or from workers' compensation carriers can conduct worksite evaluations and monitoring and advise about interventions. The practitioner may find it useful to contact the local state Department of Environmental Protection or city departments of public health for environmental problems.",
"   </p>",
"   <p>",
"    The practitioner can also help an affected worker obtain workers' compensation when justified. The definition of \"work-related\" may vary by state, but usually implies that it is more likely than not that some activity at work precipitated, hastened, aggravated, or contributed to the injury or illness. The workers' compensation system is state-based; the practitioner needs to become familiar with the state regulations of his or her practice. Workers' compensation can provide benefits for work time lost, permanent disability, medical care expenses, and rehabilitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32326?source=see_link\">",
"     \"Social Security Disability Insurance and workers' compensation in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efforts to control home environmental exposures can also be helpful. As an example, practitioners can advise asthmatic patients on measures to reduce environmental triggers. In a study of children with asthma, interventions that resulted in reducing levels of cockroach allergen and dust mite allergen in the bedroom were significantly correlated with reduced complications from asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14553/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H614596665\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental and occupational issues have an important place in primary care practice, emergency medicine, pediatrics, and various medical specialties. Work or environmental exposures may be linked to an individual patient's symptoms. A patient's reported environmental exposures may prompt important interventions to prevent future illnesses or injuries.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Environmental and work exposures can cause or aggravate a variety of common diseases such as asthma, carpal tunnel syndrome, dermatitis, hepatitis B, and cancer. In many cases, the work- or environment-related illnesses do not have unique clinical presentations. Some exposures cause immediate or subacute symptoms (such as allergic reactions and acute chemical reactions), while others lead to more delayed effects (such as cancer or pneumoconiosis). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first step in the",
"      <span class=\"nowrap\">",
"       occupational/environmental",
"      </span>",
"      history is a survey of all patients, including relevant questions and attention to the chief complaint (or diagnosis) for clues suggesting a relationship to activities at work or at home (",
"      <a class=\"graphic graphic_algorithm graphicRef81539 \" href=\"UTD.htm?27/26/28067\">",
"       algorithm 1",
"      </a>",
"      ). Questions may include a list of current and longest held jobs, a brief current job description, and inquiries about changes in or concerns regarding exposures or hazards at work or at home. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Occupational and environmental history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the history raises concerns about exposures, it is usually necessary to measure the exposure in order to assess the level of risk",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      relationship to any symptoms. Documenting and quantifying exposures can involve performing biological monitoring tests of the affected person as well as evaluating the work or environmental site. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Documenting and quantifying exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to consider whether others have been exposed and need to be evaluated and treated once the diagnosis of a work- or environment-related illness has been made. It may be necessary to make an intervention to decrease or eliminate exposures in order to prevent illness in others. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/1\">",
"      Kales SN, Christiani DC. Acute chemical emergencies. N Engl J Med 2004; 350:800.",
"     </a>",
"    </li>",
"    <li>",
"     ACP Online. Bioterrorism resources. Available at: www.acponline.org/bioterro/ (Accessed on March 05, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/3\">",
"      Landrigan PJ, Baker DB. The recognition and control of occupational disease. JAMA 1991; 266:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/4\">",
"      McCally M, Cassel CK. Medical responsibility and global environmental change. Ann Intern Med 1990; 113:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/5\">",
"      Bunyavanich S, Landrigan CP, McMichael AJ, Epstein PR. The impact of climate change on child health. Ambul Pediatr 2003; 3:44.",
"     </a>",
"    </li>",
"    <li>",
"     Bureau of Labor Statistics. Economic News Release: Census of Fatal Occupational Injuries Summary, 2010. US Department of Labor 2011. Available at: file://www.bls.gov/news.release/cfoi.nr0.htm (Accessed on April 15, 2012).",
"    </li>",
"    <li>",
"     Bureau of Labor Statistics. Workplace injuries and illnesses in 2008. US Department of Labor 2009. Available at: www.bls.gov/news.release/pdf/osh.pdf (Accessed on February 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/8\">",
"      Leigh JP, Markowitz SB, Fahs M, et al. Occupational injury and illness in the United States. Estimates of costs, morbidity, and mortality. Arch Intern Med 1997; 157:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/9\">",
"      Milton DK, Solomon GM, Rosiello RA, Herrick RF. Risk and incidence of asthma attributable to occupational exposure among HMO members. Am J Ind Med 1998; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/10\">",
"      Samet JM, Geyh AS, Utell MJ. The legacy of World Trade Center dust. N Engl J Med 2007; 356:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/11\">",
"      Herbert R, Moline J, Skloot G, et al. The World Trade Center disaster and the health of workers: five-year assessment of a unique medical screening program. Environ Health Perspect 2006; 114:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/12\">",
"      Banauch GI, Hall C, Weiden M, et al. Pulmonary function after exposure to the World Trade Center collapse in the New York City Fire Department. Am J Respir Crit Care Med 2006; 174:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/13\">",
"      Weiden MD, Ferrier N, Nolan A, et al. Obstructive airways disease with air trapping among firefighters exposed to World Trade Center dust. Chest 2010; 137:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/14\">",
"      Izbicki G, Chavko R, Banauch GI, et al. World Trade Center \"sarcoid-like\" granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007; 131:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/15\">",
"      Kales SN, Soteriades ES, Christophi CA, Christiani DC. Emergency duties and deaths from heart disease among firefighters in the United States. N Engl J Med 2007; 356:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/16\">",
"      Landrigan PJ, Schechter CB, Lipton JM, et al. Environmental pollutants and disease in American children: estimates of morbidity, mortality, and costs for lead poisoning, asthma, cancer, and developmental disabilities. Environ Health Perspect 2002; 110:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/17\">",
"      Landrigan PJ, Trasande L, Thorpe LE, et al. The National Children's Study: a 21-year prospective study of 100,000 American children. Pediatrics 2006; 118:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/18\">",
"      Dockery DW, Pope CA 3rd, Xu X, et al. An association between air pollution and mortality in six U.S. cities. N Engl J Med 1993; 329:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/19\">",
"      Samet JM, Dominici F, Curriero FC, et al. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med 2000; 343:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/20\">",
"      Clancy L, Goodman P, Sinclair H, Dockery DW. Effect of air-pollution control on death rates in Dublin, Ireland: an intervention study. Lancet 2002; 360:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/21\">",
"      Brunekreef B, Holgate ST. Air pollution and health. Lancet 2002; 360:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/22\">",
"      Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. Circulation 2001; 103:2810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/23\">",
"      Hong YC, Lee JT, Kim H, et al. Effects of air pollutants on acute stroke mortality. Environ Health Perspect 2002; 110:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/24\">",
"      McConnell R, Berhane K, Gilliland F, et al. Asthma in exercising children exposed to ozone: a cohort study. Lancet 2002; 359:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/25\">",
"      Dockery DW, Luttmann-Gibson H, Rich DQ, et al. Association of air pollution with increased incidence of ventricular tachyarrhythmias recorded by implanted cardioverter defibrillators. Environ Health Perspect 2005; 113:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/26\">",
"      Mustafic H, Jabre P, Caussin C, et al. Main air pollutants and myocardial infarction: a systematic review and meta-analysis. JAMA 2012; 307:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/27\">",
"      Gauderman WJ, Avol E, Gilliland F, et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med 2004; 351:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/28\">",
"      Kulkarni N, Pierse N, Rushton L, Grigg J. Carbon in airway macrophages and lung function in children. N Engl J Med 2006; 355:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/29\">",
"      Gauderman WJ. Air pollution and children--an unhealthy mix. N Engl J Med 2006; 355:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/30\">",
"      Pope CA 3rd, Ezzati M, Dockery DW. Fine-particulate air pollution and life expectancy in the United States. N Engl J Med 2009; 360:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/31\">",
"      Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med 1997; 336:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/32\">",
"      Chan-Yeung M, Malo JL. Occupational asthma. N Engl J Med 1995; 333:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Asthma--United States, 1982-1992. MMWR Morb Mortal Wkly Rep 1995; 43:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/34\">",
"      Mendell MJ, Mirer AG, Cheung K, et al. Respiratory and allergic health effects of dampness, mold, and dampness-related agents: a review of the epidemiologic evidence. Environ Health Perspect 2011; 119:748.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Damp Indoor Spaces and Health, National Acadamies Press, Washington, DC 2004.",
"    </li>",
"    <li>",
"     American College of Occupational and Environmental Medicine (ACOEM). Adverse Human Health Effects Associated with Molds in the Indoor Environment. ACOEM 2011. Available at: file://www.acoem.org/AdverseHumanHealthEffects_Molds.aspx (Accessed on June 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/37\">",
"      Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/38\">",
"      Leaf A. Potential health effects of global climatic and environmental changes. N Engl J Med 1989; 321:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/39\">",
"      McMichael AJ, Woodruff RE, Hales S. Climate change and human health: present and future risks. Lancet 2006; 367:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/40\">",
"      Schwartz BS, Parker C, Glass TA, Hu H. Global environmental change: what can health care providers and the environmental health community do about it now? Environ Health Perspect 2006; 114:1807.",
"     </a>",
"    </li>",
"    <li>",
"     Intergovernmental Panel on Climate Change. Summary for Policymakers. In: Climate Change 2007: Impacts, Adaptation and Vulnerability - Contribution of Working",
"Group II to the Fourth Assessment Report of the Intergovernmental Panel on Climate Change. Parry ML, Canziani OF, Palutikof JP, et al. (Eds). Cambridge University Press, Cambridge 2007. Available at: file://www.ipcc.ch/pdf/assessment-report/ar4/wg2/ar4-wg2-spm.pdf (Accessed on February 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/42\">",
"      Patz JA, Epstein PR, Burke TA, Balbus JM. Global climate change and emerging infectious diseases. JAMA 1996; 275:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/43\">",
"      Frumkin H. Health, equity, and the built environment. Environ Health Perspect 2005; 113:A290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/44\">",
"      Rao M, Prasad S, Adshead F, Tissera H. The built environment and health. Lancet 2007; 370:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/45\">",
"      Wilkinson P, Smith KR, Beevers S, et al. Energy, energy efficiency, and the built environment. Lancet 2007; 370:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/46\">",
"      Li F, Harmer PA, Cardinal BJ, et al. Built environment, adiposity, and physical activity in adults aged 50-75. Am J Prev Med 2008; 35:38.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Built Environment / Healthy Community Design. US Department of Health and Human Services. Available at: www.cdc.gov/nceh/ehs/Topics/BuiltEnvironment.htm (Accessed on February 01, 2010).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Workplace Safety &amp; Health Topics: Nanotechnology. Available at: file://www.cdc.gov/niosh/topics/nanotech/ (Accessed on June 11, 2012).",
"    </li>",
"    <li>",
"     National Institute for Occupational Safety and Health (NIOSH). Approaches to Safe Nanotechnology: Managing the Health and Safety Concerns Associated with Engineered Nanomaterials. Centers for Disease Control and Prevention 2009. Available at: file://www.cdc.gov/niosh/docs/2009-125/ (Accessed on June 11, 2012).",
"    </li>",
"    <li>",
"     National Institute for Occupational Safety and Health (NIOSH). A Story of Impact: NIOSH Research Methods Demonstrate that Breathing Nanoparticles May Result in Damaging Health Effects. Centers for Disease Control and Prevention 2010. Available at: file://www.cdc.gov/niosh/docs/2010-158/ (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/51\">",
"      Kessler R. Engineered nanoparticles in consumer products: understanding a new ingredient. Environ Health Perspect 2011; 119:a120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/52\">",
"      Hamburg MA. Science and regulation. FDA's approach to regulation of products of nanotechnology. Science 2012; 336:299.",
"     </a>",
"    </li>",
"    <li>",
"     ATSDR. Case Studies in Environmental Medicine: Taking an exposure history. Case Studies in Environmental Medicine. ATSDR Publication No: ATSDR-HE-CS-2001-0002. Agency for Toxic Substances and Disease Registry, US Department of Health and Human Services, Atlanta 2000. p. 63.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/54\">",
"      Goldman RH, Peters JM. The occupational and environmental health history. JAMA 1981; 246:2831.",
"     </a>",
"    </li>",
"    <li>",
"     Wegman DH, Levy, BS, Halperin WE. Recognizing occupational disease. In: Occupational Health: Recognizing and Preventing Work-Related Disease, 4th ed, Levy BS, Wegman DH (Eds), Lipppincott Williams &amp; Wilkins, Philadelphia 2000. p.99.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/56\">",
"      Okumura T, Takasu N, Ishimatsu S, et al. Report on 640 victims of the Tokyo subway sarin attack. Ann Emerg Med 1996; 28:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/57\">",
"      Brooks SM, Weiss MA, Bernstein IL. Reactive airways dysfunction syndrome (RADS). Persistent asthma syndrome after high level irritant exposures. Chest 1985; 88:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/58\">",
"      Prezant DJ, Weiden M, Banauch GI, et al. Cough and bronchial responsiveness in firefighters at the World Trade Center site. N Engl J Med 2002; 347:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/59\">",
"      Banauch GI, Alleyne D, Sanchez R, et al. Persistent hyperreactivity and reactive airway dysfunction in firefighters at the World Trade Center. Am J Respir Crit Care Med 2003; 168:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/60\">",
"      Banauch GI, Dhala A, Alleyne D, et al. Bronchial hyperreactivity and other inhalation lung injuries in rescue/recovery workers after the World Trade Center collapse. Crit Care Med 2005; 33:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/61\">",
"      Rutstein DD, Mullan RJ, Frazier TM, et al. Sentinel Health Events (occupational): a basis for physician recognition and public health surveillance. Am J Public Health 1983; 73:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/62\">",
"      Mullan RJ, Murthy LI. Occupational sentinel health events: an up-dated list for physician recognition and public health surveillance. Am J Ind Med 1991; 19:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/63\">",
"      Kern DG, Crausman RS, Durand KT, et al. Flock worker's lung: chronic interstitial lung disease in the nylon flocking industry. Ann Intern Med 1998; 129:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/64\">",
"      Kern DG, Kuhn C 3rd, Ely EW, et al. Flock worker's lung: broadening the spectrum of clinicopathology, narrowing the spectrum of suspected etiologies. Chest 2000; 117:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/65\">",
"      Kreiss K, Gomaa A, Kullman G, et al. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med 2002; 347:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/66\">",
"      Kullman G, Boylstein R, Jones W, et al. Characterization of respiratory exposures at a microwave popcorn plant with cases of bronchiolitis obliterans. J Occup Environ Hyg 2005; 2:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/67\">",
"      Himmelstein JS, Frumkin H. The right to know about toxic exposures. Implications for physicians. N Engl J Med 1985; 312:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/68\">",
"      Quang LS, Woolf AD. Children's unique vulnerabilities to environmental exposures. Environmental Epidemiology and Toxicology 2000; 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Environmental Health American Academy of Pediatrics. Pediatric Environmental Health, 2nd ed, Etzel RA (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/70\">",
"      Etzel RA. Indoor air pollutants in homes and schools. Pediatr Clin North Am 2001; 48:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/71\">",
"      Balk SJ. The environmental history: asking the right questions. Contemp Pediatr 1996; 13:19.",
"     </a>",
"    </li>",
"    <li>",
"     Lauwerys RR, Hoet P. Industrial Chemical Exposure - Guidelines for Biological Monitoring, 3rd ed, Lewis Publishers, Boca Raton 2001. p.638.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/73\">",
"      Steindel SJ, Howanitz PJ. The uncertainty of hair analysis for trace metals. JAMA 2001; 285:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/74\">",
"      Kales SN, Goldman RH. Mercury exposure: current concepts, controversies, and a clinic's experience. J Occup Environ Med 2002; 44:143.",
"     </a>",
"    </li>",
"    <li>",
"     Burgess W. Recognition of Health Hazards in Industry: A Review of Materials and Processes, 2nd ed, Wiley, New York New York.",
"    </li>",
"    <li>",
"     A Practical Approach to Occupational and Environmental Medicine, 3rd ed, McCunney RJ (Ed), Lippincott Williams &amp; Wilkins, Philadelphia Philadelphia. p.952.",
"    </li>",
"    <li>",
"     Environmental and Occupational Medicine, 4th ed, Rom W (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/78\">",
"      Beckett WS. Occupational respiratory diseases. N Engl J Med 2000; 342:406.",
"     </a>",
"    </li>",
"    <li>",
"     Hathaway GJ, Proctor NH, Hughes JP. Chemical Hazard of the Workplace, 5th ed, John Wiley &amp; Sons, Hoboken, NJ 2004. p.785.",
"    </li>",
"    <li>",
"     Occupational Health: Recognizing and Preventing Work-Related Disease, 5th ed, Levy BS, Wegman DH, Baron SL, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.773.",
"    </li>",
"    <li>",
"     LaDou J. Current Occupational and Environmental Medicine, 4th ed, McGraw-Hill, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/82\">",
"      Siemiatycki J, Richardson L, Straif K, et al. Listing occupational carcinogens. Environ Health Perspect 2004; 112:1447.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenstock L, Cullen MR, Brodkin CR, Redlich CA. Textbook of clinical occupational and environmental medicine, 2nd ed, Saunders, Philadelphia 2004.",
"    </li>",
"    <li>",
"     Board on Health Promotion and Disease Prevention, Institute of Medicine. Damp indoor spaces and health. The National Academies Press 2004. Available at: www.nap.edu/books/0309091934/html/ (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     Storey E, Dangman KH, Schenck P, et al. Guidance for Clinicians on the Recognition and Management of Health Effects Related to Mold Exposure and Moisture Indoors. University of Connecticut Health Center Division of Occupational and Environmental Medicine 2004. Available at: oehc.uchc.edu/clinser/MOLD%20GUIDE.pdf (Accessed on December 02, 2004).",
"    </li>",
"    <li>",
"     US Environmental Protection Agency. A Brief Guide to Mold, Moisture, and Your Home. Available at: www.epa.gov/iaq/molds/moldguide.html (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/87\">",
"      Brandt M, Brown C, Burkhart J, et al. Mold prevention strategies and possible health effects in the aftermath of hurricanes and major floods. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14553/abstract/88\">",
"      Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004; 351:1068.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2749 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14553=[""].join("\n");
var outline_f14_13_14553=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H614596665\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OCCUPATIONAL AND ENVIRONMENTAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pediatric environmental health history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DOCUMENTING AND QUANTIFYING EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MAKING A CAUSAL CONNECTION BETWEEN EXPOSURE AND ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H614596665\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2749\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2749|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?27/26/28067\" title=\"algorithm 1\">",
"      Occupation environment history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2749|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/19/27964\" title=\"table 1\">",
"      Etiology short term problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/22/18796\" title=\"table 2\">",
"      Etiology long term problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/32/19980\" title=\"table 3\">",
"      Dangerous household products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/32/39436\" title=\"table 4\">",
"      Hazards in hobbies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8730?source=related_link\">",
"      Arsenic exposure and poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=related_link\">",
"      Asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/20/8521?source=related_link\">",
"      Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=related_link\">",
"      Information and educational resources for occupational and environmental health issues in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=related_link\">",
"      Occupational and environmental risks to reproduction in females",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5194?source=related_link\">",
"      Secondhand smoke exposure: Effects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32326?source=related_link\">",
"      Social Security Disability Insurance and workers' compensation in the United States",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_13_14554="Clinical manifestations of Parkinson disease";
var content_f14_13_14554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations of Parkinson disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/13/14554/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/13/14554/contributors\">",
"     Kelvin L Chou, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/13/14554/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/13/14554/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/13/14554/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/13/14554/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/13/14554/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;First described by James Parkinson in his classic 1817 monograph, \"An Essay on the Shaking Palsy\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/1\">",
"     1",
"    </a>",
"    ], Parkinson disease (PD; also known as paralysis agitans) is a progressive neurodegenerative disease that affects between 100 and 200 per 100,000 people over 40, and over 1 million people in North America alone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Parkinson disease is uncommon in people younger than 40, and the incidence of the disease increases rapidly over 60 years, with a mean age at diagnosis of 70.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While PD has traditionally been considered a motor system disorder, it is now recognized to be a complex condition with diverse clinical features that include neuropsychiatric and other nonmotor manifestations in addition to its motor symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/5\">",
"     5",
"    </a>",
"    ]. An accurate diagnosis of PD rests on the clinician's ability to recognize its characteristic signs and associated symptoms, especially in the early stages.",
"   </p>",
"   <p>",
"    This topic will review the clinical manifestations of PD. The diagnosis and treatment of PD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link\">",
"     \"Diagnosis of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link\">",
"     \"Pharmacologic treatment of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4277?source=see_link\">",
"     \"Nonpharmacologic management of Parkinson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=see_link\">",
"     \"Management of comorbid problems associated with Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149298288\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of Parkinson disease is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology and pathogenesis of Parkinson disease\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDINAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal features of PD are tremor, bradykinesia, and rigidity. A fourth feature, postural instability, is commonly mentioned, although it does not generally occur until much later in the course of the disease and is thus not included in any published diagnostic criteria for PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The severity of motor symptoms appears to be an independent predictor of mortality in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tremor in PD, typically described as \"pill-rolling\", is a rest tremor, meaning that it is most noticeable when the tremulous body part is supported by gravity and not engaged in purposeful activities. Tremors in other conditions, such as essential tremor or multiple sclerosis, are typically action tremors, in which the tremor occurs when the affected limb is being used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link\">",
"     \"Overview of tremor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not unusual for a parkinsonian tremor to be present with postural maneuvers or with action, but in such cases, the tremor is typically much more severe at rest. Because parkinsonian tremor decreases with purposeful action, it is usually the least disabling of the cardinal manifestations. However, when the tremor is severe, it can be difficult to distinguish a primary resting tremor from a primary action tremor. Some patients with PD may have a re-emergent tremor: a postural tremor that manifests after a latency of several seconds and has a frequency typical of the rest tremor in PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This distinction is important, as patients with PD who have a re-emergent postural tremor may be misdiagnosed as having essential tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tremor of early PD is most often intermittent, and may not be noticeable to others. In fact, about half of patients with PD report a sensation of internal tremulousness in the limbs or body that is unrelated to the presence of observable tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/14\">",
"     14",
"    </a>",
"    ]. However, as the disease progresses, tremor usually becomes evident.",
"   </p>",
"   <p>",
"    In the clinical setting, tremor in the limbs can be seen when the patient is relaxed with the hands resting quietly on the lap. Distracting the patient by asking him or her to perform mental calculations or voluntary repetitive movements of the contralateral limb often accentuates a mild tremor and may uncover a latent tremor. A resting hand tremor may be present only during the gait evaluation.",
"   </p>",
"   <p>",
"    The frequency of the tremor in PD is between 3 and 7 Hz, and most often is between 4 and 5 Hz [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/15\">",
"     15",
"    </a>",
"    ]. Tremor is the presenting symptom in approximately 70 percent of patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/16\">",
"     16",
"    </a>",
"    ], and the percentage of patients with tremor at some point in the course of the disease is high, ranging from 79 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Tremor usually starts unilaterally in the hand, and then spreads contralaterally several years after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/21\">",
"     21",
"    </a>",
"    ]. The side that is initially affected tends to be the more affected side throughout the course of the disease.",
"   </p>",
"   <p>",
"    The tremor of PD can also involve the legs, lips, jaw, and tongue, but rarely involves the head [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/15,22\">",
"     15,22",
"    </a>",
"    ]. Anxiety, emotional excitement, or stressful situations can exacerbate the tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bradykinesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bradykinesia is a generalized slowness of movement. It is arguably the major cause of disability in PD and is eventually seen in almost all patients. While it is the most common feature in PD, it is also the most difficult symptom for patients to describe. \"Weakness,\" \"incoordination,\" and \"tiredness\" are often used to describe the decreased ability to initiate voluntary movement.",
"   </p>",
"   <p>",
"    In the arms, bradykinesia typically starts distally with decreased manual dexterity of the fingers. Patients often complain of difficulty performing simple tasks, such as buttoning clothes, tying shoelaces, double clicking a computer mouse, typing, or lifting coins from a pocket or purse.",
"   </p>",
"   <p>",
"    In the legs, common complaints related to bradykinesia when walking include dragging the legs, shorter (shuffling) steps, or a feeling of unsteadiness. Patients may also have difficulty standing up from a chair or getting out of a car. As the disease progresses, gait freezing and festination may develop. James Parkinson defined festination as \"an irresistible impulse to take much quicker and shorter steps, and thereby to adopt unwillingly a running pace\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical examination of bradykinesia includes evaluation of limb movements on each side of the body. The speed, amplitude, and rhythm of finger tapping, hand gripping, pronation-supination hand movements, and heel or toe tapping should be carefully observed. In mild PD, these tasks usually show some slowing and decreased amplitude when observed for more than a few seconds. As the disease progresses movements become less coordinated, with frequent hesitations or arrests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rigidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigidity is an increased resistance to passive movement about a joint and occurs in approximately 90 percent of patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Rigidity, like tremor and bradykinesia, often begins unilaterally, and typically on the same side as the tremor if one is present. Rigidity eventually progresses to the contralateral side, and remains asymmetric throughout the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cogwheel rigidity can be seen in PD, and the term refers to a ratchety pattern of resistance and relaxation as the examiner moves the limb through its full range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/23\">",
"     23",
"    </a>",
"    ]. This phenomenon is thought to be a manifestation of tremor superimposed on increased tone [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/24\">",
"     24",
"    </a>",
"    ]. However, not all patients with PD have cogwheel rigidity; many instead will have lead-pipe rigidity, a tonic resistance that is smooth throughout the entire range of passive movement.",
"   </p>",
"   <p>",
"    Rigidity can affect any part of the body, and may contribute to complaints of stiffness and pain. Features, such as the striatal hand (extension of the proximal and distal interphalangeal joints with flexion at the metacarpophalangeal joints), decreased arm swing with walking, and the typical stooped posture, result, at least in part, from rigidity.",
"   </p>",
"   <p>",
"    At the bedside, rigidity is tested by passively manipulating the limbs. It can be brought out by having the patient perform repetitive maneuvers using the contralateral limb or by performing mental arithmetic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Postural instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postural instability is an impairment of centrally-mediated postural reflexes that cause a feeling of imbalance and a tendency to fall with a significant risk of injury. Because postural instability usually does not appear until later in the course of PD, patients with parkinsonian signs who fall early in the course of the illness most likely have another parkinsonian syndrome, such as progressive supranuclear palsy or multiple system atrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of Parkinson disease\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postural instability is tested clinically with the \"pull\" test, where the examiner stands behind the patient and firmly pulls the patient by the shoulders. Patients with normal postural reflexes should be able to maintain balance and retropulse (step backward) no more than one step. Patients with PD and postural instability, on the other hand, are likely to fall or take multiple steps backwards.",
"   </p>",
"   <p>",
"    Initially, a positive pull test may be the only sign of balance impairment. However, as postural instability progresses, the gait may show signs of festination. Once postural reflexes are lost, patients are generally wheelchair-bound.",
"   </p>",
"   <p>",
"    Among the primary motor features of PD, postural instability is the least responsive to dopaminergic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, postural instability and gait difficulty are major contributors to disability in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL SUBTYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some investigators have postulated that the rate of disease progression in PD varies for certain clinically defined subgroups or subtypes of PD.",
"   </p>",
"   <p>",
"    The major subtypes are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tremor dominant",
"     </li>",
"     <li>",
"      Akinetic-rigid",
"     </li>",
"     <li>",
"      Postural instability and gait difficulty",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies have compared the tremor dominant subtype to either the akinetic-rigid or the postural instability and gait difficulty subtypes, with the tremor dominant subtype being associated with slower progression and less neuropsychologic impairment than the other two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/27-30\">",
"     27-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some clinicians may find these groupings useful, clinical PD progression is unfortunately variable, and subtypes can change in an individual as the disease progresses. Thus, there currently are no symptoms or signs in idiopathic PD that allow a practitioner to accurately predict the future course of PD for any given individual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER MOTOR FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the cardinal manifestations just discussed, there are a number of other motor features seen in Parkinson disease (PD) (",
"    <a class=\"graphic graphic_table graphicRef81338 \" href=\"UTD.htm?21/3/21564\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Craniofacial",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypomimia (masked facial expression)",
"     </li>",
"     <li>",
"      Decreased spontaneous eye blink rate",
"     </li>",
"     <li>",
"      Speech impairment, including hypokinetic dysarthria, hypophonia, and palilalia (repetition of a phrase or word with increasing rapidity)",
"     </li>",
"     <li>",
"      Dysphagia",
"     </li>",
"     <li>",
"      Sialorrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Blurred vision",
"     </li>",
"     <li>",
"      Impaired contrast sensitivity",
"     </li>",
"     <li>",
"      Hypometric saccades",
"     </li>",
"     <li>",
"      Impaired vestibuloocular reflex",
"     </li>",
"     <li>",
"      Impaired upward gaze and convergence",
"     </li>",
"     <li>",
"      Eyelid opening apraxia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Musculoskeletal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Micrographia",
"     </li>",
"     <li>",
"      Dystonia",
"     </li>",
"     <li>",
"      Myoclonus",
"     </li>",
"     <li>",
"      Stooped posture",
"     </li>",
"     <li>",
"      Camptocormia (severe anterior flexion of the thoracolumbar spine)",
"     </li>",
"     <li>",
"      Kyphosis",
"     </li>",
"     <li>",
"      Scoliosis",
"     </li>",
"     <li>",
"      Difficulty turning in bed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gait",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Shuffling, short-stepped gait",
"     </li>",
"     <li>",
"      Freezing",
"     </li>",
"     <li>",
"      Festination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these features result from one or more of the cardinal manifestations. As examples, decreases in spontaneous associated movements, such as loss of gestures during conversation, decreased eye blinking, or facial masking, probably result from a combination of bradykinesia and rigidity. Dysphagia is due to bradykinesia of the pharyngeal musculature, which can lead to pooling of saliva in the mouth and drooling (sialorrhea) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NONMOTOR SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parkinson disease (PD) has traditionally been considered a motor system disorder, but it is now widely recognized to be a complex disorder with diverse clinical features that include neuropsychiatric and nonmotor manifestations in addition to its motor symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/5,32,33\">",
"     5,32,33",
"    </a>",
"    ]. These features include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cognitive dysfunction and dementia",
"     </li>",
"     <li>",
"      Psychosis and hallucinations",
"     </li>",
"     <li>",
"      Mood disorders including depression, anxiety, and",
"      <span class=\"nowrap\">",
"       apathy/abulia",
"      </span>",
"     </li>",
"     <li>",
"      Sleep disturbances",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Autonomic dysfunction",
"     </li>",
"     <li>",
"      Olfactory dysfunction",
"     </li>",
"     <li>",
"      Pain and sensory disturbances",
"     </li>",
"     <li>",
"      Dermatologic findings (seborrhea)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a multicenter survey of over 1000 patients with PD, virtually all (97 percent) patients reported nonmotor symptoms, with each patient experiencing an average of approximately eight nonmotor symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/33\">",
"     33",
"    </a>",
"    ]. Nonmotor symptoms in the psychiatric domain occurred most frequently. Psychiatric symptoms such as psychosis or dementia may cause more disability than the motor features and may be more difficult to treat. In a single center survey of 265 patients with PD, pain, mood disorders, and sleep problems were the most troublesome nonmotor symptoms occurring in both early and late stage PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, certain nonmotor features of PD (eg, olfactory dysfunction, constipation, depression, and REM sleep behavior disorder) may present before the motor ones [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/5\">",
"     5",
"    </a>",
"    ]. The most clinically relevant nonmotor manifestations of PD will be reviewed here individually.",
"   </p>",
"   <p>",
"    The management of nonmotor symptoms of PD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=see_link\">",
"     \"Management of comorbid problems associated with Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cognitive dysfunction and dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive dysfunction and dementia are common in PD, and the presence of dementia appears to be an independent predictor of mortality in PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/10\">",
"     10",
"    </a>",
"    ]. In community-based studies, the prevalence of dementia in PD is as high as 41 percent, and in longitudinal studies, the cumulative incidence of dementia in PD is as high as 78 percent. Older age and severity of PD motor symptoms are consistently associated with an increased risk of developing dementia in prevalence and incidence studies. Later age of onset of PD, longer duration of PD symptoms, the presence of hallucinations, depressive symptoms, and a family history of dementia may also be risk factors for dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=see_link&amp;anchor=H2#H2\">",
"     \"Parkinson disease dementia\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dementia of PD is classically considered a subcortical dementia, with psychomotor retardation, memory difficulty, and altered personality. Patients with PD typically report problems with executive function (decision making or multi-tasking), memory retrieval, and visuospatial misperception. Deficits in executive functioning are often the earliest indicators of disturbed cognition. This is in contrast to Alzheimer disease (AD), the prototypical cortical dementia, with features of aphasia and apraxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=see_link&amp;anchor=H8#H8\">",
"     \"Parkinson disease dementia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anatomic and pathologic basis of Parkinson disease dementia (PDD) is not fully understood. Neuropathologic studies have shown that patients with PD and dementia have a mixture of cortical neuronal Lewy inclusion bodies filled with alpha synuclein and the signature amyloid plaques and neurofibrillary tangles of AD. However, the degree of Lewy body pathology (Lewy bodies and Lewy neurites) correlates better with cognitive decline and dementia than does the degree of Alzheimer pathology, which is relatively modest in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=see_link&amp;anchor=H6#H6\">",
"     \"Parkinson disease dementia\", section on 'Neuropathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dementia usually occurs late in the course of PD. Complicating the diagnosis of dementia in PD is the entity of dementia with Lewy bodies (DLB). This illness is characterized primarily by dementia, but it also has parkinsonian features, visual hallucinations, and fluctuating cognition. Because of the overlapping clinical as well as pathological similarities (Lewy bodies in the limbic cortex and neocortex) between DLB and PD with dementia, many experts believe the two conditions may be two ends of the same disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/41/34455?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinically, patients are diagnosed with PD dementia if their illness begins with PD and they develop dementia at least a year after the onset of parkinsonian motor symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=see_link&amp;anchor=H22#H22\">",
"     \"Parkinson disease dementia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When dementia begins before or concurrently with parkinsonian motor symptoms, DLB is the more likely diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychosis and hallucinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosis occurs in 20 to 40 percent of drug-treated patients with PD, and visual hallucinations are the most common psychotic symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Auditory, olfactory, and tactile hallucinations also occur in PD, although less frequently, and generally in conjunction with visual hallucinations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/35,38\">",
"     35,38",
"    </a>",
"    ]. The prevalence and severity of hallucinations increase over time in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to the patient with visual hallucinations\", section on 'Neurodegenerative disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When psychosis occurs, it is attributable to the underlying Lewy body disease, to antiparkinson drug therapy, or a combination of the two. All antiparkinsonian medications have been reported to induce psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], yet certain drugs are more likely than others to cause psychotic symptoms. For example, large trials of dopamine agonists have demonstrated that visual hallucinations are more likely to result from these agents than levodopa [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Psychotic symptoms may persist but generally resolve when PD medications are discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the duration or dose of anti-parkinsonian drug therapy correlates poorly with the severity of psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delusions can also be a prominent feature of psychosis in PD, and are usually paranoid in nature. Common delusions include spousal infidelity, people stealing money, intruders living in the house, or nurses planning harmful plots. Many patients with PD who have psychotic symptoms nevertheless retain the insight that their hallucinations are not real. However, patients with PD can also be delirious or demented and manifest psychosis as a result. The patients in this latter category tend to be less responsive to treatment.",
"   </p>",
"   <p>",
"    Studies have shown that psychosis, not motor dysfunction, is the single greatest risk factor for nursing home placement in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Psychosis is also associated with increased caregiver burden [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/48\">",
"     48",
"    </a>",
"    ] and an increased risk of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/10,49\">",
"     10,49",
"    </a>",
"    ]. Commonly reported risk factors for psychosis in PD include the use of high doses of antiparkinson drugs, the presence of dementia, advancing age, impaired vision, depression, presence of sleep disorders, high comorbid disease burden, and longer disease duration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/36,45,50,51\">",
"     36,45,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mood disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression, anxiety, and abulia or apathy are mood disorders that occur most often in patients with PD. As noted above, mood disorders were ranked among the most troublesome nonmotor symptoms in a survey of patients with both early and late stage PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is the most common psychiatric disturbance seen in PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/52\">",
"     52",
"    </a>",
"    ]. Though generally mild to moderate in severity, depressive symptoms in PD are associated with a negative impact on motor disability and decreased quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates for the prevalence of depression in PD vary, but up to 50 percent of patients have depressive symptoms, occasionally as a presenting complaint [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/52,55-57\">",
"     52,55-57",
"    </a>",
"    ]. The rates for major depressive disorder in PD are less, ranging from less than 10 percent in community studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/56,58\">",
"     56,58",
"    </a>",
"    ], to 20 percent in specialty movement disorder clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Despite the high prevalence, however, depression in PD remains undertreated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/55,59,61\">",
"     55,59,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recognizing depressive features in PD is a challenge. The psychomotor slowing and blunted affect commonly seen with depression often resemble the bradykinesia and masked facial expression seen in PD. Furthermore, somatic features of depression, such as decreased appetite, difficulty with concentration, and sleep disturbances, are commonly seen in patients with PD who do not have depression.",
"   </p>",
"   <p>",
"    Patients with PD who develop depression usually present with sadness, anhedonia, and decreased interest in activities. Guilt and feelings of worthlessness may occur less frequently in PD-related depression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/62\">",
"     62",
"    </a>",
"    ]. Suicide occurs at approximately the same rate in PD as in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/63\">",
"     63",
"    </a>",
"    ], but suicide rates may be increased after deep brain stimulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H16#H16\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Risk of suicide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anxiety is the next most frequent psychiatric disturbance in PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/52\">",
"     52",
"    </a>",
"    ] and is estimated to occur in 29 to 38 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Although all types of anxiety disorders have been reported in PD, their relative frequencies in PD are unknown. However, panic disorder and generalized anxiety disorder appear to be the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], and these syndromes commonly accompany depressive symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/66\">",
"     66",
"    </a>",
"    ]. Depression and anxiety are also associated with \"on-off\" fluctuations, with worsened mood and anxiety during \"off\" periods, and with improvement when in the \"on\" state [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Apathy and abulia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apathy has been defined as a primary loss of motivation, characterized by diminished speech, motor activity, and emotional expression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/72\">",
"     72",
"    </a>",
"    ]. This definition of apathy is essentially synonymous with that of abulia, which has been defined as a loss of the impulse, will, or motivation to think, speak, and act. Diminished motivation is the key concept in both apathy and abulia. The neurologic basis of apathy and abulia is most commonly ascribed to frontal lobe and limbic system dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/73-75\">",
"     73-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although apathy frequently occurs with depression, it can occur in some patients with PD who do not have depression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/76\">",
"     76",
"    </a>",
"    ]. A potentially useful discriminating characteristic is mood, which is neutral in apathy and negative in depression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are scant, the prevalence of apathy in the absence of depression in patients with PD ranges from 12 to 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/76-80\">",
"     76-80",
"    </a>",
"    ]. As an example, one study compared a series of 80 patients with PD with 20 patients with idiopathic adult-onset dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/79\">",
"     79",
"    </a>",
"    ]. The frequency of apathy was significantly higher in patients with PD than those with dystonia (51 versus 20 percent), and apathy in the absence of depression was frequent in patients with PD but not dystonia (29 versus 0 percent). In contrast, patients with PD and dystonia had similar rates of depression without apathy (4 versus 10 percent) and similar rates of apathy with depression (23 versus 20 percent). The investigators concluded that apathy may be a core feature of PD.",
"   </p>",
"   <p>",
"    The presence of apathy has a negative impact on quality of life in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/33\">",
"     33",
"    </a>",
"    ]. Dementia, a rapid decline in speech, and decline in axial motor impairment may be risk factors for developing apathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sleep disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disorders affect between 74 and 98 percent of patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/82\">",
"     82",
"    </a>",
"    ]. As noted above, sleep difficulty was ranked as one of the most troublesome nonmotor symptoms in a survey of patients with both early and late stage PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/34\">",
"     34",
"    </a>",
"    ]. The most common sleep disturbances in PD are sleep fragmentation (frequent awakening throughout the night) and early morning awakening.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective eight-year longitudinal cohort study, insomnia (including sleep initiation problems, sleep fragmentation, or early awakening) was reported by 54 to 60 percent patients with PD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/83\">",
"       83",
"      </a>",
"      ]. On multivariate analysis, insomnia was associated with depressive symptoms, female sex, and disease duration.",
"     </li>",
"     <li>",
"      It is estimated that about 40 percent of patients with PD take medications for sleep, significantly more than taken in the general elderly population [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/83,84\">",
"       83,84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are many potential causes of frequent awakenings in PD, but the most common are nocturia, difficulty turning over in bed, cramps, vivid dreams or nightmares, and pain (especially in the neck or back) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/83,85,86\">",
"     83,85,86",
"    </a>",
"    ]. Tremor may also contribute to sleep fragmentation. The rest tremor in PD disappears with rapid eye movement (REM) sleep, but recurs during light sleep and may awaken the patient as a result [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/87\">",
"     87",
"    </a>",
"    ]. Some patients may have painful dystonia, especially of the legs, that typically occurs in the early morning and disrupts sleep. Depression is also commonly associated with poor sleep efficiency, decreased sleep time, and early morning awakening [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of restless legs syndrome (RLS) are often reported in PD. Restless legs syndrome is a movement disorder characterized by an urge to move the limbs, associated with an unpleasant sensation that occurs mainly or exclusively at night, emerges or worsens with rest, and improves with movement, especially walking. The prevalence of RLS in patients with PD is uncertain, as data are inconsistent. Furthermore, the prevalence of RLS in PD is difficult to assess because of overlapping clinical features between RLS and PD, such as wearing-off symptoms related to levodopa therapy, and akathisia (a state of motor restlessness characterized by the inability to sit or lie still). These issues are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H5#H5\">",
"     \"Restless legs syndrome\", section on 'Secondary RLS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Periodic limb movements of sleep (PLMS) are frequently but not always associated with RLS. The symptoms of PLMS are typically slow rhythmic movements of the legs, consisting of dorsal flexion of the foot and great toe [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/89\">",
"     89",
"    </a>",
"    ]. In some patients, flexion of the knee and hip may also occur. Estimates of the prevalence of PLMS in patients with PD range from 30 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapid eye movement (REM) sleep behavior disorder (or RBD) is another nocturnal disorder commonly seen in patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/91\">",
"     91",
"    </a>",
"    ]. This disorder is characterized by vigorous movements that are related to increased muscle tone during REM sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/92\">",
"     92",
"    </a>",
"    ]. Patients with RBD often act out their dreams and exhibit vocalizations as well as flailing, kicking, and punching motions of the limbs. Some patients may injure themselves or their bed partners. Behaviors related to RBD are reported to occur in 15 to 47 percent of patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/91,93,94\">",
"     91,93,94",
"    </a>",
"    ], and over one-third of presumably idiopathic RBD cases may develop PD, often years after the onset of RBD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Excessive daytime somnolence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive daytime somnolence (EDS) has long been recognized as a problem in PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/50,96,97\">",
"     50,96,97",
"    </a>",
"    ]. The prevalence of EDS in PD varies according to study methodology, but estimates range from 33 to 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. Some patients may just be sleepy, while others have additional unintended sleep episodes or sudden sleep \"attacks\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/101\">",
"     101",
"    </a>",
"    ]. Excessive daytime somnolence and sudden somnolence can be a hazard for patients with PD who drive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excessive daytime somnolence in PD is likely multifactorial. Possible risk factors include difficulty sleeping at night, depression, dementia, dopaminergic treatment, high comorbid disease burden, and male gender [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/51,103-107\">",
"     51,103-107",
"    </a>",
"    ]. It has also been argued that EDS may be intrinsic to the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is a common problem in patients with PD, with prevalence rates of 33 to 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/64,97,109-114\">",
"     64,97,109-114",
"    </a>",
"    ]. In a population-based longitudinal cohort study of fatigue in 233 patients with PD, the following observations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The proportion of patients with PD who had mental fatigue increased from 36 to 56 percent over eight years of follow-up",
"     </li>",
"     <li>",
"      Fatigue was significantly related to PD progression, depression, and EDS",
"     </li>",
"     <li>",
"      The prevalence of fatigue remained high (32 to 39 percent over the study period) even in patients without depression and EDS",
"     </li>",
"     <li>",
"      When present in patients with PD, fatigue was persistent in 56 percent and intermittent in 44 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although fatigue is associated with depression and EDS, several studies have found that patients with PD who do not have depression or EDS nonetheless have a high prevalence of fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/109,110,113\">",
"     109,110,113",
"    </a>",
"    ]. These data support the hypothesis that fatigue is an independent symptom of PD that overlaps with, but is not causally related to, depression and EDS.",
"   </p>",
"   <p>",
"    The pathophysiology of fatigue in PD is virtually unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Autonomic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic problems in PD include orthostasis, constipation, dysphagia, diaphoresis, urinary difficulties, and sexual dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. These problems are also present in multiple system atrophy (MSA), making it difficult to distinguish the two disorders. The autonomic symptoms in MSA, however, are generally more severe than in PD. Furthermore, MSA tends to be less responsive to levodopa as the disease progresses, and MSA is often associated with cerebellar and pyramidal findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of Parkinson disease\", section on 'Multiple system atrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Orthostatic hypotension can occur in up to 58 percent of patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/115,117\">",
"     115,117",
"    </a>",
"    ] and can be aggravated or caused by antiparkinsonian agents. Common urinary symptoms in patients with PD include frequency, urgency, and urge incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/118\">",
"     118",
"    </a>",
"    ]. The most common abnormality on urodynamic evaluation is reduced bladder capacity because of involuntary detrusor muscle contractions at early stages of bladder filling [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual dysfunction in PD can range from underactivity to hypersexuality. Underactive sexual behavior in PD commonly manifests as decreased interest and drive [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/120,121\">",
"     120,121",
"    </a>",
"    ] and can be due to depression [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/122\">",
"     122",
"    </a>",
"    ], axial rigidity, or bradykinesia. Over half of male patients may have the inability to achieve or maintain an erection, while female patients with PD often report vaginal tightness, dryness, and an inability to achieve orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/121,123,124\">",
"     121,123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue is that hypersexuality can be associated with antiparkinsonian therapies, both pharmacologic and surgical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=see_link&amp;anchor=H21#H21\">",
"     \"Pharmacologic treatment of Parkinson disease\", section on 'Impulse control disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgical treatment of Parkinson disease\", section on 'Deep brain stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Olfactory dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Olfactory dysfunction is common in PD; deficits in odor identification, discrimination, and detection have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/125\">",
"     125",
"    </a>",
"    ]. These deficits in olfaction may precede motor symptoms or occur relatively early in the course of PD, and they may not be noticed by the patients themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/126,127\">",
"     126,127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painful sensory symptoms are reported in up to 46 percent of patients with PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/128\">",
"     128",
"    </a>",
"    ]. As noted above, pain was ranked as one of the most troublesome nonmotor symptoms in a survey of patients with both early and late stage PD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/34\">",
"     34",
"    </a>",
"    ]. The pain can be lancinating, burning, or tingling, and can be generalized or localized to different areas of the body, including the face, abdomen, genitals, and joints [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/128-130\">",
"     128-130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Painful sensations in PD tend to correlate with motor fluctuations. Dystonia, which is often painful, is a common symptom in PD. It can occur spontaneously in early PD, or it can occur when levodopa wears off. Morning dystonia affecting the foot is a common \"off\" response to abstinence from levodopa during sleep. [",
"    <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/131\">",
"     131",
"    </a>",
"    ]. However, levodopa-induced dyskinesia can be dystonic and painful as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18857?source=see_link\">",
"     \"Motor fluctuations and dyskinesia in Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21879867\">",
"    <span class=\"h1\">",
"     DISEASE PROGRESSION AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, progression in PD is variable, and there currently are no symptoms or signs in idiopathic PD that allow a practitioner to accurately predict the future course of PD for any given individual. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical subtypes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, several observations provide insight into the general rate of disease progression in PD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early landmark study, the proportion of patients with PD who were severely disabled or dead within five years of disease onset was approximately 25 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/16\">",
"       16",
"      </a>",
"      ]. This increased to 67 percent at five to nine years, and 80 percent at 10 to 14 years. A small group of atypical patients had slow disease progression, maintaining balance and postural stability for &ge;10 years, and lacking severe disability even at &ge;20 years.",
"     </li>",
"     <li>",
"      A later study of 618 patients with PD found that the transition from disease impairment to disability occurred generally between three and seven years after the onset of PD [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/132\">",
"       132",
"      </a>",
"      ]. Impairment was defined by difficulty with daily activities without loss of independent function, while disability was defined by loss of independent function.",
"     </li>",
"     <li>",
"      Although some patients live with PD for 20 to 30 years [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/133\">",
"       133",
"      </a>",
"      ], most studies suggest that mortality is increased for patients with PD compared with age-matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?14/13/14554/abstract/134-136\">",
"       134-136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The prevalence of dementia in PD is approximately 40 percent, and increases with age and disease duration. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Cognitive dysfunction and dementia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=see_link&amp;anchor=H2#H2\">",
"       \"Parkinson disease dementia\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=see_link\">",
"       \"Patient information: Parkinson disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=see_link\">",
"       \"Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cardinal features of Parkinson disease (PD) are tremor, bradykinesia, and rigidity. Postural instability is another feature commonly mentioned in this category, but it generally occurs late in the course of the disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cardinal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the cardinal manifestations, other motor features of PD include craniofacial (eg, masked facial expression, hypophonia), visual (eg, hypometric saccades, eyelid opening apraxia), musculoskeletal (eg, micrographia, stooped posture), and gait (eg, shuffling, short-stepped gait, freezing) abnormalities (",
"      <a class=\"graphic graphic_table graphicRef81338 \" href=\"UTD.htm?21/3/21564\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other motor features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While PD has traditionally been considered a motor system disorder, it is now widely recognized to be a complex disorder with diverse clinical features that include neuropsychiatric and nonmotor manifestations (",
"      <a class=\"graphic graphic_table graphicRef71879 \" href=\"UTD.htm?3/44/3787\">",
"       table 2",
"      </a>",
"      ) in addition to its motor symptomatology. These features include the following (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Nonmotor symptoms'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cognitive dysfunction (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Cognitive dysfunction and dementia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Psychosis (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Psychosis and hallucinations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Mood disorders including depression, anxiety, and",
"      <span class=\"nowrap\">",
"       apathy/abulia",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Mood disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Sleep disturbances (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Sleep disorders'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Fatigue (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Fatigue'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Autonomic dysfunction (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Autonomic dysfunction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Olfactory dysfunction (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Olfactory dysfunction'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pain and sensory disturbances (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Pain'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Dermatologic findings (seborrhea)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Parkinson J. An Essay on the Shaking Palsy, Sherwood, Neely, and Jones, London 1817.",
"    </li>",
"    <li>",
"     Marras, C, Tanner, CM. Epidemiology of Parkinson's Disease. In: Movement Disorders: Neurologic Principles and Practice, 2nd, Watts, RL, Koller, WC (Eds), The McGraw-Hill Companies, New York 2004. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/3\">",
"      Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/4\">",
"      Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/5\">",
"      Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/6\">",
"      Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/7\">",
"      Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/8\">",
"      Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/9\">",
"      Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990; 53:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/10\">",
"      Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 2010; 75:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/11\">",
"      Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/12\">",
"      Louis ED, Levy G, C&ocirc;te LJ, et al. Clinical correlates of action tremor in Parkinson disease. Arch Neurol 2001; 58:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/13\">",
"      Jain S, Lo SE, Louis ED. Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol 2006; 63:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/14\">",
"      Shulman LM, Singer C, Bean JA, Weiner WJ. Internal tremor in patients with Parkinson's disease. Mov Disord 1996; 11:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/15\">",
"      Findley LJ, Gresty MA, Halmagyi GM. Tremor, the cogwheel phenomenon and clonus in Parkinson's disease. J Neurol Neurosurg Psychiatry 1981; 44:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/16\">",
"      Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/17\">",
"      Hughes AJ, Daniel SE, Lees AJ. The clinical features of Parkinson's disease in 100 histologically proven cases. Adv Neurol 1993; 60:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/18\">",
"      Martin WE, Loewenson RB, Resch JA, Baker AB. Parkinson's disease. Clinical analysis of 100 patients. Neurology 1973; 23:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/19\">",
"      Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997; 48:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/20\">",
"      Rajput AH, Rozdilsky B, Ang L. Occurrence of resting tremor in Parkinson's disease. Neurology 1991; 41:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/21\">",
"      Scott RM, Brody JA, Schwab RS, Cooper IS. Progression of unilateral tremor and rigidity in Parkinson's disease. Neurology 1970; 20:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/22\">",
"      Hunker CJ, Abbs JH. Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue, and index finger. Mov Disord 1990; 5:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/23\">",
"      Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998; 13 Suppl 3:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/24\">",
"      LANCE JW, SCHWAB RS, PETERSON EA. Action tremor and the cogwheel phenomenon in Parkinson's disease. Brain 1963; 86:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/25\">",
"      Koller WC, Glatt S, Vetere-Overfield B, Hassanein R. Falls and Parkinson's disease. Clin Neuropharmacol 1989; 12:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/26\">",
"      Muslimovic D, Post B, Speelman JD, et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008; 70:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/27\">",
"      Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 1985; 35:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/28\">",
"      Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990; 40:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/29\">",
"      Hershey LA, Feldman BJ, Kim KY, et al. Tremor at onset. Predictor of cognitive and motor outcome in Parkinson's disease? Arch Neurol 1991; 48:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/30\">",
"      Rajput AH, Voll A, Rajput ML, et al. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 2009; 73:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/31\">",
"      Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology 1992; 42:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/32\">",
"      Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol 2009; 66:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/33\">",
"      Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/34\">",
"      Politis M, Wu K, Molloy S, et al. Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010; 25:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/35\">",
"      F&eacute;nelon G, Mahieux F, Huon R, Zi&eacute;gler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123 ( Pt 4):733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/36\">",
"      Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996; 53:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/37\">",
"      Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord 2012; 27:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/38\">",
"      Chou KL, Messing S, Oakes D, et al. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005; 28:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/39\">",
"      Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 2005; 64:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/40\">",
"      Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982; 139:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/41\">",
"      Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991; 39:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/42\">",
"      Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000; 284:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/43\">",
"      Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/44\">",
"      Friedman JH. 'Drug holidays' in the treatment of Parkinson's disease. A brief review. Arch Intern Med 1985; 145:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/45\">",
"      Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/46\">",
"      Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/47\">",
"      Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/48\">",
"      Aarsland D, Br&oslash;nnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/49\">",
"      Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003; 60:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/50\">",
"      Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/51\">",
"      Biglan KM, Holloway RG Jr, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/52\">",
"      Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/53\">",
"      Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004; 52:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/54\">",
"      Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/55\">",
"      Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007; 69:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/56\">",
"      Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996; 53:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/57\">",
"      Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/58\">",
"      Leentjens AF, Marinus J, Van Hilten JJ, et al. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci 2003; 15:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/59\">",
"      Weintraub D, Moberg PJ, Duda JE, et al. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 2003; 16:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/60\">",
"      Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis 1990; 178:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/61\">",
"      Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 1999; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/62\">",
"      Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/63\">",
"      Stenager EN, Wermuth L, Stenager E, Boldsen J. Suicide in patients with Parkinson's disease. An epidemiological study. Acta Psychiatr Scand 1994; 90:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/64\">",
"      Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001; 16:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/65\">",
"      Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/66\">",
"      Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/67\">",
"      Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol 2005; 96:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/68\">",
"      Nuti A, Ceravolo R, Piccinni A, et al. Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol 2004; 11:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/69\">",
"      Maricle RA, Nutt JG, Carter JH. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings. Mov Disord 1995; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/70\">",
"      Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995; 45:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/71\">",
"      Menza MA, Sage J, Marshall E, et al. Mood changes and \"on-off\" phenomena in Parkinson's disease. Mov Disord 1990; 5:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/72\">",
"      Richard IH. Apathy does not equal depression in Parkinson disease: why we should care. Neurology 2006; 67:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/73\">",
"      Reijnders JS, Scholtissen B, Weber WE, et al. Neuroanatomical correlates of apathy in Parkinson's disease: A magnetic resonance imaging study using voxel-based morphometry. Mov Disord 2010; 25:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/74\">",
"      Skidmore FM, Yang M, Baxter L, et al. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/75\">",
"      Robert G, Le Jeune F, Lozachmeur C, et al. Apathy in patients with Parkinson disease without dementia or depression: a PET study. Neurology 2012; 79:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/76\">",
"      Pedersen KF, Larsen JP, Alves G, Aarsland D. Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. Parkinsonism Relat Disord 2009; 15:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/77\">",
"      Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/78\">",
"      Isella V, Melzi P, Grimaldi M, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002; 17:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/79\">",
"      Kirsch-Darrow L, Fernandez HH, Fernandez HF, et al. Dissociating apathy and depression in Parkinson disease. Neurology 2006; 67:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/80\">",
"      Starkstein SE, Merello M, Jorge R, et al. The syndromal validity and nosological position of apathy in Parkinson's disease. Mov Disord 2009; 24:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/81\">",
"      Pedersen KF, Alves G, Aarsland D, Larsen JP. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neurosurg Psychiatry 2009; 80:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/82\">",
"      Partinen M. Sleep disorder related to Parkinson's disease. J Neurol 1997; 244:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/83\">",
"      Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP. Insomnia in Parkinson's disease: frequency and progression over time. J Neurol Neurosurg Psychiatry 2007; 78:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/84\">",
"      Tandberg E, Larsen JP, Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998; 13:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/85\">",
"      Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson's disease. Mov Disord 2002; 17:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/86\">",
"      Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988; 11:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/87\">",
"      Askenasy JJ, Yahr MD. Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep. J Neurol Neurosurg Psychiatry 1990; 53:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/88\">",
"      Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry 2005; 66:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/89\">",
"      Wetter TC, Pollm&auml;cher T. Restless legs and periodic leg movements in sleep syndromes. J Neurol 1997; 244:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/90\">",
"      Poewe W, H&ouml;gl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology 2004; 63:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/91\">",
"      Sixel-D&ouml;ring F, Trautmann E, Mollenhauer B, Trenkwalder C. Associated factors for REM sleep behavior disorder in Parkinson disease. Neurology 2011; 77:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/92\">",
"      Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 2002; 25:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/93\">",
"      Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998; 51:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/94\">",
"      Gjerstad MD, Boeve B, Wentzel-Larsen T, et al. Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time. J Neurol Neurosurg Psychiatry 2008; 79:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/95\">",
"      Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/96\">",
"      Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov Disord 1990; 5:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/97\">",
"      van Hilten JJ, Weggeman M, van der Velde EA, et al. Sleep, excessive daytime sleepiness and fatigue in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/98\">",
"      Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/99\">",
"      H&ouml;gl B, Seppi K, Brandauer E, et al. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 2003; 18:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/100\">",
"      Henderson JM, Lu Y, Wang S, et al. Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. J Neurol Neurosurg Psychiatry 2003; 74:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/101\">",
"      Roth T, Rye DB, Borchert LD, et al. Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med 2003; 4:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/102\">",
"      Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/103\">",
"      Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/104\">",
"      Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol 2004; 61:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/105\">",
"      Avorn J, Schneeweiss S, Sudarsky LR, et al. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol 2005; 62:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/106\">",
"      Gjerstad MD, Alves G, Wentzel-Larsen T, et al. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology 2006; 67:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/107\">",
"      Bliwise DL, Trotti LM, Wilson AG, et al. Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class. Mov Disord 2012; 27:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/108\">",
"      Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/109\">",
"      Friedman J, Friedman H. Fatigue in Parkinson's disease. Neurology 1993; 43:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/110\">",
"      Karlsen K, Larsen JP, Tandberg E, J&oslash;rgensen K. Fatigue in patients with Parkinson's disease. Mov Disord 1999; 14:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/111\">",
"      Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/112\">",
"      Herlofson K, Larsen JP. The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurol Scand 2003; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/113\">",
"      Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 2004; 63:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/114\">",
"      Schifitto G, Friedman JH, Oakes D, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008; 71:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/115\">",
"      Allan LM, Ballard CG, Allen J, et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 2007; 78:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/116\">",
"      Verbaan D, Marinus J, Visser M, et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007; 69:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/117\">",
"      Senard JM, Ra&iuml; S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/118\">",
"      Lemack GE, Dewey RB Jr, Roehrborn CG, et al. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 2000; 56:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/119\">",
"      Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 2000; 164:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/120\">",
"      Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 1990; 53:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/121\">",
"      Koller WC, Vetere-Overfield B, Williamson A, et al. Sexual dysfunction in Parkinson's disease. Clin Neuropharmacol 1990; 13:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/122\">",
"      Jacobs H, Vieregge A, Vieregge P. Sexuality in young patients with Parkinson's disease: a population based comparison with healthy controls. J Neurol Neurosurg Psychiatry 2000; 69:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/123\">",
"      Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 1992; 32:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/124\">",
"      Welsh M, Hung L, Waters CH. Sexuality in women with Parkinson's disease. Mov Disord 1997; 12:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/125\">",
"      Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord 2001; 16:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/126\">",
"      Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/127\">",
"      Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008; 63:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/128\">",
"      Goetz CG, Tanner CM, Levy M, et al. Pain in Parkinson's disease. Mov Disord 1986; 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/129\">",
"      Hillen ME, Sage JI. Nonmotor fluctuations in patients with Parkinson's disease. Neurology 1996; 47:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/130\">",
"      Ford B, Louis ED, Greene P, Fahn S. Oral and genital pain syndromes in Parkinson's disease. Mov Disord 1996; 11:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/131\">",
"      Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/132\">",
"      Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. Mov Disord 2008; 23:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/133\">",
"      Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/134\">",
"      Diem-Zangerl A, Seppi K, Wenning GK, et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009; 24:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/135\">",
"      Hely MA, Morris JG, Traficante R, et al. The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999; 67:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/13/14554/abstract/136\">",
"      Ishihara LS, Cheesbrough A, Brayne C, Schrag A. Estimated life expectancy of Parkinson's patients compared with the UK population. J Neurol Neurosurg Psychiatry 2007; 78:1304.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4903 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14554=[""].join("\n");
var outline_f14_13_14554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H149298288\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDINAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bradykinesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rigidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Postural instability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL SUBTYPES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER MOTOR FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NONMOTOR SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cognitive dysfunction and dementia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychosis and hallucinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mood disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Anxiety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Apathy and abulia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Excessive daytime somnolence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Autonomic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Olfactory dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21879867\">",
"      DISEASE PROGRESSION AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/3/21564\" title=\"table 1\">",
"      Motor features of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/44/3787\" title=\"table 2\">",
"      Nonmotor symptoms of Parkinson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=related_link\">",
"      Approach to the patient with visual hallucinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/41/34455?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36970?source=related_link\">",
"      Etiology and pathogenesis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=related_link\">",
"      Management of comorbid problems associated with Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18857?source=related_link\">",
"      Motor fluctuations and dyskinesia in Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4277?source=related_link\">",
"      Nonpharmacologic management of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=related_link\">",
"      Overview of tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/36/15946?source=related_link\">",
"      Parkinson disease dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/40/13954?source=related_link\">",
"      Patient information: Parkinson disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/4/5188?source=related_link\">",
"      Patient information: Parkinson disease symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32105?source=related_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_13_14555="Pancreatic sphnctr HTN stenting";
var content_f14_13_14555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pancreatic stenting after biliary sphincterotomy for sphincter of Oddi dysfunction in patients with pancreatic sphincter hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Therapy",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Pancreatitis, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Total",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle2\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle2\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stent (n = 41)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No stent (n = 39)",
"       </td>",
"       <td>",
"        26*",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * p = 0.003 (N.B. incidence of pancreatitis was 7 percent in the stent group when including two patients who developed pancreatitis after stent removal).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tarnasky PR, et al. Gastroenterology 1998; 15:1518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14555=[""].join("\n");
var outline_f14_13_14555=null;
var title_f14_13_14556="Anatomic diagnosis of weakness";
var content_f14_13_14556=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61167&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of weakness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Diagnostic category",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Site of lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Upper motor neuron",
"       </td>",
"       <td class=\"subtitle2\">",
"        Anterior horn cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Peripheral nerve",
"       </td>",
"       <td class=\"subtitle2\">",
"        NM junction",
"       </td>",
"       <td class=\"subtitle2\">",
"        Muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genetic",
"       </td>",
"       <td>",
"        Leukodystrophies",
"       </td>",
"       <td>",
"        Spinal muscular atrophy",
"       </td>",
"       <td>",
"        Peroneal muscular atrophy",
"       </td>",
"       <td>",
"        Myasthenia gravis",
"       </td>",
"       <td>",
"        Muscular dystrophies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory",
"       </td>",
"       <td>",
"        Vasculitis",
"       </td>",
"       <td>",
"        Amyotrophic lateral sclerosis",
"       </td>",
"       <td>",
"        Guillain- Barre",
"       </td>",
"       <td>",
"        Myasthenia gravis",
"       </td>",
"       <td>",
"        Polymyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious",
"       </td>",
"       <td>",
"        Brain abscess",
"       </td>",
"       <td>",
"        Poliomyelitis",
"       </td>",
"       <td>",
"        Leprosy",
"       </td>",
"       <td>",
"        Botulism",
"       </td>",
"       <td>",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplastic",
"       </td>",
"       <td>",
"        Brain tumor",
"       </td>",
"       <td>",
"        Paraneoplastic syndrome",
"       </td>",
"       <td>",
"        Myeloma/ amyloid",
"       </td>",
"       <td>",
"        Eaton-Lambert syndrome",
"       </td>",
"       <td>",
"        Malignancy- associated myositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxic/drug",
"       </td>",
"       <td>",
"        Radiation",
"       </td>",
"       <td>",
"        Lead",
"       </td>",
"       <td>",
"        Lead",
"       </td>",
"       <td>",
"        Organophosphate poisoning",
"       </td>",
"       <td>",
"        Steroid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic/ endocrine",
"       </td>",
"       <td>",
"        Vitamin B12 deficiency",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Diabetes",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        <p>",
"         Hypothyroid",
"        </p>",
"        <p>",
"         Hypoglycemia",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14556=[""].join("\n");
var outline_f14_13_14556=null;
var title_f14_13_14557="Rapid overview of hypertensive emergencies in children";
var content_f14_13_14557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypertensive emergencies and urgencies in children - rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hypertensive emergency - symptomatic severe hypertension or rapid increase in blood pressure associated with one or more of the following signs of target-organ damage:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Seizures or encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Papilledema and retinal hemorrhage or exudates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Heart failure&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertensive urgency - severe hypertension or rapid increase in blood pressure",
"        <strong>",
"         WITHOUT",
"        </strong>",
"        the presence of severe target-organ damage or major symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other findings - findings suggesting a specific underlying etiology for hypertension include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hematuria, proteinuria, and edema (glomerulonephritis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ataxia, focal neurologic deficits,&nbsp;lethargy, coma&nbsp;(intracranial mass lesion or intracranial trauma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diminished femoral pulses or lower extremity BP (coarctation of the aorta)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sympathomimetic overdose (eg, cocaine, amphetamine ingestion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pregnancy (ecclampsia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abdominal or flank bruit (renovascular disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confirm severely elevated blood pressure with strict attention to BP cuff size and placement*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measure 4 limb BP, especially in infants and young children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exclude other causes of severe hypertension (eg, primary head trauma, intracranial mass lesion, coarctation of the aorta, sympathomimetic ingestion&bull;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood studies: CBC with differential and reticulocyte count; serum electrolytes including calcium, blood urea nitrogen, and creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine studies: microscopic urinalysis and urine culture; urine pregnancy test in postmenarchal females, urine drug screen for cocaine, amphetamines, and PCP if drug use suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other diagnostic studies: EKG, chest radiograph (heart failure); Echocardiogram if rapidly available, Head CT if signs of trauma or intracranial mass lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess airway and breathing. Perform endotracheal intubation as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain vascular access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain intraarterial line for BP measurement or frequently measure BP by auscultation or rapidly cycling oscillometric BP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not delay treatment for arterial cannulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For hypertensive emergencies, lower BP by no more than 25 percent over the first 8 hours using IV medication (See Table \"Intravenous drugs for treatment of hypertensive emergencies and urgencies in children\". Treatment should be started immediately. If possible, consult with pediatric nephrologist or other physician with expertise in managing pediatric hypertensive emergencies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For hypertensive urgencies, may use either an intravenous or oral medication depending on the clinical circumstances and desired rapidity of antihypertensive effect. (See Table \"Oral drugs for treatment of hypertensive urgencies in children\" and see Table \"Intravenous drugs for treatment of hypertensive emergencies and urgencies in children\").",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ICP: intracranial pressure; BP: blood pressure; CBC: complete blood count; PCP: phencyclidine; EKG: electrocardiogram; CT: computed tomography.",
"     <br>",
"      * Auscultation is preferred. A BP cuff that is too small will artificially elevate BP.",
"      <br>",
"       &bull; Mixed alpha and beta sympathomimetic ingestions may be accompanied by tachycardia, hypertension, hyperthermia, widened pulse pressure, delirium, seizures, dilated reactive pupils, diaphoresis, and pallor.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14557=[""].join("\n");
var outline_f14_13_14557=null;
var title_f14_13_14558="Ixodes scapularis";
var content_f14_13_14558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    An adult female Ixodes scapularis (blacklegged tick)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 180px; height: 179px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Champman, AS, Bakken, JS, Folk, SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichiosis, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14558=[""].join("\n");
var outline_f14_13_14558=null;
var title_f14_13_14559="Pediatric headache and focal neurologic examination";
var content_f14_13_14559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Headache in child with focal neurologic examination or papilledema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 544px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT: computed tomography; CSF: cerebrospinal fluid; RBCs: red blood cells; WBCs: white blood cells.",
"     <br>",
"      * Distinguish idiopathic intracranial hypertension from cerebral venous thrombosis by obtaining magnetic resonance imaging or magnetic resonance venogram.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_13_14559=[""].join("\n");
var outline_f14_13_14559=null;
